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Zusammenfassung 
Die vorliegende Arbeit befaßt sich mit Naturstoffen aus Myxobakterien. Mittels LC-MS 
wurde in Extrakten von Myxococcus xanthus Kulturen nach neuen Sekundärmetaboliten 
gesucht. Insgesamt wurden 4 unterschiedliche Substanzfamilien isoliert und charakterisiert. 
Die Identifizierung der zugrundeliegenden Biosynthesegencluster zeigt interessante Einblicke 
in unterschiedliche Biosynthesewege von Myxobakterien. 
Das Cittilingencluster wurde im Genom von M. xanthus Stämmen identifiziert. Für einen 
myxobakteriellen Sekundärmetaboliten konnte durch heterologe Expression in S. aurantiaca 
Sga 15 erstmalig bewiesen werden, dass dieser ribosomalen Ursprungs ist. Die Modifikation 
des genetischen Codes führte zu neuen Cittilinen. 
Die neuen Myxoprincomide werden durch einen NRPS/PKS-Hybrid Biosyntheseweg 
gebildet. 10 Myxoprincomidderivate wurden aus M. xanthus DK897 isoliert. Mit 39 
katalytischen Domänen ist es das bislang größte myxobakterielle Biosynthesegen. Aufgrund 
ungewöhnlicher Aminosäuren sowie seltener Strukturmerkmale, ergibt sich insbesondere im 
Vergleich zu M. xanthus DK1622 für die Myxoprincomide eine außergewöhnliche 
Biosynthese. Erstaunlich ist auch die Vielzahl von 10 Derivaten, die größtenteils als 
Intermediate der Biosynthese hydrolytisch freigesetzt werden. 
Des Weiteren wurden Prechondrochloren von einer C. crocatus Cm c5 Mutante sowie neue 
Spirangiene mit einem verkürzten Chromophor von einer zufälligen S. cellulosum So ce90 
Mutante isoliert und strukturell aufgeklärt. 
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Abstract 
This thesis deals with natural products from myxobacteria. Myxococcus xanthus extracts were 
screened by LC-MS for novel secondary metabolites. Altogether 4 different substance 
families were isolated and characterized. Identification and analysis of the associated 
biosynthetic gene clusters allows interesting insights into diverse biosynthetic routes of 
myxobacteria. 
The cittilin gene cluster was identified in the genome of M. xanthus. For the first time, in case 
of a myxobacterial secondary metabolite, it could be demonstrated by heterologous 
expression in S. aurantiaca Sga 15 that the cittilin precursor peptide is built by the ribosome. 
Modification of the genetic code yielded novel cittilin derivates. 
The novel myxoprincomides (mxp) core structure is produced by a NRPS/PKS hybrid 
biosynthetic pathway in M. xanthus DK897 and DK1622. 10 mxp derivates from DK897 were 
isolated and correlated to the so far largest myxobacterial biosynthetic gene exhibiting 39 
catalytic domains. The mxp biosynthesis is exciting due to incorporation of unusual amino 
acids and other rare structural features, particularly in comparison to mxp of DK1622. 
Strikingly, the number of 10 mxp derivates mainly representing hydrolytically released 
intermediates of the biosynthesis. 
Prechondrochloren was isolated from a C. crocatus Cm c5 mutant and structurally elucidated. 
Furthermore it was shown that a spontaneous mutant of S. cellulosum So ce90 produces novel 
spirangien derivates with a shortened chromophore. 
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Introduction 
1. Natural products as a source of pharmaceuticals 
Microorganisms produce large numbers of structurally diverse secondary metabolites and thus 
constitute an invaluable source of new drugs. Some of these natural products (NPs) exhibit a 
wide range of biological activities like anti-cancer, antifungal, herbicidal, insecticidal or 
immunosuppressive. 
[1-4]
 Many drugs are isolated from natural sources (e.g. taxol, rapamycin, 
vancomycin) or derived from NPs (ß-lactams, steroids, macrolides). In other cases, only the 
pharmacophore is based on a natural compound, as in the case of Lipitor
®
, a drug used to treat 
high cholesterol levels. Natural compounds are therefore a very useful launching point for 
drug development. As an example, small modifications to the structure of epothilone, a 
secondary metabolite originally isolated from the myxobacterium Sorangium cellulosum, 
recently led to the establishment of a new anticancer drug, Ixabepilone
®
. 
[5]
 That means if NPs 
are not used as found in nature, they often are used as lead structures for novel drug 
development. NPs have traditionally also been a rich source of antibiotics; the first antibiotic, 
penicillin, was a chance discovery from a fungi by Alexander Fleming. Some compounds 
have also been adopted for use in agriculture as herbicides or as insecticides. 
[4]
 
 
Natural products often show huge structural diversity that is difficult to achieve via organic 
synthesis. The annual percentage is currently estimated at around 50% of pharmaceutical sales 
derived from natural sources. 
[1;6]
 Assumptions on the overall influence of NPs to the 
discovery and development of pharmaceutical treatments are up to 75%. 
[7]
 Prominent 
examples used in clinical therapy are the erythromycin (antibiotic) and rapamycin 
(immunosuppressant), salinosporamide (proteasome inhibitor), glycopeptides like 
vancomycin (antibiotic), and the lipopeptide daptomycin (antibiotic). 
[1;8-11]
  
Pathogens are becoming increasingly multi-drug resistant. Standard therapies are no longer 
sufficient, and even second and third-line drugs are not active enough against emerging multi-
drug resistant strains. 
[4;12]
 As anti-microbial drugs lose their effectiveness, it becomes even 
more critical to search for novel biologically active NPs. As new sources of chemical 
diversity, NPs are essential to continuously drive new drug discovery or development. 
[7]
 
Several major pharmaceutical companies have abandoned the field, focusing rather on 
chemical synthesis, and high-throughput screening of synthetic libraries, but smaller 
companies and research groups continue the search for new NPs. 
[13]
 From 2000 to 2008, 300 
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secondary metabolites with antimicrobial activity were discovered. 
[14] 
In 2008, 1065 new NPs 
of marine origin were reported. 
[15]
 
Natural compounds perform better in bioactivity assays, showing higher hit rates compared to 
synthetic libraries. Combinatorial synthesis did not result in a large improvement in drug 
development, largely due to a lack of “structural complexity” compared to bioactive natural 
products. 
[16]
 NPs generally have lower numbers of nitrogen, halogen, and sulfur atoms but 
higher amounts of oxygen. 
[17]
 Another reason for better activity of NPs might be that they 
have been selected for through an evolutionary process. 
[18]
  
Bioactive compounds mainly originate from four different groups: bacteria (33%), plants 
(27%), fungi (15%), and animals (13%). 
[17]
 In the case of microorganisms, some bacterial 
orders, such as the Actinomycetales, have been intensively investigated. Thus, in order to 
increase the chance of finding a novel compound it is worth looking for other species to find 
novel structures and modes of action. 
[19]
 So far, only around 1 % of the prokaryotes have 
been cultivated, 
[4]
 and an even lower percentage is expected for bacteria from unusual 
habitats, 
[20]
 organisms which are very difficult to culture in the lab, 
[21]
 or pathogens. 
[22]
 
However, laboratory conditions are being established for more and more bacteria, such as 
cyanobacteria, 
[23]
 marine actinomycetes, 
[24]
 some bacterial endosymbionts, 
[25;26]
 
pseudomonads, and myxobacteria. 
[27;28]
 Regarding myxobacteria marine environments or 
other less explored habitats are of great interest for the isolation of novel species. 
[12;29]
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2. Common features of myxobacteria  
Myxobacteria are Gram-negative bacteria belonging to the delta subgroup of proteobacteria, 
which can be isolated from different habitats like soil, herbivore dung, decaying plant mass 
and tree bark, showing that they are able to adapt to diverse environments. 
[30-32]
 Recently 
myxobacterial isolates from marine environments have been described and halophilic strains 
from terrestrial sources have been reported. 
[33;34]
  
Their cells are typically rod-shaped and often rather large (4 – 12 μm long and 0.7 – 1.2 μm 
wide in their vegetative form). Some genera can be cultivated in dispersion, others will form 
clumps, even after several passages. 
[35]
 
Compared to other bacteria, myxobacteria have some noticeable features: 
[36]
 The capability to 
glide on solid surfaces, building swarms, degrading macromolecules, and preying on living 
microorganisms are their main characteristics. Myxobacteria possess a sort of “social” 
behavior as they swarm and collectively hunt for other microorganisms such as bacteria and 
fungi. 
[37;38]
 For that reason, myxobacteria can be called “micropredators”. [33] To achieve this, 
they excrete enzymes which lyse other organism so that proteins and lipids can be consumed. 
The species Sorangium cellulosum is not a predator but with the help of exo-enzymes it is 
even able to degrade cellulose as a nutrition source. 
[35;38]
 
Under starvation conditions, myxobacteria start a multicellular development cycle. Cells 
aggregate, building characteristic multi-cellular fruiting bodies (Figure 1) containing 
myxospores 
[38;39]
 which are resistant against extreme environmental conditions like 
temperature changes, desiccation, and UV radiation. 
[33]
 As soon as environmental conditions 
become more favorable, the myxospores are retransformed into normal vegetative cells. The 
shape of the fruiting bodies varies a lot and can therefore be used for taxonomic 
classification. 
[35;40]
 Myxobacteria belong to the order Mycococcales, which can be 
distinguished into the three suborders Nannocystineae, Cystobacterineae and 
Sorangiineae. 
[41]
 
 
Figure 1:  Fruiting bodies of Myxococcus xanthus, Chondromyces crocatus, Sorangium cellulosum 
(magnification: left 64x, middle 30x, right 60x; pictures R. O. Garcia) 
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Due to their fascinating behavior, myxobacteria have long been studied by microbiologists. 
More recently they have also been established to be multi-producers of secondary metabolites 
and therefore they represent a valuable source for natural products. 
[42;43]
 Alongside to the two 
other significant wells for natural compounds, the actinomycetes and fungi. Most of the 
secondary metabolite research with myxobacteria has been performed at the German Research 
Center for Biotechnology (Braunschweig, Germany; recently renamed to Helmholtz Center 
for Infection Research). At this center, more than 7500 myxobacterial strains have been 
isolated and characterized, from which over 100 different core structures with around 500 
derivatives have been described to date, with more continuously being found. 
[30;38;44]
 Further 
work to increase the number of different species and families is ongoing, with a high 
expectancy for the uncovering of new substance classes. 
[30;40] 
In the past, myxobacteria have 
been considered exotic organisms but over time they have become more understood and 
established. 
[45;46] 
Many of the isolated compounds show novel structural diversity. When bioactivity is 
detected, it can often be attributed to an outstanding mode of action. 
[44-47]
 This finding is 
especially valuable for new lead structures for drug development, making myxobacterial 
research even more attractive.  
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3. Myxobacteria as multi-producers of secondary metabolites 
To date, 67 different substance classes from myxobacteria have been published, but there is 
evidence of more than 100 diverse core structures. As many of them have further derivatives, 
there are over 500 substances known. 
[30;48]
 Several different scaffolds of NPs can be 
produced by myxobacteria, some unique and others already known from other bacteria. The 
structural diversity varies from polyketides (PKs), non-ribosomal peptides (NRPs), and 
hybrids thereof, to alkaloids, terpenoids, and phenyl-propanoids. 
[45;49]
  
A huge number of myxobacterial metabolites exhibit biological activities. The range is very 
broad from antibacterial and cytotoxic to pheromone-like effects. These diverse activities 
make myxobacterial metabolites highly relevant in clinical research, but we have only barely 
scratched the surface of myxobacterial secondary metabolism. 
[30;50;51]
 However, not all 
substances can be assigned to a biological function or mode of action. 29% show antibacterial 
activity, and the most frequently observed bioactivity of myxobacterial metabolites is anti-
fungal activity (54%). 
[44]
  
Distinct structure types can have the same general bioactivity but different modes of action. 
Epothilone (1) and tubulysin (2), 
[52;53]
 for example, are cytotoxic, both acting on the 
cytoskeleton of eukaryotic cells, but their effects are different. Both cause cell cycle arrest and 
induce apoptosis, 
[52;54]
 but tubulysin (2) inhibits the polymerization of tubulin, while 1 
stabilizes microtubules. It binds to ß-tubulin and induces microtubule polymerization at the 
cytoskeleton of eukaryotic cells. 
[55-57]  
A derivative of 1 has been established as an anti-cancer drug. In 2007, Ixabepilone
®
 
(Ixempra) was approved for the US market as the first myxobacteria derived compound for 
clinical use against breast cancer. Other compounds interacting with the cytoskeleton 
produced from myxobacteria are disorazol (4), 
[58]
 chondramide (5), 
[59]
 and rhizopodin 
(6). 
[60;61]
 A further potential antitumor drug is argyrin (3), which inhibits the proteasome. 
[62] 
Soraphen (7), a metabolite from Sorangium cellulosum has an anti-fungal effect and was 
evaluated to be used in plant protection. 
[63]
 However, further studies showed a teratogenic 
effect, stopping further investigations. In eukaryotic cells, it interacts with acetyl-CoA 
carboxylase and inhibits its activity. 
[64;65]
 As the acetyl-CoA carboxylase is important for 
fatty acid synthesis it could be useful for treatment of cancer 
[66]
 and obesity 
[67]
. 
Stigmatellin (8), as well, has anti-fungal activity, with a different mode of action compared to 
7. 
[65;68]
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Thuggacins (9) are bioactive compounds against Mycobacterium tuberculosis and other 
Gram-positive bacteria, inhibiting the respiratory chain of the bacteria. 
[69;70]
 Further 
mentionable are myxothiazol (10) and melithiazols (11), targeting the mitochondrial electron 
transport chain. 
[71;72]
 Sorangicin (13), myxopyronin (12), and corralopyronin (14) affect 
eubacterial RNA polymerases. 
[73-75]
 Protein synthesis is targeted by myxovalargin (18) 
[76]
. 
Chondrochloren (15), partly investigated in this work, has an antibiotic effect. 
[77] 
The typical 
earthy smell of myxobacteria is due to geosmin (16). 
[78]
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Figure 2:  Epothilon B (1), Tubulysin A (2), Argyrin A (3), Disorazol A1 (4), Chondramid A (5), 
Rhizopodin (6), Soraphen A1α (7), Stigmatellin A (8), Thuggacin A (9). 
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Figure 3:  Myxothiazol A (10), Melithiazol A (11), Myxopyronin A (12), Sorangicin A (13), 
Corallopyronin A (14), Chondrochloren A (15), Geosmin (16), Aurafuron A (17), 
Myxovalargin A (18), Chivosazol A (19).  
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4. Secondary metabolites of Myxococcus xanthus 
The myxobacterium Myxococcus xanthus DK1622 is a model strain for prokaryotic 
multicellular differentiation and thus has become the best-studied myxobacterium. Although it 
was used extensively for investigations of the bacterial life-cycle, it was long believed to be a 
non-producer of secondary metabolites. However, since the genome of DK1622 was 
sequenced, it is known to contain 18 gene clusters for secondary metabolite production. 
[79]
 
Biosynthesis of secondary metabolites is often encoded in gene clusters within the genome. 
The part of the genome in DK1622 dedicated to secondary metabolites (more than 8.5%) is 
much higher in comparison to other natural product producers such as Streptomyces 
coelicolor (4.5%) and S. avermitilis (6.6%). 
[80;81]
 The strain DK1622 produces myxalamides 
(20) 
[82]
, myxochelin (21) 
[83]
, myxovirescin (22) 
[84]
, myxochromides (23) 
[85]
, DKxanthene 
(24) 
[86]
 and two others that are the subject of investigation in the course of this thesis: cittilin 
and myxoprincomide. However, there are 18 different biosynthetic gene clusters in the 
genome and until now it was thus not possible to assign each single one to a detectable 
compound. It is possible that not all gene clusters are expressed under given cultivation 
conditions, as expression may need to be induced. 
[87]
 Or production levels can be very low if 
a compound is not needed; for example, if an excess of iron is present, an iron chelator like 21 
is not required for growth, meaning that production of that compound will be down-regulated 
by the cell. Another possibility for the lack of a compound could be its degradation as 
observed in the case of chivosazol (19) at later time points during cultivation. 
[88]
 However, 
transcriptomic and proteomic investigations of DK1622 showed that almost all clusters are 
active during lab cultivation. 
[89;90]
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Figure 4:  Myxalamide A (20), Myxochelin A (21), Myxovirescin A1 (22), Myxochromide A1 (23), 
DKxanthen534 (24).  
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5. Biosynthetic machinery for secondary metabolite formation in 
bacteria 
In addition to the discovery of new structures, their corresponding biosynthetic pathways are 
attaining more and more interest. 
[46]
 Knowledge of the biosynthetic pathway offers the 
possibility to manipulate it genetically and therewith to increase yields or obtain new 
derivatives. 
[91]
 This information can also be used to express biosynthetic gene clusters in 
heterologous hosts. 
[92] 
Within the last decade, a large number of biosynthetic gene clusters have been identified. This 
genetic information enables the prediction of unknown pathways and subsequently new 
structures. 
[93-96] 
Myxobacteria have very large genomes compared to other bacteria, as revealed by genome 
sequencing of Myxococcus xanthus DK1622 and Sorangium cellulosum So ce56. A large 
genome size seems to be characteristic for myxobacteria and is littered with secondary 
metabolite gene clusters, 
[97]
 making them very likely to be a rich source of currently 
unknown secondary metabolites. 
Most myxobacterial products are polyketides (PKs), nonribosomal peptides (NRPs)
 [98]
 , or 
hybrids of both 
[42;43]
; recent investigations partly described in this thesis show as well 
ribosomally produced compounds. In addition to these NP groups, steroids have been found in 
myxobacteria, which is rather unusual for prokaryotes. 
[99]
 
 
5.1 Biochemistry of nonribosomal peptide synthetases and polyketide 
synthases 
The origin of two large groups of secondary metabolites, the polyketides and non-ribosomal 
peptides, are products of multi-step biosynthetic pathways. The underlying biosyntheses is 
directed by complex biosynthetic machineries, such biosynthetic machineries are polyketide 
synthases (PKS) and non-ribosomal peptide synthetases (NPRS). Aurafuron (17) and 
soraphen (7) for instance are myxobacterial metabolites generated by pure PKSs. 
[100]
 While 
myxochelin (21) is a myxobacterial representative resulting of a NRPS pathway. 
These PKS and NRPS multi-enzymes condense different substrate units (monomeric building 
blocks) with each other to form a final product. Multi-enzymes consist out of repeated 
functional units which are called modules. One module is in charge of the incorporation of 
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one building block. A module is further divided into domains which are responsible for single 
reaction steps.  
This is analogous to an assembly line, where one module is responsible for one component 
here for the incorporation of one building block. 
[101;102]
 Single domains within each module 
perform each necessary enzymatic reaction.  
PKS and NRPS use similar mechanisms for product chain elongation. The general mechanism 
is explained by the “multiple carrier thio-template mechanism” model. It shows how substrate 
and intermediates are activated and processed. 
[103;104]
 All building blocks are covalently 
tethered to a carrier protein (CP) via a thioester bond to the terminal thiol of 
4'-phosphopantetheine (4’-ppant) arm in every module. NRPS CPs are peptidyl CPs (or PCPs) 
and PKS are acyl CPs (or ACPs). Each CP has to be converted from its inactive form (apo) to 
its active form (holo) by a phosphopantetheinyltransferase (PPTase) enzyme (Figure 
5). 
[105;106]
 The coenzyme A is post-translational attached by the PPTase to a highly conserved 
serine residue located in the carrier domain of PKS or NRPS proteins. 
[107]
  
The phosphopantetheine arm fulfills two functions. One is to tether the intermediate 
covalently to the module. And the second one is the transport of the intermediate to each 
active site within the module and to pass it on to the downstream module. 
[107]
 This can be 
done because of the high flexibility of the approx. 20Ǻ long ppant arm. 
 
Figure 5:  Posttranslational activation of the apo-carrier protein via the 
phosphopantetheinyltransferase into the active holo-carrier protein. 
In some cases, NRPS or PKS work in an archetypal manner, with each module being used 
once (noniterative) and the reactions taking place in the order of domain arrangement in the 
genes, following the so-called “co-linearity rule”. [108] If so bioinformatic tools can be used to 
predict the specificity of the domains such that the utilized monomeric building blocks are 
known. 
[102;105;109]
 When the genes are arranged in the classical order, then in principle it is 
feasible to predict the final structure in silico and the bacterial extract can be analyzed for the 
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expected compound. However, this is only possible if the gene cluster fits to the “colinearity 
rule”, with every domain performing its predicted reaction one after another without 
exception. 
[110]
 Unfortunately, in many cases, especially for myxobacteria, the correlation 
between gene and function is not straightforwardly identified, as iterative use of modules 
(more than one round of chain extension is catalyzed by a module) or skipping of modules (a 
module is omitted) occurs or unusual starter units or building blocks are incorporated. 
[47;108]
  
 
5.1.1 Biochemistry of nonribosomal peptide synthetases  
Nonribosomal peptide synthetases (NRPS) appear mainly in bacteria and fungi. In the 
biosynthesis of NRPS, single amino acids are attached to each other. The core NRPS module 
consists of an adenylation (A) domain, a condensation (C) domain, and a peptidyl carrier 
protein (PCP, or thiolation (T) domain). Within the loading (or starting) module the C domain 
is typically lacking. 
[105]
 NRPS biosynthesis starts with the selection and activation of a 
specific amino acid chosen by the A domain. In comparison to ribosomal peptide synthesis, 
non-proteinogenic amino acids and aryl acids can also be selected, increasing the structural 
diversity of NRPS. 
[105;106]
 The selected amino acid is activated by the A domain, a process 
which consumes ATP (Figure 6).  
 
 
Figure 6:  Substrate recognition and activation and by the adenylation domain. 
The selected amino acid is loaded and covalent bound onto the PCP of the loading module. 
Another amino acid is selected and loaded by the A domain of the following module onto the 
PCP of this module. In the next step the condensation of both amino acids catalyzed by the C 
domain takes place. The N-terminal end of the PCP-bound amino acid attacks the acyl group 
of the substrate bound to the preceding PCP in the assembly line. By this nucleophilic 
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reaction, a new peptide bond is formed and the substrate is extended by one amino acid 
(Figure 7). These steps are repeated by every module until the last one in the assembly line is 
reached. The last module typically contains a thioesterase (TE) domain, which is in charge of 
releasing the complete product from its assembly line. Either by catalyzing the hydrolysis of 
the enzyme-bound thioester intermediate to build a free carboxylic acid, or by internal 
macrocyclization. 
[108]
 The free acid is hydrolyzed in the presence of water. While for the ring 
closure, a nucleophile (typically a -OH or -NH2 group) from somewhere in the backbone is 
required to form the ring at the PCP-bound acyl group. 
 
 
Figure 7: Schematic representation of reactions performed by nonribosomal peptide synthetases 
(NRPS). Selection and activation of the starter unit by the A domain of module n. And 
selection and activation of the elongation unit by the A domain of module n+1. After the 
starter unit and the elongation unit are covalently linked to the PCPs the elongation 
occurs via condensation catalyzed by the C domain. This results in a chain transfer to 
module n+1.  
Aside from these minimal modules (containing C, A, PCP domain) there are several optional 
domains that are able to alter the product during assembly. Methyltransferase (MT) domains 
methylate nitrogens, oxygens, or carbons, and are often integrated into A domains. 
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Heterocyclization (HC) domains are able to form heterocycles by using the side chains of 
threonine, cysteine, serine and acyl groups from the backbone. 
[106]
 Oxidation (Ox) domains 
can further oxidize the compound using FMN as cofactor. They often exist together with other 
domains and are integrated into A domains. 
[106]
 Epimerase (E) domains can invert 
α-stereocenters of amino acids to the D-form. But there are also known cases where D-amino 
acids are directly incorporated, as in the case of cyclosporine. 
[111]
 Or in other cases, the C 
domain is capable of both reactions the condensation and the epimerization. 
[112]
  
The products can be further modified via tailoring enzymes, resulting in halogenation or 
cross-linking of amino acid side chains. 
[108;113]
 Such post-NRPS modifications by additional 
enzymes are quite common. Noteworthy are glycosylations, hydroxylations, acylations, 
double bond introduction, removal, O-, N- or C-methylations, or epoxidations.
[106] 
 
Since the crystal structure of the gramicidin S synthetase PheA was analyzed in detail the A 
domain specificity can be predicted from the primary sequence of the protein. From the 
crystal structure it was observed that 8 to 10 amino acid residues in the binding pocket are 
critical for the recognition of the incorporated amino acid. 
[114-116]
 But structural data is only 
available for a limited number of A domains and therefore the deduced nonribosmal code is 
not yet fully understood. Thus it is still not possible to confidently predict every specific 
amino acid chosen by the each A domain.  
 
5.1.2 Polyketide synthases 
The compound backbone of a polyketide (PK) is constructed by acyl-CoAs. The biosynthetic 
principle of a polyketide synthase (PKS) is similar to fatty acid biosynthesis and comparable 
to NRPSs. There are three essential domains in a minimal module, as well as some additional 
ones. The three core domains are the acyltransferase (AT), the ketosynthase (KS) and the acyl 
carrier protein (ACP). The AT acts analogously to the A domain in NRPS biosynthesis. The 
starting AT selects the starter unit, usually an acetyl- or a propionyl-CoA. Exceptions such as 
branched-chain CoAs or aromatic carboxylic acids are also known. 
[98;117-119]
 For chain 
extension, malonyl-CoA or methylmalonyl-CoA are typically employed. Nonetheless, 
hydroxymalonyl-CoA, methoxymalonyl-CoA, and aminomalonyl-CoA have also been 
reported. 
[120-123]
 The selected building blocks of the AT domains can be predicted in silico, 
too, like for the A domains. This predication relies on conserved amino acid motifs within the 
sequence. 
[109;124;125]
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The selected extender unit is transferred onto the 4'-PPant arm of the acyl carrier protein 
(ACP), similar to the PCP in NRPS biosynthesis. The extender unit bound to the ACP is 
decarboxylated to build an enolate which attacks the thioester of the KS. As result the 
extender unit is condensed with the intermediate via a Claisen-like condensation catalyzed by 
the KS (Figure 8). The KS in the PKS synthesis is the analog to the C domain in the NRPS 
pathway. But compared to the C domains the polyketide intermediate is covalently bound to 
the KS. The intermediate is transferred by transthioesterification from the ACP to the 
conserved active site cysteine of the KS. Resulting in an extended intermediate covalently 
bound to the ACP of the extension module. From that point it can be continued with the 
subsequent module.  
 
Figure 8:  Schematic biosynthesis of polyketide synthase (PKS). The selection of starter unit is 
performed by the AT domain and the unit is then loaded onto ACP. The extension on 
ACP2 is accomplished by decarboxylative condensation by a KS domain. 
 
These minimum modules can be supplemented by several reductive domains: β-ketoacyl 
reductase (KR), which reduce a keto group to an alcohol; β-hydroxyacyl dehydratases (DH), 
which eliminate water and form a double bond; and enoyl reductases (ER), capable of 
reducing this double bond to a methylene group. In addition, there are C-, O-, and N-
methyltransferases (MT).  
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PKS systems are classified into different groups depending on their enzymatic pathways. In 
bacteria, the most common are type I PKSs. Here, we have modular organization, where each 
module fulfills one round of chain extension. 
[106;110]
 The multifunctional enzymes contain 
non-iterative modules. 
[110]
 Good examples of type I PKS products are erythromycin, 
monensin, and amphotericin. 
Type II PKSs are iteratively-acting multienzyme complexes, often producing aromatic or 
polycyclic polyketides, 
[126]
 such as tetracycline and daunorubicin. Similar to chalcone 
synthase are the type III PKSs. These type III PKSs are homodimeric enzymes acting 
iteratively. Flaviolin for example is a result of a type III PKS biosynthesis. 
 
5.1.3 PKS-NRPS hybrids 
NRPS-PKS hybrid metabolites are a composed of short chain carboxylic acids and amino 
acids. 
[127]
 The PKS and the NRPS machinery can be combined to produce mixed products. 
These hybrid products can either be produced in one assembly chain or in two. In the latter 
one PKS and one NRPS assembly produce each an intermediate which is then stitched 
together post-synthetically; 
[128;129]
 coronatine for example is produced via this 
mechanism. 
[130-132]
 In hybrid assembly lines the KS domains are modified to accept a peptidyl 
intermediate for condensation; conversely, the C domain must accept a ketide. The same 
holds true for PCPs and ACPs; they must interact with each other or at least submit the 
intermediates to each other, in order to form a functional assembly line. To overcome such 
difficulties, the different modules are connected by “linkers” and “docking domains”. 
Chondrochloren (15), which is also a subject of investigation in the present work, is the 
product of a hybrid PKS-NRPS biosynthetic pathway (Figure 9). 
[133]
 In total, the 
chondrochloren gene cluster exhibits 12 open reading frames, five of which are PKS genes 
and one NRPS gene. It is a neat example where different numbers of reductive domains are 
also present in each module. The biosynthesis begins with a butyrate starter unit chosen by 
coenzyme A ligase (CL). Module one houses a full reductive loop (DH, ER, KR); while 
module two contains only a DH and a KR domain; and module three has just one inactive DH 
domain. Module four is similar to module two and the last PKS module has a KR and a MT, 
followed by four ORFs with different functions. The NRPS module contains the core domains 
(C, A, PCP) and a TE. After the release of the compound by the TE, it is further modified by 
CndG which decarboxylates the pre-chondrochlorens. 
[134]
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Figure 9:  Mixed PKS-NRPS biosynthetic pathway of chondrochloren A and B. cndA to cndE are 
PKS genes, cndF is a NRPS gene; CL = CoA-ligase; ACP = acyl carrier protein; KS = 
ketosynthase; AT = acyltransferase; DH = dehydratase; ER = enoyl reductase; KR = β-
ketoacyl reductases; MT = methyltransferase; C = condensation; A = adenylation; PCP = 
peptidyl carrier protein; TE = thioesterase. 
 
5.2 Post-assembly line modifications 
The released product can further be modified by other enzymes, yielding the final 
product. 
[135;136]
 Possible modifications include methylation, glycosylation, halogenation, and 
hydroxylation. 
[110;135;137]
 Halogenation and glycosylation are unusual for most myxobacterial 
compounds, but are known in some cases e.g. in the biosynthesis of chondrochloren (Figure 
9) (halogenation), and chivosazol (19) (glycosylation). 
[29;45;47;75;138]
 More common are 
acylations, hydroxylations and methylations. 
[43]
 Often, these final modification steps are 
essential for the bioactivity of the molecule. Investigations on such enzymes are usually 
aimed at substrate specificity determination to find out whether they exhibit potential for use 
as biocatalysts. 
[139]
 Glycotransferases and P450 enzymes have been shown to be useful for 
such applications. 
[140-142]
 Genetic manipulation, for example, enabled different sugar 
substrates to be accepted and subsequently attached to the original core structure. 
[140]
  
Introduction 
 
 
19 
 
5.3 Biochemistry of ribosomally-produced peptides 
NRPS and PKS are usually encoded by large, highly conserved genes that are easily 
detectable in the genome. In contrast, genes for ribosomally synthesized peptides are short 
and not as obvious. 
In ribosomal peptide (RP) synthesis, only the 20 proteinogenic amino acids are incorporated, 
as encoded by the triplet in the mRNA. Normally, a precursor peptide is encoded in front of 
the peptide sequence, which codes for a recognition sequence for a protease. 
[143;144]
 Further 
sequences for peptide-modifying enzymes involved in post-translational modifications are 
often arranged nearby. The general layout of an RP biosynthetic gene encodes a signal 
peptide, leader peptide, and a core peptide, followed by a recognition sequence (Figure 10). 
The N-terminal leader and the C-terminal core peptide are crucial for processing. The 
precursor peptide encodes a peptide leader extension at the N-terminus. The C-terminal side 
codes for the core peptide, leading to the mature natural compound. The stretch of sequence 
next to it is called recognition sequence. There are several hypotheses concerning the function 
of the leader peptide, though it most likely acts as a secretion signal. Several other functions 
have been postulated; one is that it has a recognition motif for post-translational modification 
enzymes. Moreover, it may also contribute to the folding of the precursor peptide and 
stabilize it against degradation. Another idea is that it inactivates the precursor peptide inside 
the cell. The exact function of the leader peptide likely differs for every compound class. 
[145]
 
 
 
Figure 10:  Scheme of a ribosomally produced peptide. The N-terminal leader and C-terminal core 
peptide are absolutely required. Often, a signal peptide is attached to the N-terminus and 
a recognition sequence to C-terminus. The ribosomally synthesized precursor peptide can 
be modified by post-translational modification enzymes. A protease releases the product, 
which is further transported out of the cell. 
Introduction 
 
 
20 
Natural products of ribosomal origin are described in literature as bacteriocins, 
[146;147]
 
comprising of the lantibiotics and the microcins. Lantibiotics are described as antimicrobial 
substances containing intramolecular thioether cross-links found between dehydroalanine, 
dehydrobutyrine, and cysteine residues (Figure 11). 
[145;148]
 Lantibiotics are split up into four 
different subgroups. 
[149;150]
 And if there is no biological function known, they are mentioned 
in literature as lantipeptides. 
[149]
 
 
Figure 11:  Thioether cross-link formation like it occurs in lantibiotics. At first D-alanine or rather ß-
hydroxyaspartic acid is dehydrated. Then these dehydro amino acids can form a thioether 
crosslink together with cysteine. 
Microcins are low molecular mass antibacterial peptides from enterobacteria. They are 
secreted in defense against other prokaryotic species. They generally weigh less than 10 kDa 
and secretion into the extracellular medium involves ABC (ATP-binding cassette)-type 
transporters. 
[151]
 
Other notable RPs are the lasso peptides, thiostrepton 
[152]
, thiocillin 
[153]
, and thiopeptide 
[154]
. 
RPs from plants are cyanopeptides and cylotides; from fungi, α-amanitin [155] is a common 
example. Further cyclic peptides called cyanobactins, with similar gene cluster architecture, 
were recently discovered from cyanobacteria. 
[156;157]
 With the help of genome mining, several 
gene clusters responsible for thiopeptides were identified. 
[158]
 In all these cases, the gene 
cluster contained a precursor peptide coding for the protease recognition sequence and further 
sequences for post-translational modification enzymes. The coding sequences are flanked by a 
leading recognition sequence and motifs for start and stop cyclization signals. 
[143;144]
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The cyclic octapeptides patellamides (25) 
[144]
 were the first RPs isolated which are not part of 
the already long-known group of bacteriocins. Following that, trichamide (26) 
[159]
, 
microcylamide (27) 
[157]
 and the microviridins (28) 
[160]
 were published. Lately, the pace of 
discovery of ribosomally-produced natural products has been rapid. 
[144;152;155;160-163]
  
 
Figure 12:  Patellamide (25), Trichamide (26), Microcyclamide (27), Microviridin (28). 
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6. Discovery of novel myxobacterial metabolites, their structural 
characterization and elucidation of underlying biosynthetic 
pathways 
As a group, myxobacteria together produce a huge variety of secondary metabolites. Many of 
these discovered structure types are novel. The species Sorangium cellulosum for instance 
produces a host of antibiotics, many of them reveal unique structural features compared to NP 
from other microorganisms. 
[27;48]
 Although over 100 different myxobacterial core structures 
are known up to date it is likely that this is only the surface of the whole myxobacterial 
secondary metabolism. 
[48]
 To illustrate that the analysis of the genome of M. xanthus 
DK1622 revealed 18 PKS, NRPS, or hybrid gene clusters encoding for secondary 
metabolites. 
[79]
 However, prior to this study only five published compounds have been 
characterized and correlated to their corresponding gene clusters. 
That means 13 secondary metabolites have not been detected or at least not isolated and 
characterized. A possible reason for that might be the failure to find or to detect the missing 
compounds in a screening. This may not be solely due to unfavorable cultivation 
conditions, 
[87]
 but it could also be a matter of detection sensitivity. Manual data analysis is 
not able to realize small differences within the data. Therefore, new screening platforms have 
to be developed with a low detection limit. Furthermore statistical methods can be 
implemented to decrease the manual burden of analysis. 
[51;164] 
The detection limit depends on the screening method. Investigations of secondary metabolite 
via mass spectrometry (MS) for example, require only a few micrograms of substance. MS 
can provide a wealth of information, allowing the prediction of a sum formula, as well as 
reveal structural information by fragmentation patterns. Structure elucidation is essential for 
further studies on the metabolite, like analysis of its biosynthetic gene clusters or for the 
chemical synthesis. However, larger amounts are required to obtain sufficient information for 
complete structure elucidation by other methods.  
Together with the MS information nuclear magnetic resonance (NMR) spectroscopy or X-ray 
crystallography are used for complete structure elucidation. Compared to MS the NMR 
spectroscopy and the X-ray crystallography have the advantage that these are non-destructive 
methods. One distinct benefit of NMR spectrometry compared to X-ray crystallography is that 
it does not require any crystals, which need even more material. 
[165]
 Furthermore NMR can 
be coupled to HPLC systems. 
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However if only small amounts of a compound are available sensitive methods are needed. To 
increase the sensitivity of NMR spectroscopy, the magnetic field can be increased or the 
probe can be modified. As changes in the magnetic field are limited due to technical reasons, 
it is more practical to change the probe. Capillary and micro-cryoprobes are valuable 
developments that help to increase the sensitivity in NMR spectroscopy. These probes result 
in a 10 – 20-fold increase in mass sensitivity compared to a conventional 5 mm probe. Of 
course one reason for the enhancement is a more concentrated sample due to less solvent 
(5 mm tube approx. 600 µL; 1.7 mm tube approx. 35 µL and 1 mm tube approx.7 µL). 
Another reason is that nearly all electronic noise is eliminated with the cryoprobes as they are 
chilled to 20 K. 
[165]
 
Typically NMR data interpretation leads to the correct molecular structure of a secondary 
metabolite. But if the interpretation of the NMR data is difficult in silico prediction of the 
structure might be helpful. For such prediction the biosynthetic gene cluster sequence has to 
be available. In silico Modules and domains will be assigned and substrate specificities will 
be predicted. But as these predictions are not always possible or reliable, finally the structure 
of the metabolite is still needed. 
Another alternative to identify unknown structures of compound which are only available in 
insufficient amounts is to increase their production rate by genetic engineering, followed by 
subsequent compound isolation. For doing genetic engineering the knowledge of the 
biosynthetic gene cluster is needed. Such information is also of increasing relevance for all 
biologically active compounds as sufficient yields of product are often not achievable by total 
synthesis. As well, the underlying enzymatic functions may be of interest to create novel 
derivatives by manipulation of the biosynthetic pathway. 
[91]
 Often these compounds have the 
same mode-of-action but differ in efficacy. It may also be advantageous to transfer the 
complete biosynthetic gene cluster into a new host with easier cultivation properties. 
[92]
 For 
example, a good heterologous expression host may be simpler to handle or has faster growth 
than the native organism and therefore it can be used to produce larger amounts of a natural 
compound. 
Recently, more and more gene cluster information is obtained by sequencing complete 
genomes. The genome is analyzed in silico for biosynthetic genes, followed by targeted gene 
inactivation within a cluster of interest. Subsequent comparative analysis of secondary 
metabolome between wild type and mutant leads to a correlation of the biosynthetic genes. A 
lack of metabolite production indicates the inactivation of the correct gene cluster. 
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As costs for genome sequencing decrease, the technique of genome mining is more often 
applied. 
[166-168]
 Within the next few years an enormous boost of sequenced microorganisms is 
expected. By August 2009, around 800 bacterial genomes had been sequenced and about 700 
incomplete ones have been deposited in the publicly accessible databases. 
[145]
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7. Outline of this work 
The purpose of this thesis was to investigate the secondary metabolism of myxobacteria, with 
major focus on the search for novel natural products from these microorganisms. The goal 
was to discover novel secondary metabolites and to isolate and characterize them with 
spectroscopic methods. The secondary metabolite profiles of M. xanthus strains should be 
screened for novel substances via HPLC-MS (high performance liquid chromatography 
coupled with mass spectrometry). 
As bacteria produce secondary metabolites via several different biosynthetic pathways, 
another goal was to examine how the compounds are generated, which genetic machinery is 
involved, and what possibilities there are to manipulate them to obtain unnatural derivatives. 
 
Chapter 1 explores the topic of the bicyclic tetrapeptide cittilin (RP66453, Figure 13) 
produced by M. xanthus. 
[169-171]
 Investigations of further M. xanthus isolates revealed that the 
majority of the strains produce cittilin. 
[51]
 Its production is described form an Actinomycetes 
strain, too. 
[172]
 Two cittilin derivatives are known, differing from each other by a methylation 
of the hydroxyl group of the first tyrosine. But the structural striking features of cittilin are the 
two aryl crosslinks between the tyrosine rings; one is a carbon link, but the other an ether 
connection. Cittilin B has been described as a neurotensin antagonist (neurotensin receptor 
from guinea pigs IC50 = 30 mg / mL). 
[170;172]
 Therefore, it might be used as a lead structure 
for the development of antipsychotic pharmaceuticals. 
 
Figure 13:  Cittilin A (29) and B (30), secondary metabolites produced by many M. xanthus strains. 
The genetic origin of cittilin remained elusive so far. The question of an NRPS or a ribosomal 
biosynthetic locus emerged. Therefore, the first goal was to identify the genes responsible for 
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the cittilin pathway. The genome of DK1622 and DK896 were screened for the genetic origin 
of cittilin and the biosynthetic pathway was assessed.  
Efforts were also made to exploit the biosynthetic machinery for the generation of novel 
cittilin derivatives by genetic engineering. The results were monitored by high performance 
liquid chromatography coupled to high resolution mass spectrometry (HPLC-HRMS) and 
HRMS/MS. 
 
M. xanthus was shown to be a multi-producer of secondary metabolites. For DK1622 it was 
reported that it exhibits further gene clusters for unknown secondary metabolites. In a 
screening of 98 M. xanthus strains several unknown secondary metabolites were discovered 
but neither there structure nor their corresponding biosynthetic genes were known. 
[51]
 
Therefore, the goal was to isolate and structurally characterize some of these unknown 
M. xanthus compounds with all structural variants. By feeding of isotope labeled precursors, 
HR-MS and HR-MS/MS analysis, in combination of NMR-based experiments, the novel 
compounds were characterized. The data from different methods were pooled to generate a 
molecular “dossier” used in suggesting a final structure. 
Beside the structure, the correlation of the biosynthetic gene cluster was of special interest. 
After identification of the responsible genes in silico gene analysis, genetic manipulation of 
producers and feeding experiments led to further understanding of biosynthetic pathways. 
Furthermore it is possible to optimize the production rate by promoter insertion. That led to 
sufficient yields for isolation of compounds that were only produced in small quantities. 
The novel myxoprincomides and their biosynthetic pathways are illustrated in chapter 2. 
Myxoprincomides of DK897 are described in chapter 2A while the analogous version of 
DK1622 was investigated in chapter 2B. 
 
Chapter 3 deals with chondrochloren, a secondary metabolite with weak antibiotic activity 
produced by Chondromyces crocatus Cm c5. 
[77]
 Its biosynthesis has been described by 
Rachid et al. 
[133]
 But the exact formation of the final product remained elusive. Therefore, 
S. Rachid has inactivated the oxidative decarboxylase CndG in the chondrochloren gene 
cluster. The obtained mutant produced carboxylated chondrochloren A and B (pre-
chondrochlorens) instead of the chondrochloren itself (Figure 14). This so called pre-
chondrochloren were isolated so that it could be used for in vitro experiments to identify the 
molecular mechanisms underlying the decarboxylation. 
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Figure 14:  Pre-chondrochloren A (31, left) and B are converted by CndG to Chondrochloren A (32, right) 
and B. 
 
Novel spirangiens are presented in Chapter 4. These secondary metabolites are produced by 
Sorangium cellulosum So ce90, best known as a producer of epothilone. 
[173;174]
 Spirangien 
(Figure 15) has been previously shown to exhibit antifungal and highly cytotoxic properties. 
Spirangien contains a polyketide backbone with a spiroketal in the centre and a chromophore 
consisting of five conjugated double bonds.  
 
Figure 15:  Spirangien A (33, R = Me) and Spirangien B (34, R = Et) produced by Sorangium 
cellulosum So ce90. 
In the course on the identification of the biosynthetic gene clusters by Frank et al. 
[175]
, a 
spontaneous mutant occurred. It lacked spirangien production but four novel derivatives with 
lower molecular weight were detected. To reveal the molecular mechanisms underlying in the 
production of the novel spirangien derivatives these light- and oxygen-sensitive compounds 
were isolated and characterized by NMR experiments. 
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Chapter 1 
 
Cittilin, an unusual ribosomally produced secondary 
metabolite from Myxococcus xanthus 
 
Abstract 
Cittilins are bicyclic tetrapeptides which are produced by the majority of known Myxococcus 
xanthus strains. Unlike many other myxobacterial secondary metabolites the cittilins are no 
products of NRPS-based biosynthesis, instead they are formed via the bacterial ribosome. In 
this work the biosynthetic machinery underlying the formation of cittilins is investigated. 
Heterologous expression of the cit operon in the myxobacterium S. aurantiaca confirms the 
ribosome-dependent biosynthetic route, and knockout experiments provide evidence for the 
involvement of a methyltransferase and a P450 oxidoreductase in the post-translational 
modification of cittilins. Furthermore, the possibility to generate novel cittilin derivatives by 
directed mutagenesis of the gene encoding cittilin precursor is demonstrated. 
 
Introduction  
Myxobacteria are a rich source of natural products. More than 100 core structures of 
secondary metabolites from myxobacteria are known. 
[38]
 The best studied myxobacterium is 
Myxococcus xanthus DK1622, which was intensely investigated because of its intriguing 
biological characteristics. But DK1622 has also been shown to produce several secondary 
metabolites: the myxalamides 
[82]
, the myxochelins 
[83]
, the myxovirescins 
[84]
, the 
myxochromides 
[85]
, DKxanthenes 
[86]
 myxoprincomides 
[176]
 and cittilins. The cittilins A (35) 
and B (RP-66453; 36) are produced by more than half of all known Myxococcus xanthus 
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strains investigated in a M. xanthus screening 
[51]
 and by some Streptomyces sp.. The cittilins 
were originally isolated and their planar structures solved by Trowitzsch-Kienast and 
coworkers in the course of their work on the myxobacterial metabolite saframcin. 
[169-171]
 The 
structure of cittilin B (36) has previously been reported from Streptomyces strain 9738, where 
it was named RP-66453 (36). Studies have shown that 36 binds specifically to the neurotensin 
receptor from guinea-pig (IC50 = 4.86 x 10
-5
 M). 
[170;172]
 This drug target is very important for 
the development of antipsychotic pharmaceuticals. Chemical modification of the molecule 
indeed yielded in an effective and patented neurotensin antagonists, which may be useful for 
treatment of Alzheimer's and Parkinson's diseases. 
[177]
 Two natural cittilin derivatives are 
known, 35 and 36, the difference being a methyl substitution at the hydroxyl group of the first 
tyrosine ring. The cittilins are bicyclic tetrapeptides, containing three tyrosine residues and 
one isoleucine amino acid residue. The tyrosine rings are connected via a C-C bridge and a C-
O-C linkage, similarly to the substructure found in balhimycin. 
[178]
 Thus, the cittilins belong 
to a group of macrocycles with aryl – aryl and aryl – aryl - ether bonds like in vancomycin 
(37), kistamine 
[179]
 and chloropeptin 
[180]
. It has been shown that formation of these aryl 
bonds can be catalyzed in nature by cytochrome P450 enzymes. The biosynthesis of 
vancomycin (37) constitutes a well-studied example for both types of bond-forming reactions. 
[181]
 
The absolute stereochemistry of the cittilins was not solved after the initial isolation and NMR 
analysis by Trowitzsch-Kienast et al. nor by Helynck et al.. Stereochemcial determination was 
accomplished later by total synthesis; all five carbonic stereo centers and the atropisomerism 
of the biaryl axis have been determined by Boger et al. 
[182-185] 
The absolute configuration of 
(36) has been assigned for the carbonic stereo centers as all S configuration which means that 
all amino acids are in the L-configuration and the molecule axis has a R configuration. 
 
Figure 16: 35 Cittilin A      36 Cittilin B (RP-66453) 
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Many secondary metabolites produced by myxobacteria or other microorganisms are peptides. 
The structural class of peptides is biosynthetically often derived from non-ribosomal peptide 
synthetase (NRPS) assembly lines. 
[105]
 A typical example for such an NRPS product is the 
antibiotic gramicidin. 
[186;187]
 It is a linear peptide made from combinations of up to 15 D and 
L amino acids. However, in a growing number of recent reports it has been shown that such 
highly modified peptides like the patellamides (38) 
[144]
 and the microviridins (28) can also be 
produced by a ribosomal pathway. 
[157;160]
 Exhibiting various tailoring enzymes for peptide 
modifications like cyclases, methyltransferases to give some examples. The ribosomal peptide 
(RP) synthesis incorporates only the 20 proteinogenic amino acids which are encoded by the 
three letter code. The RP synthesis is the general way for the primary metabolism to 
synthesize peptides. For the secondary metabolism a typical RP gene cluster contains a signal 
peptide, a leader peptide, a core peptide followed by a recognition sequence and further 
modifying enzymes. 
[143;144]
 Such biosynthetic architecture is known form microcins and 
lantibiotics, both are two long known classes of ribosomal peptides. Another big group 
comprises the recently published cyanobactins produced by cyanobacteria. 
[156;157]
 
 
 
Figure 17: Vancomycin (37)  Patellamide (38)    Microviridin (39)  
In this work the cittilins A (35) and B (36) are revealed as representatives of a novel class of 
ribosomal peptides. In comparison to the previously known groups, the cittilins exhibit a 
fascinating structure consisting of a bicyclic cross-linked tetrapeptide. The cyclization is 
unusual as it is neither formed by a typical peptide – peptide backbone ring closure as found 
Chapter 1: Cittilin 
 
 
32 
in 38 nor does it incorporate cysteine residues as in the case of the lantibiotics. 
[145;148]
 The C-
C and C-O connectivity in the cittilin structure thus resembles more the non-ribosomally 
generated vancomycin (37). 
[181] 
Here it could be shown by heterologous expression that cittilin is biosynthetically produced 
by a ribosome-dependent pathway. Cittilin is the first known myxobacterial compound for 
which the ribosomal synthesis could be demonstrated. Aside from a very short sequence 
region, only one P450 enzyme and one methyltransferase is required to generate cittilin. 
Efforts were also made to exploit the cittilin biosynthetic machinery for the generation of 
novel derivatives by genetic engineering. 
 
Results and Discussion 
During the LC-MS guided workup of an M. xanthus DK897 extract a compound giving rise to 
a signal of m/z = 631.2754 [M+H]
+
, which matched the molecular formula of Cittilin A (calc. 
for C34H39N4O8, 631.2762 [M+H]
+
). Its MS and MS
2
 spectra are depicted in Figure 18. The 
corresponding peak showed a UV maximum at 290 nm (Supplementary figure 4) and was 
present in fair amounts to be isolated. The extract was partitioned by a methanolic Sephadex
®
 
LH20 column, followed by gradient silica gel column. A final methanol - water (3:2) 
Sephadex
®
 LH20 column yielded the pure compound. The structure was subsequently solved 
by NMR spectroscopy (data presented in Table 1). A comparison of the final structure with 
literature data revealed the compounds as the known cittilins A and B.  
 
Figure 18:  MS spectrum of cittilin A (top) and its MS2 spectrum (bottom).  
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Amino acid Position 
Cittilin A
 
1
H (J ) 
 
13
C 
Cittilin B
 
1
H (J ) 
 
13
C 
 
m
 
ppm (Hz) ppm ppm (Hz) ppm  
Tyrosine 1 1-CO  169.9  170.1  
 2-CH 4.21 53.8 4.08 54.1 m 
 3a-CHH 3.46 36.7 3.41 37.6 m 
 3b-CHH 3.05 (6 / 15) 36.7 2.99 (6 / 15) 37.6 dd 
 4-C  129.7  128.0  
 5-CH 6.92 137.0 6.90 137.0 m 
 6-C  125.9  125.6  
 7-C  157.9  155.9  
 8-CH 7.21 (2 / 8) 131.7 7.19 (2 / 8) 131.7 dd 
 9-CH 7.01 (9) 112.0 6.98 (8) 111.8 d 
 O-CH3 3.88 56.3   s 
       
Isoleucine 1-CO  169.9 - 171.7  
 2-CH 4.20 60.1 4.16 60.0 m 
 3-CH 1.77 37.1 1.77 37.1 m 
 4a-CHH 1.61 26.3 1.62 26.4 m 
 4b-CHH 1.27 26.3 1.26 26.4 m 
 5-CH3 0.95 (7) 15.7 0.96 (6) 15.9 d 
 6-CH3 0.92 (7) 11.0 0.92 (7) 10.9 t 
       
Tyrosine 2 1-CO  173.0  171.5  
 2-CH 3.68 59.8 3.68 59.8 m 
 3a-CHH 3.10 (2 / 14) 40.7 3.16 (2 / 13) 40.7 dd 
 3b-CHH 2.47 (4 / 13) 41.0 2.47 (4 / 14) 40.9 dd 
 4-C  136.6  135.4  
 5-CH 5.78 (2) 120.7 5.80 (2) 120.8 d 
 6-C  154.2  152.6  
 7-C  145.2  143.3  
 8-C  129.7  129.6  
 9-CH 6.62 (2) 126.3 6.63 (2) 126.4 d 
       
Tyrosine 3 1-CO  176.8  175.2  
 2-CH 4.30 54.2 4.26 54.7 m 
 3a-CHH 3.61 37.3 3.61 37.4 m 
 3b-CHH 2.98 (7 / 14) 37.3 2.94 (m) 37.4 dd 
 4-C  135.5  133.9  
 5-CH 7.22 135.4 7.19 135.4 m 
 6-CH 6.83 (3 / 8) 124.8 6.79 (3 / 9) 124.6 dd 
 7-C  164.5  162.5  
 8-CH 7.47 (2 / 8) 127.0 7.45 (3 / 9) 127.0 dd 
 9-CH 7.35 (2 /8) 130.7 7.36 (2 /8) 131.0 dd 
Table 1:  1H and 13C NMR spectral data of the cittilin A and B; recorded at 500 and 125 MHz in 
CD3OD; d, doublet; dd, doublet of doublets; s, singlet; m, multiplet. 
 
Chapter 1: Cittilin 
 
 
34 
Aiming at the analysis of intra-species metabolite diversity, a worldwide LC-MS based screen 
of 98 M. xanthus isolates has been performed previously and revealed altogether 69 strains as 
producers of cittilins. 
[51] 
LC-MS analysis of M. xanthus DK1622 extracts highlighted this 
strain as a cittilin producer as well. Therefore we set out to search the genome sequence data 
available for DK1622 
[79]
 for a potential cittilin biosynthesis gene cluster. We initially 
performed a query for typical NRPS genes based on a retro-biosynthetic analysis of cittilin. If 
cittilins were produced by a typical NRPS pathway, the gene cluster would be expected to 
contain four modules: a loading module and three extension modules with the C-terminus 
containing a thioesterase (TE) domain. The adenylation (A) domain specificities should then 
match the incorporation of three tyrosine units and one isoleucine. Furthermore a 
methyltransferase (MT) and genes facilitating the cyclization would be expected. 
Aromatization and heterocyclization processes are commonly observed for natural products 
and some well described examples exist. 
[188]
 In the case of PKS or NRPS-directed 
biosynthesis dedicated cyclization domains effect the ring formation. When a peptide is 
cyclized at the end of an assembly, the intramolecular cyclization is usually catalyzed by a 
thioesterase. Aryl – aryl linkages as they are found in the vancomycin type of peptides, 
however, have been shown to be introduced by the action of P450 enzymes. 
[181;189]
 
Yet another cyclization mode is found in the lantibiotics, where cyclizations happen in two 
sequential steps. Following the removal of a hydroxyl group of a threonine or serine by 
dehydration, a second cyclization step links the unsaturated group with a thiol group of a 
cysteine. These dehydration cyclization processes are often performed by a bifunctional 
synthetase such as LanM. 
[190]
 
 
All A domains in NRPS clusters in the genome of DK1622 were analyzed, but no NRPS 
cluster matching the retrobiosynthetic prediction could be spotted within the genome. 
Therefore we reasoned that an alternative biosynthetic pathway should exist. As cittilin 
contains only proteinogenic amino acids we considered the possibility that it could be 
assembled in ribosomal manner with additional post-translational modifications. Therefore, 
the genome was searched for a sequence encoding for ribosomal peptide biosynthesis like for 
bacteriocin-like ribosomal biosynthesis. 
[191]
 To search for a potentially matching genetic 
region the degenerated genetic code for the amino acid sequence YIYY was used as a query 
term on both strands in the DK1622 genome. Exactly one small open reading frame (orf) of 
231 bp length was detected which was followed by genes encoding for a P450 and a 
methyltransferase. Additionally, a set of ABC transporter genes was identified upstream of 
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this region. Such short orfs are difficult to detect during automatic genome annotation, as one 
typically expects much longer orfs for regions encoding biosynthetic pathways. Sequence 
analysis of the short orf reveals a hypothetical leader peptide encoding region followed by the 
12 bp stretch encoding the YIYY core peptide, terminated by a stop codon. This arrangement 
is highly unusual for ribosomal biosynthetic gene clusters, since the core peptide region 
usually continues with a recognition sequence for processing the peptide. But no typical 
motifs like the double glycine motif 
[190]
 for a recognition site for a processing protease could 
be located neither before nor after the core peptide. 
Therefore the region encoding the cittilin leader peptide was further investigated. For in-silico 
statements more sequence data from four strains cittilin producing strains (DK1622, DK897, 
A47, ST200611) were analyzed. None of them contained typical cleavage motifs, known from 
other RP, like a GG or GA 
[190]
 within the precursor peptide.  
Among the cittilin producing strains with known cittilin gene sequences, one strain 
(ST200611) was found where the hypothetical leader peptide sequence is different from the 
other strains. In ST200611 the leader peptide is 310 bp long instead of 231 bp in the other 
strains DK897, DK1622 and A47. These three other strains have exactly the same length and 
the identity on the protein level is 95 % which is a highly conserved region (Figure 19). 
 
Figure 19:  Cittilin leader peptide alignment of M. xanthus DK1622, A47 and DK897. 
Only within the first 17 amino acids are some modifications. Compared to the sequence of 
ST200611 the identity is much less (Figure 20). ST200611 contains several stop codons 
within the sequence. As all the other strains have very high similarity it could be a matter of 
sequencing errors. Therefore the region was re-sequenced via amplification by PCR. The 
sequence analysis revealed that the original sequence is indeed correct. Thus, the shortest 
encoding region without a stop codon would be 78 bp long. That means that the other 
encoding sequence before that region is apparently not absolute necessary. Consequently, a 
maximum of 26 amino acids (EFAMKKALYSLAVLMRFARADKLSAPYIYY* see Figure 
20) could be already sufficient to form a functional cittilin leader peptide.  
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Figure 20:  Cittilin leader peptide alignment of DK1622, A47, DK897 and ST200611. 
 
 
Figure 21:  Orf of YIYY region in genome of M. xanthus DK1622, maximum leader peptide (216 bp), 
ribosomal binding site (RBS), minimum leader peptide (69 bp), core peptide (12 bp) 
followed by a stop codon.  
Immediately upstream of these 78 bp stretch a possible ribosomal binding site (RBS, 
AGGAG) is present. That means that the maximum leader peptide can be reduced to 69 bp 
(Figure 21). But no further statement can be made about the function of the leader peptide. 
But it suggests that this unique sequence is involved in the processing of the tetrapeptide, or it 
stabilizes the precursor peptide against degradation. 
[145]
 To get more information about it 
could be useful to analyze the leader peptide of the other known cittilin M. xanthus producers, 
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as several are noted in a big screening project 
[51]
 e.g.: A2, A66, A98. Of course the sequence 
of Streptomyces producer strains would be very interesting as well, but finally it has to be 
proven by biochemical experiments. 
Upstream of the leader peptide region a set of ABC transporter genes are located (four orfs).  
Genes encoding possible modifying enzymes are located directly downstream of the core 
peptide sequence: a P450 and a methyltransferase. The predicted orfs in the vicinity of the 
core peptide locus are shown in Figure 22. 
The orf encoding a putative P450 enzyme starts only a few base pairs after the core peptide 
region. A protein blast search on “http://blast.ncbi.nlm.nih.gov/Blast.cgi” identified it as 
cytochrome P450 family protein, and the closest relatives are from bacterium Ellin514, 
Nostoc punctiforme PCC 73102 and Bacillus halodurans C-125 as. The typical function of 
P450 enzymes is to catalyze regiospecific and stereospecificly the oxidation of non-activated 
hydrocarbons. 
[192]
 The next open reading frame encodes for an S-adenosylmethionine-
dependent methyltransferase (MT). 
[193]
 Those MTs are typically able to attach methyl groups 
to hydroxyl groups. Here the best similarity to other methyltransferases is to genes from 
Methanoculleus marisnigri JR1, Frankia sp. EUN1f and Streptomyces sp. AA4. 
 
Figure 22:  Orfs around the cittilin core peptide: hyp = FAD-binding domain protein, 
monooxygenase; ABC III = periplasmic ferric siderophore-binding protein; perm = 
permease protein; ABC II = permease protein; ABC I = ATP-binding protein 
The P450 enzyme could take part in the cyclization of cittilin. It has two C-C linked tyrosine 
rings and two C-O-C bound tyrosines. These structural fragments are analogous to those 
found in vancomycin (37). In the vancomycin (37) biosynthesis the oxygenases OxyA, -B und 
-C are responsible for the connection. OxyA and OxyB are in charge of C-C connection and 
OxyC for the phenolic coupling. 
[181;189]
 These oxygenases are P450 enzymes and they 
perform the ring closure during the formation of the backbone. 
[189]
 Modifying enzymes in the 
RP biosynthesis are comparable enzymes and often similar to the ones in the NRPS 
biosynthesis. 
[194]
 Therefore it is most likely that the two rings of cittilin are formed via a 
similar mechanism. The methylation might be performed by the methyltransferase which is 
encoded adjacent to the P450. 
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In order to prove the involvement of the putative P450 enzyme and the methyltransferase in 
the biosynthesis of cittilin, knockout mutants were created by insertional inactivation in 
DK1622. For the P450 knockout mutant a single crossover experiment was performed. An 
internal fragment of approximately 500 bp was amplified by PCR, cloned into the pCR2.1-
TOPO vector (Invitrogen) and the resulting plasmid was introduced into the strain like it is 
often described in literature. 
[195-198]
 In the case of the methyltransferase which has a size of 
615 bp a stop codon and a frame shift were additionally added into its DNA sequence to 
ensure that the gene in the resulting mutant is inactive. 
 
Figure 23:  Extracted ion chromatogram for the mass of cittilin from crude extracts of wild type 
(above), P450- mutant (below). 
The P450 mutant showed complete abolishment of cittilin production as judged on the basis 
of LC-MS measurements (Figure 23). However, no evidence for production of the unmodified 
tetrapeptide YIYY was found. In order to exclude the possibility that failure of detection was 
due to insufficient sensitivity during the analysis, samples were compared to a synthetic 
reference for YIYY, and thereby the absence of the unmodified tetrapeptide was confirmed. 
Reasons for that might be degradation, or no secretion out of the cell, or unmodified 
tetrapeptide is only separated after it was processed by the P450. A second P450 enzyme 
could not be detected directly in the region of the cluster. But an oxidoreductase was detected 
2.7 kbp downstream of the methyltransferase (refer to Supplementary figure 10). 
Investigations of its effect on cittilin biosynthesis are ongoing. As well as the influence of a 
peptidase upstream of this oxidoreductase. However the heterologous expression showed that 
both linkages can be build if only the P450 enzyme is present.  
This is surprising as the cross links are different, the first one is a C-O linkage and the second 
one a C-C bond. Furthermore, in the case of the vancomycin (37) biosynthesis two different 
P450 enzymes are known to be responsible for these two reactions. 
[181;189]
 Therefore it cannot 
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be excluded that another enzyme encoded somewhere else in the DK1622 genome might do 
this task. 
The outcome of the methyltransferase inactivation experiment was not as unambiguous; here 
cittilin A production was still noticeable, albeit with a strong reduction in yield. It may be 
concluded that other methyltransferases in the genome are able to complement its function in 
the knockout mutant. That is known from other natural products, like in the case of 
myxochelins, where other methyltransferases encoded in the genome complement the 
knockout of the methyltransferase in the myxochelins biosynthetic gene cluster. 
[199]
 
In order to narrow down which genes are essential for cittilin biosynthesis, a heterologous 
expression of the cittilin gene locus was preformed. The gene cluster was initially amplified 
by two PCRs (1
st
 leader and core peptide; 2
nd
 P450 and methyltransferase), subcloned and 
then stitched together in the final expression vector pCK (Supplementary figure 1) to yield the 
plasmid pCK-Cittilin. The pCK plasmid 
[90]
 contains an Mx8-phage derived attP site and an 
intP site, and thus is able to integrate into the phage attachment site of various myxobacteria. 
The cloned cittilin cluster in the plasmid pCK-Cittilin is under the control of the T7A1 
promoter. T7A1 has been shown to successfully drive expression in myxobacteria. 
[200]
 As 
host strain Stigmatella aurantiaca Sg a15 was chosen, because it was expected that this host 
would supply similar cellular machinery 
[92]
 to M. xanthus and evidently no cittilin gene 
cluster is present in its genome. After transformation of the pCK-Cittilin plasmid into S. 
aurantiaca Sg a15, the heterologous expression clones were cultivated and extracts analyzed 
by LC-HR-MS measurements. Cittilin production could be detected as judged on the basis of 
high-resolution LC-MS data and tandem-MS analysis (Figure 24). Retention time and 
fragmentation pattern are clearly identical with those recorded from cittilin of the natural 
producer strain DK897 (Figure 24 and Figure 18) although the observed production level in 
the heterologous expression experiment was rather low. 
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Figure 24:  A: top base peak chromatogram of an extract from S. aurantiaca Sg a15 mutant 
comprising the cittilin genes, middle extracted ion chromatogram (EIC) of the cittilin of 
the same extract, bottom: EIC of cittilin of Sg a15 wild type extract. B: monoisotopic mass 
of cittilin produced by the Sg a15 mutant at the same retention time as the cittilin from 
DK897. C: Fragmentation pattern of cittilin produce by the Sg a15 mutant. 
This heterologous expression of cittilin shows that the essential genes for cittilin biosynthesis 
have been identified. According to the heterologous expression results, fundamental functions 
are the leader peptide, the core peptide, a P450 enzyme and a methyltransferase.  
In comparison to other known gene clusters of ribosomal peptides, the cittilin gene cluster 
exhibits some striking differences. For example, the coding sequence for a recognition site for 
a protease could not be discovered, moreover there are currently no detectable motifs for start 
or stop cyclization. 
[143;144]
 In the case of the cyanobactins the core peptide is flanked by 
putative start and stop recognition sequences. 
[156]
 Furthermore, normally the leader and the 
core peptide are separated by a GG or GA cleavage motif. 
[190]
 This indicates that a different 
recognition sequence is used in case of cittilins. Whether the leader peptide has a role to 
stabilize the precursor peptide against degradation or inactivates it inside the cell remains 
elusive. In general it has been noted that the exact function of leader peptides differs for every 
compound class. 
[145]
 
Besides Stigmatella aurantiaca Sg a15, M. xanthus A47 was tested as heterologous host for 
expression experiments of cittilin as it is a close relative to the native host, DK1622. 
MS
2
 spectra of cittilin 
HR-MS spectra of cittilin 
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Phenotypically A47 does not produce cittilin, but compared to the other heterologous strains 
Stigmatella aurantiaca Sg a15 and M. xanthus A47 produced cittilin amounts in the same 
range of the wild type strain DK897. This big difference is not easily explainable, as Sg a15 
seems to meet all requirements for the production as well and the introduced plasmid (pCK-
Cittilin) was exactly the same. Therefore available contigs containing genome sequence of 
strain A47 were analyzed for the cittilin cluster and revealed that parts of the cluster are 
present (Figure 25). The ABC transporter genes, the leader and the core peptide exist, and an 
apparently truncated P450-encoding gene is present, too. However, genes downstream of the 
P450 gene including the methyltransferase are absent. Hence no cittilin can be produced, but 
the immature peptide which is not cyclized and methylated might be released. A matching 
YIYY tetrapeptide could however not be detected using sensitive HR-LC-MS measurements, 
a result which is in agreement to the analysis of the P450 knockout mutant. For the 
heterologous expression experiment, the pCK-Cittilin plasmid integrates into the phage 
attachment site of the bacteria, which leads to a genotype in which the genes for the leader 
and the core peptide are then present twice in the genome. This could possibly increase the 
intracellular level of the tetrapeptide peptide, but more importantly it complements the A47 
strain with functional P450- and methyltransferase-encoding genes. A possible reason for 
increased production could be the natural presence of the ABC transporter genes in strain A47 
as they might play a role in processing the mature peptide. They are lacking in case of the 
heterologous expression in Sg a15, offering an explanation for minor cittilin production (ABC 
transporter genes see later on in this chapter). 
 
Figure 25:  Above complete cittilin gene cluster in DK897 and DK1622, below cittilin cluster in A47 
with defective P450 and no methyltransferase. hyp = FAD-binding domain protein, 
monooxygenase; ABC III = periplasmic ferric siderophore binding protein; perm = 
permease protein; ABC II = permease protein; ABC I = ATP-binding protein; leader 
peptide; YIYY = core peptide; P450; Met = methyltransferase. 
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As major constituent parts of the cittilin gene cluster appear to be intact in strain A47, it 
should be possible to activate it by addition of the missing genes. When the P450 and the 
methyltransferase are introduced, the gene cluster should in principle contain all necessary 
genes to resume cittilin production. The two missing genes were amplified from the 
pCKCittilin expression construct and cloned into the pCK vector. Here the genes are under 
the control of a T7A1 promoter. The resulting pCK-P450-Met plasmid was introduced into 
the strain A47. Obtained clones were cultivated and analyzed via HPLC-MS measurements. 
No cittilin production was detected. The reasons for the lack of production are not clear. One 
possibility might be that the genes are not directly behind the gene cluster as in this strategy 
the plasmid integrates into the phage attachment site. Another explanation could be that the 
P450 is shorter than predicted (the protein start could be at a different position / later on in the 
sequence) and therefore not under the control of the T7A1 promoter. Possible start codons are 
102 bp or 360 bp after the so far expected gene start. But if that is the case the gene should be 
still under the control of the natural promoter.  
Further attempts for gene cluster reactivation in A47 should be done. Alternative start codons 
for the P450-encoding gene should be tested. As an option, the genomic integration via 
single-crossover recombination downstream of the cittilin-encoding region could be 
performed by using a different plasmid which does not integrate into the phage attachment 
site. This way, it should be possible to reactivate the biosynthetic pathway, if no additional 
non-obvious mutations are present which could hypothetically render the genes naturally 
present in A47 as non-functional. 
 
Schmidt et al. have shown in their study of the patellamide biosynthetic pathway that it is 
possible to create a peptide library by site directed mutagenesis of the encoding sequence by 
PCR. 
[143]
 Making use of the knowledge that the essential functions of the cittilin gene cluster 
are now established, new cittilin derivatives were created by amplifying the core and leader 
peptide whereat the sequence of the core peptide was modified by the oligonucleotides. For 
this method the natural SpeI site and the NdeI restriction site for cloning the cluster into the 
pCK vector were used. The modified regions were sequenced for correctness. To keep the 
main architecture the three tyrosines remained untouched, and only the isoleucine was 
exchanged against glycine, alanine, asparagine and valine as a proof of principle. As the 
production rate in the heterologous host Sg a15 is very low, the pCK-cittilin vectors were 
transferred into the natural host strain M. xanthus DK897. The recombinant cittilin clones 
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produced, beside the normal cittilin, also new "unnatural" cittilin derivatives (Figure 26, 
Figure 27).  
 
Figure 26:  Cittilin A and the new cittilin derivatives where the isoleucine is exchanged against: 
leucine, valine, alanine, asparagine and glycine. 
Production of novel cittilin derivatives was unambiguously proven by LC-HR-MS and 
tandem MS and it was confirmed that none of the new substances are produced by the wild 
type DK897 (Figure 27). For val-cittilin we virtually detect two matching peaks at distinct 
retention times, as it has the same mass as the natural cittilin B. All measured masses agree 
well with the proposed molecular formulas for the new derivatives (Figure 28). As isoleucine 
can be exchanged by five other structurally diverse amino acids, it is supposable that the other 
proteinogenic amino acids could also be incorporated at the same position. However, when 
one of the tyrosine would be replaced the complete core structure is likely to undergo an 
unforeseeable change, and thus the respective experiment was not attempted in this study. In 
addition, it is unclear how in the case of Tyr substitution a cyclization would be performed by 
the biosynthetic machinery. This issue remains to be clarified in future studies. 
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Figure 27:  HR-MS chromatograms: left DK897 wild type, right DK897 mutants; top BPC, EIC on 
masses of cittilin (calc. 631.2762), gly-cittilin (calc. 575.2136), val-cittilin / cittilin B (calc. 
617.2606), ala-cittilin (calc. 589.2293) and asn-cittilin (calc. 632.2351). 
Novel cittilin derivatives were not only generated in M. xanthus DK897 but also in 
M. xanthus A9, A23 and Stigmatella aurantiaca Sg a15. The production rates were very low 
and routine LC-MS analysis did not show much production. Therefore a selective ion 
monitoring (SIM) scan from 550 - 650 m/z was preformed. With this method it was possible 
to detect some of the expected compounds in small traces, namely the leu-cittilin, asp-cittilin 
and gly-cittilin derivatives. To prove the identity of these compounds MS
2
 experiments were 
executed. This experiment showed for the leucine derivative the same fragmentation pattern 
as the one of cittilin (Figure 29). 
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Figure 28:  HR-MS spectra of the new cittilin derivatives: Val-cittilin (m/z measured 617.2598), Gly-
cittilin (m/z measured 575.2141), Asn-cittilin (m/z measured 632.2371), Ala-cittilin (m/z 
measured 589.2297). 
 
Figure 29:  A: SIM scan 550 -650 m/z of Leu A23 mutant extract; B: mass spectra of leu-cittilin; C: 
MS2 of leu-cittilin 
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These results show in general that cittilin cannot only be modified artificially in the wild type 
strain, it is possible in heterologous host, too.  
 
By the heterologous expression of the cittilin gene cluster it was shown that one P450 is 
apparently sufficient for the bicyclization of the peptide. But in other cases like in the 
vancomycin two different enzyme are in charge of that. 
[181;189]
 It was thought, that the hyp 
gene in front of the ABC transporter might encode for another P450 enzyme, but in strain 
ST200611 it does not exist (Figure 30). ST200611 has a different hyp2 gene in opposite 
direction at that position. The closest relative in a blast search is a dipeptidyl aminopeptidase / 
acylaminoacyl peptidase from Rhodococcus erythropolis SK121. Therefore it can be expected 
that hyp is not an essential part in the cittilin pathway.  
 
Figure 30:  Top: cittilin gene cluster in DK897 and DK1622, below cittilin cluster in ST200611. hyp = 
FAD-binding domain protein, monooxygenase; ABC III = periplasmic ferric siderophore 
binding protein; perm = permease protein; ABC II = permease protein; ABC I = ATP-
binding protein; leader peptide; YIYY = core peptide; P450; Met = methyltransferase 
hyp2 = dipeptidyl aminopeptidase / acylaminoacyl peptidase. 
Another possibility for a second P450 enzyme would be that a different enzyme is taking over 
this job, but this second enzyme would then have to be present as well in the heterologous 
host strain Sg a15.  
To answer the question if one P450 enzyme is able to perform two reactions, a C-C and a 
phenolic connection, the enzyme should be expressed and an in vitro assay with the precursor 
peptide should be carried out. Hence at first an expression construct for protein expression 
had to be designed, so that the protein can be isolated by chromatographic methods. Therefore 
a tag has to be fused to the protein which can be removed later on. Furthermore it had to be 
decided at which side the tag should be attached. For it, the P450 was compared to the 
vancomycin types of P450, they contain there characteristic sequence motive at the C-
terminus 
[189;201]
, so it was assumed that it is the same case here. Therefore the tag should be 
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placed at the N-terminus. Primers were designed to amplify the P450 gene and to introduce 
restriction sites which enable it to be introduced in the pSUMO ck4 vector (LifeSensors) 
(Supplementary figure 2) and the pet-28a vector (Supplementary figure 3). Both vectors 
contain a tag sequence which is arranged at the N-terminus of the protein. The P450 gene of 
DK1622 was amplified by Phusion
®
 polymerase (Finnzymes) and cloned into both vectors. 
The proteins were extracted from the received clones and loaded on a SDS-Gel. No band with 
a correct size could be detected on the gel. Therefore the plasmid was transformed into the 
BL21
+
 and examined in the same manner. A band with the correct size at 54 kDa was detected 
in the pellet but not in the supernatant (Figure 31). The band was analyzed via MALDI and 
proven to be the correct P450 protein. 
 
 
Figure 31:  SDS gel: left marker; middle pellet; right supernatant; the 54 kDA band (marked with 
arrow and cut out for analysis) was analyzed via MALDI. 
To get the P450 protein into the soluble phase it was expressed together with some 
chaperones pGro7 (TaKaRa), pKJE7 (TaKaRa) and pL1SL2 
[202]
 in BL21
+
 and the latter in 
Rosetta as well. Clones with the TaKaRa plasmids were induced with L-Arabinose and IPTG, 
pL1SL2 only with IPTG. The cultures were treated as described above. The result is shown in 
Figure 32 no P450 enzyme in the soluble phase only in the pellet. To make sure that the 
slightly bigger bands are not the intended proteins they were analyzed by MALDI as well. But 
the bands were identified as chaperones. 
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Figure 32:  SDS gel: 1. Marker; pellets of 2. pGro7, 3. pKJE7, 4. pL1SL2; supernatant of: 5. pGro7, 6. 
pKJE7 and 7. pL1SL2; the marked region were analyzed by MALDI. 
These results demonstrate that it is not easy to bring the P450 protein from the cittilin cluster 
into a soluble form. Here more advanced techniques are required. As a workaround, an assay 
with the cells of these expression mutants and the tetrapeptide YIYY was attempted. Cells 
were sonicated and the linear tetrapeptide was added. The mixture was extracted with 
acetonitrile and analyzed in the HPLC-MS to see if YIYY is converted into cittilin. But no 
cittilin was found, and after incubation the tetrapeptide could not be detected anymore. This 
finding hints at a rapid degradation processes. In this case it might be useful to express the 
whole leader peptide as a fusion protein as this might protect it from degradation.  
As no pure enzyme could be isolated and the assay with the crude cells failed, no conclusion 
can be made about the enzymatic function of the cyclization procedure of cittilin. Therefore 
this interesting point remains open for further investigations whether the P450 enzyme is able 
to perform two reactions a C-C and a phenolic connection or not. If it performs both, it might 
be a simultaneous reaction. Alternatively a different enzyme which is present as well in the 
heterologous host strain is performing this job, although this possibility is considered to be 
rather unlikely. 
 
Due to the low production rate in the heterologous expression strain Sg a15 compared to the 
natural producer M. xanthus DK897, the impact of ABC transporter genes was addressed. 
Such putative ABC transporter system exists upstream of the leader peptide region (refer to 
Figure 22). ABC I is an ATP-binding protein, ABC II and perm are permeases, the ABC III is 
a periplasmic ferric siderophore-binding protein. Upstream of that a hypothetical protein is 
encoded, exhibiting similarity to other genes with unknown function from Rhodococcus 
 1  2  3 4 5 6 7 1
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opacus B4 and Anabaena variabilis ATCC 29413. Furthermore it shows partial similarity to a 
monooxygenase FAD-binding protein from Nitrosococcus halophilus Nc4, which belongs to 
the family of 2-polyprenyl-6-methoxyphenol hydroxylases and is related to FAD-dependent 
oxidoreductases. 
These genes in front of the cittilin gene cluster might have an important role in processing the 
peptide. In view of literature reports 
[157;160;203]
 from other RP biosynthetic systems, such a 
role would be conceivable. The ABC (ATP-binding cassette)-type transporters are similar to 
the microcin biosynthetic gene cluster, where they are involved in secretion of the product 
into the extracellular medium. 
[151]
 Additional evidence for the involvement of the ABC 
transporter in cittilin production comes from the fact that these genes are present in every 
cittilin producing strain (where the cittilin sequence is known). Furthermore the Dittmann 
group could show that if they express the genes of the RP microviridin without an ABC 
transporter, the production level is very low. Moreover they were able to detect unprocessed 
compounds which contained amino acids of the leader peptide as well. However, during 
heterologous production of cittilin no unprocessed peptides were detected in the present study, 
here the transporter genes were absent. To find out if the transporter genes have an effect on 
the biosynthesis, in first instance for processing the mature peptide, an attempt was made to 
clone these genes upstream of the gene cluster and thus co-express them together with the 
cittilin cluster. As heterologous hosts M. xanthus A9 (a none cittilin producing M. xanthus 
strain) and Stigmatella aurantiaca Sg a15 were used. 
By PCR it was tried to amplify the genes in one piece (~ 5 kbp) by different polymerases 
(Taq, Phusion, HotStartTaq, KOD, GoTaq), different sets of primers and different qualities of 
genomic DNA of diverse strains. Sometimes some DNA bands were spotted but never in the 
correct size. A reason for this might be several repeats in this genome region. Hence the four 
ABC transporter genes in front of the cittilin encoding area were amplified separately to get 
small fragments at around 1 kb. To stitch the sections together on both sides of each gene, 
restriction sites had to be introduced. As only one clear ribosomal binding site (RBS) could be 
found (between ABCIII and Perm), artificial RBSs were introduced by the plasmid. The 
advantage of this strategy is that it can be shown if all four genes are necessary, typically 
ABC transporters are encoded in four genes. The single genes were cloned into the pCK-
cittilin plasmid. Restriction enzymes which do not cut in the pCK-cittilin vector, nor in the 
ABC genes and in the cittilin cluster had to be found. 12 enzymes were possible: AsiSI, AvrII, 
BamHI, BspTI, Eco105I, KspAI PacI, PmeI, PsiI, SnaBI, SspI, SwaI. As it is not clear what 
the regions between the genes are good for (and some genes are overlapping) any 
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modifications of intergenic region was to be avoided. Therefore mutations had to be 
integrated into the second or third amino acid of the genes. At the 5` end an NdeI restriction 
site was always introduced followed by another restriction site (Figure 33). On the other side 
the same restriction enzyme which was introduced in the gene before was added by a primer. 
When the cluster was stitched together the NdeI site was always deleted inside the encoding 
sequence.  
 
Figure 33:  Cittilin gene cluster with ABC transporter genes, restriction sites indicated by black bar, 
yellow arrows: primers which were used to introduce restriction sites. 
By introducing the restriction sites at the beginning of the genes following changes will occur 
in the amino acid sequence (marked in bold; original sequence => mutated sequence): ABCI: 
MIEAK => MIGSK, ABCII: VPAN => VNIN, Perm: VKRAF => VKLKF, ABCIII: 
VSPSN => VVNSN and Hyp: no changes. 
To find out which ABC gene set is really needed for the best expression the amount of cittilin 
was quantified by LC-MS measurements. For that purpose the mutants were cultivated in 
duplicates (Sg a15) or rather triplicates (A9). The cultures were extracted and quantified by 
HPLC-HR-MS measurements. An internal standard (Coumarin 314) was used for 
quantitation. The peak area of cittilin-derived MS signals were integrated and quantified by 
the Bruker QuantAnalysis software. Furthermore the data were corrected by cell density of 
the cultures. 
 
All mutants of M. xanthus A9 produced more or less the same amount of cittilin (Figure 34). 
ABCI clones a little bit more than the others but this is within the common fault tolerance. 
Here it looks like there is no influence of the ABC transporter on the cittilin production. In the 
case of the Sg a15 mutants the picture is a different one (Figure 35), here the production 
remains at the same level if only the first three genes are present. But the mutant with all four 
genes has an increase of production of around three fold. This can be considered as reasonable 
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because only here all four proteins are expressed which normally constitute an ABC 
transporter. This result shows clearly that the ABC transporter does have an influence for 
cittilin production. On the other hand it is no dramatic increase of production. A possible 
explanation for that might be that the ABC transporter is not involved in processing the 
peptide, only in transporting it out of the cell. In the absence of the transporter genes, this 
function is possibly substituted by other transport mechanisms. As a careful speculation, one 
could hypothesize that the impact on productivity should be greater if there would be an 
involvement of the transporter in processing the mature peptide. 
 
Figure 34:  Quantification of A9 Cittilin transporter mutants with different cluster length, a, b and c 
are different clones. 
A reason for no effect in the case of M. xanthus A9 might be, that parts of the gene cluster 
may be present in the genome although A9 is a none producer of cittilin. It could be similar to 
the case of A47 where a defective cittilin gene cluster was detected, however all ABC 
transporter genes being present. Therefore an addition of the already existing genes would not 
produce a noticeable effect. Here it would be mandatory to check if A9 has such an imperfect 
gene cluster, but whole genome sequence information is not currently available for this strain 
and this problematic was not known at that time point. 
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Figure 35:  Quantification of Sg a15 cittilin mutants with different cluster length, a and b are two 
different clones. 
To sum up cittilin was isolated from the crude organic extract of M. xanthus DK897. It was 
structurally characterized and afterwards cittilin B was confirmed to be identical with RP-
66453 from a Streptomyces sp. 
[172]
. Cittilin could also be detected in DK1622; a strain for 
which complete genome information was available. 
[79]
 Here the in silico search lead to the 
identification of the biosynthetic pathway which is based on the ribosome and not as initially 
expected, from NRPS origin. A heterologous expression of the cittilin gene cluster in 
Stigmatella aurantiaca Sg a15 provided evidence for the ribosomal metabolic pathway. It 
could be shown that the leader peptide, the core peptide, a P450 and a methyltransferase are 
absolute required for the biosynthesis of the molecule. Furthermore, the simple modifiability 
of ribosomal synthesis makes it possible to successfully exchange isoleucine against other 
amino acids. Several nonnatural cittilin derivatives were created by genetic modification of 
the heterologous expression construct in the original host strain and in Sg a15. 
To conclude cittilin represents the first secondary metabolite isolated from myxobacterial 
extracts for which the ribosomal synthesis has actually been proven. The discovery of the 
biosynthetic machinery underlying its formation supports the notion that there are further 
pathways for natural product production in myxobacteria which remain to be explored. Even 
though myxobacteria are well known to be ‘superproducers’ of polyketides, non-ribosomal 
polypeptides, hybrids thereof, alkaloids, terpenoids and phenyl-propanoids. 
[45;49]
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Methods 
Cultivation and extraction: the M. xanthus strains were cultivated in CTT media (10 g 
Casitone (Difco), 10 ml 0.8 M MgSO4, 10 ml 1 M Tris-HCl pH 8.0, 1 ml K2HPO4 pH 7.6 and 
1 liter distilled water, pH adjusted to 7.6, for mutants kanamycin 50 µg / ml were added). 
Stigmatella aurantiaca grew in Tryptone-Starch (TS) medium (1 % tryptone, 1.19 % HEPES, 
0.4 % soluble starch, 0.2 % MgSO4 x 7 H2O; pH adjusted to 7.2, for mutants kanamycin 50 µg 
/ ml). Bacteria strains and mutant strains were grown 50-ml medium supplemented with 1 % 
XAD-16 resin (Sigma-Aldrich), for 72 h at 180 rpm and 30 °C in 300 ml Erlenmeyer flasks. 
The cultures were centrifugation (10 min, 8000 rpm), supernatant was discarded and the 
remaining pellet was extracted with methanol (2 x 30 ml). The solvent was removed under 
vacuum and resuspended in 1 ml methanol. 
For cittilin isolation 10 l of DK897 was cultivated in large scale in 3 l Erlenmeyer flasks 
similar as described for small amounts. The obtained extract was run on a methanolic 
Sephadex
®
 LH20 column. Cittilin containing was placed on a silica gel column which was 
run with a chloroform methanol gradient (start 9:1, end pure methanol). For further 
purification another Sephadex
®
 LH20 column was performed with H2O / MeOH (3:2). 
Mass spectrometry: For LC-HR-MS an Accela UPLC system coupled to a LTQ Orbitrap 
(Thermo Scientific) with nano electrospray ionization (ESI) (TriVersa NanoMate (Advion)) 
was used. To separate the extract a gradient was run on a RP-18 column (50 mm x 2.1 mm, 
particle size 1.7 µm; Waters Acquity BEH) with water (+ 0.1 % formic acid) and acetonitrile 
(+ 0.1 % formic acid) as solvent, flow rate of 400 μl / min, gradient: 0 min 1 % B; 1 min 1 % 
B; 10 min 99 % B; 12 min 99 % B; 12.5 min 1 % B; 14 min 1 % B. For fragmentation 
experiments 30 % collision energy was used.  
For LC-MS same solvents were used under following conditions: RP-18 column (Luna, 2.5 
µm), t = 32 °C , flow rate 400 µl / min; 2 min 5 % B, 20 min 95 %, 3 min 95 %. 
 
NMR spectroscopy: NMR measurements were performed on a 500 MHz Bruker Avance 
magnet. Using Topspin2 and deuterated solvents (methanol-d4). 
 
The tetrapeptide YIYY was synthesized by the company Gen Script. 
 
Search for the cittilin cluster: For analyzing the A domains in DK1622 the following web 
tools have been used: http://nrps.igs.umaryland.edu/nrps/index.html and http://www-
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ab.informatik.uni-tuebingen.de/toolbox/index.php?view=domainpred. Cittilin contains four 
amino acids: 3 x tyrosine and 1 x isoleucine hence four possibilities were considered for a 
ribosomal search although only tyr-tyr-ile-tyr has the correct amino acid order. The codons 
for Tyrosine are: TAT and TAC, for Isoleucine: ATT, ATC and ATA. Using the degenerated 
code: Y = T or C and H = T, C or A. TAYTAYTAYATH for tyr-tyr-tyr-ile, 
TAYTAYATHTAY for tyr-tyr-ile-tyr, TAYATHTAYTAY for tyr-ile-tyr-tyr, ATHTA 
YTAYTAY for ile-tyr-tyr-tyr. It was search in the genome on both strands. 
 
Gene knockouts: The PCR fragments were amplified from genomic DNA of M. xanthus 
DK1622 with Taqpolymerase. For the methyltransferase knockout an overlap extension PCR 
was made at 58 °C with following oligonucleotides: 1. PCR CitMet1 = 
TCAGTCCTCTGTCGATGACGAAGG, CitMet3 = CACTACCATGCGTAGTACTTCCGC 
GACGGA, product length: 192 bp. 2. PCR at 58.0°C, CitMet2 = GTCGCGGAAGTACT 
ACGCATGGTAGTGCC, Cit Met4 = TGGGCGCAACCCTGGGACATCGGAC, product 
length: 390 bp. 3. PCR, 58.0°C with the two first PCR products as template and CitMet1 and 
Cit Met4 as oligonucleotides, product length 555bp. For P450 knockout: PCR at 72°C with 
CitP450-1F = CGTGTAGCGCAGGCGAGGAAGGTC, CitP450-1R = GTGGTGGCCCTC 
ACCGAAACGATG. The PCR product was cloned into the pCR2.1topo vector (Invitrogen) 
and electro competent E. coli (DH10b) cells. The colonies were selected on Luria–Bertani 
(LB)-agar containing kanamycin sulfate (Kan, 50 mg/mL), single colonies were cultivated in 
LB medium (1.5 mL, with Kan 50 mg/mL). From these cultures plasmid was isolated using 
the Nucleospin plasmid kit (Macherey & Nagel). The obtained plasmids were used to create 
M. xanthus mutants as described previously. [195-198] 
 
Heterologous expression: to express the cittilin gene cluster, it was transferred into the pCK 
vector, restriction sites were introduced by oligonucleotides (The pCK plasmid provided Dr. 
C. Kegler). NdeI in front of the precursor peptide, HindIII before the twelve bp encoding the 
cittilin, the core peptide has a natural SpeI site, and behind the P450 an EcoRI site was 
introduced. Citt-EcoRI_rev2 = GCCTG AGGAATTCAGTCCTCTGTCGATGA, 
Citt_HindIII_rev = CGGATTTACTAGTCTAGTAATAGATATACGGGGCGGAAAGCTT 
GTCCGCG, Citt_NdeI_for3 = CATATGATGGCG CGGCGCGCCAGCCTGGGATGCAA. 
The two fragments short and long were amplified from genomic DNA of DK1622 (Figure 
36).  
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Figure 36:  Cittilin cluster with introduced restriction sites and oligonucleotides. 
The short fragment was cloned into the pSKII+ vector (pBluescript II SK(+)) vector 
(addgene) (Supplementary figure 1). The long fragment was placed into the pTOPO vector 
(pCR2.1topo vector (Invitrogen). To open pSKII+ Cittilin short SpeI was used, the long 
fragment was cleaved out of pTOPO Cittilin long with SpeI and XbaI and stitched into the 
open pSKII+ Cittilin vector. As XbaI is compatible with SpeI two orientations are possible. 
The obtained clones were screened for the correct direction via PCR (Taq, 58°C) with the 
primers CitP450-1F = CGTGTAGCGCAGGCGAGGAAGGTC and M13rev = 
GAGCGGATAACAA TTTCACACAGG. 
The cittilin cluster was transferred from pSKII+ Cittilin via NdeI and EcoRI into the pCK 
Cittilin vector. The pCKCittilin vector was cloned into electro competent E. coli (DH10b) 
cells and preceded like above (gene knockout). The resulting plasmid was electroporated into 
Stigmatella aurantiaca Sg a15 as described for M. xanthus. 
[195-198]
 
 
New cittilin derivatives: the amino acid sequence was exchanged by vary the 
oligonucleotides, considering the codon usage of Myxobacteria. The sequence of Ile was 
exchanged against one other amino acid sequence (Ala, Asn, Gly, Leu, Val). Cit PCR Asn rev 
TTTGACTAGTCTAGTAATAGTTATACGGGGCGGAAAG, Cit PCR Val rev = 
TTTGACTAGTCTAGTAATACACATACGGGGCGGAAAG, Cit PCR Leu rev = 
TTTGACTAGTCTAGTAATACAGATACGGGGCGGAAAG, Cit PCR Gly rev = 
TTTGACTAGTCTAGTAATAGCCATACGGGGCGGAAAG, Cit PCR Ala rev = 
TTTGACTAGTCTAGTAATAGGCATACGGGGCGGAAAG. Another primer was designed 
over the NdeI side of the pSKII+ Cittilin vector: Cit PCR Nde for = 
CTCGAGCCACTACCATATGATGG. PCR was done with both primers at 58 °C, Phusion 
polymerase, pSK – Cittilin vector as template. The resulting fragment of 260 bp was digested 
with SpeI and NdeI, as well as the pCK Cittilin vector. Both are stitched together and the new 
plasmids were electroporated into E.coli DH10b. The plasmids of the clones were isolated 
like described above, sequenced for correctness and transferred into the wild type stain 
DK897 (displayed before). 
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Investigation of the leader peptide: for resequencing of the leader peptide of ST200611 
primers were designed to amplify this region Citvorl 2F = 
CAGATTGAGGGCGACTGGATTGC, Citvorl 1R = GTCTTCCGACCCAGCCGTCAG. 
The PCR was done with Phusion
®
 polymerase (Finnzymes) at 58 °C, the amplificate was 
cloned into the pJet vector (Fermentas) and send for sequencing (seq-it).  
 
Re-activation of A47 gene cluster: Primers were designed for the amplification of the missing 
cittilin genes. Cit_Met_EcoRI_rev2 = TCTGCAGAATTCAGTCCTCTGTCGATGACGA, 
Cit_P450 Nde_1for = TGGAGCATATGGTTCGCTCCACCTGCGCCA. A PCR was 
performed with Phusion
®
 polymerase (Finnzymes), the amplificate digested with EcoRI and 
NdeI as well as the designated pCK vector. Both were ligated together to result in a new 
vector pCK P450 Met (Figure 37).  
 
Figure 37: Vector for the complementation of strain A47 with P450- and MT-encoding genes. 
This pCK P450 Met plasmid was electroporated into the strain A47; clones were picked and 
genetically verified. Two correct mutants were then cultivated with XAD, harvested after 
three days and their extracts were analyzed with the HPLC-MS system. 
 
P450 expression: Primers were designed to amplify the P450 gene and to introduce restriction 
sites which enable it to be introduced in the pSUMO ck4 vector (LifeSensors) (Supplementary 
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figure 2) and the pet-28a vector (Supplementary figure 3). The following primers for 
amplification of the P450 enzyme were used:  
Cit ex P450 EcoRI = TGCAGGAATTCTCATGCTCCCGCCGCATGCCGCA 
Cit ex P450 NheI = GTTCGCTCCACCTGCGCCAGGCTAGCGGCAT 
Cit ex p450 rev2 = CCGCTGAATTCTCATGCTCCCGCCGCATGCCGCACCTC 
 Cit ex p450 for2 = AGCCCGCTAGCTTGGGTCTCAAGAGCTGGTCGACGTGGGT 
Genomic DNA of DK1622 was used for amplifying the P450 gene by Phusion
®
 polymerase 
(Finnzymes). The amplificate was digested with EcoRI and NheI. The pSUMO ck4 vector 
was opened with SpeI and MunI, pET-28a vector with EcoRI and NheI. SpeI is ligatable with 
NheI and EcoRI with MunI. The PCR product was cloned into both vectors; clones were 
verified by digestion and send for sequencing. The construct was then transformed into 
chemical competent BL21 cells.  
A correct BL21 clone was cultivated in a 1 l flask (250 ml LB media) to an OD of 0.8, the 
culture was placed at 16 °C, after 20 min induced by IPGT (50 μl, 1 M, final conc. 0.2 mM) 
and cultivated over night. 1 ml of culture was centrifuged, the pellet was resuspended in 
100 μl BugBuster Master Mix (Novagen) shook at 500 rpm for 30 min, centrifuged at 4 °C for 
45 min at 13000 rpm. Pellet and supernatant were placed on a 12 % SDS-Gel. Same 
procedure was accomplished for the BL21
+
 clones. 
 
ABC transporter: The fragments were amplified by Phusion
®
 polymerase (Finnzymes), 
cloned into the pJet vector (CloneJET™, Fermentas) and sequenced for their correctness. The 
plasmids were digested with NdeI and then with the corresponding other enzyme. The ABCI 
fragment was ligated into the pCK-Cit vector in front of the cittilin cluster. The resulting 
plasmid was reopened by NdeI and the next restriction enzyme. And the next gene was added 
and so on to finally end up with five different constructs. These pCK Cit plasmids containing 
the region up to ABCI, ABCII, perm, ABCIII and hyp were introduced into A9 and Sg a15. 
The clones were analyzed for their genetically correctness by control PCR. All attempts failed 
to obtain mutants containing the hyp genes. The mutants were cultivated and the cittilin 
production was checked by HPLC-MS.  
The following primers where designed: 
Cit PCR Ile rev = TTTGACTAGTCTAGTAATAGATATACGGGGCGGAAAG 
ABC1_NdeI_BamHI_1for = ACCATATGATCGGATCCAAGAACGTCAGCAAGCGCT 
ABC2_BamHI_1rev = TTCTTGGATCCGATCATCTCGTGGCCTTTC 
ABC2_NdeI_SspI_1for = CGCATATGAATATTAACGCCCCGCCCGTCA 
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Perm_SspI_1rev = TTAATATTCACGGGCGCCTCGCTTCA 
Perm_NdeI_BspTI_1for = CCCATATGAAGCTTAAGTTCGCCGCCGCCGCCGT 
ABC3_BspTI_1rev = AACTTAAGCTTCACGGTGGGGAGGGACT 
ABC3_NdeI_KspAI_1for = CTCATATGAGTGTTAACAACAGGCGTTCCCTTC 
Hyp_KspAI_1rev = GAGTTAACCACGGTAGTCGTTGGAAAGGGTG 
Hyp_NdeI_1for = TACATATGATGGCGGGGCTGCTGAG.  
PCR conditions: Phusion, HF-Buffer, 68 °C 20 s, 1.5 min 72 °C. 30 cycles, genomic DNA of 
DK897. The obtained amplificates are ligated into the pJet vector (CloneJET™ PCR Cloning 
Kit, Fermentas), sequenced (seq-it) and placed in front of the cittilin cluster, in the pCK-Cit 
plasmid. Creation of E.coli and myxobacterial mutants as described before.  
For the quantification 15 ml TS or (A9: CTT) media plus Kan50 and 0.25 ml XAD were 
inoculated with liquid preculture. After 7 days (A9: 4 days) the OD600 was measured, cultures 
were harvested and the XAD was extracted twice with MeOH, always under same conditions 
for each sample. The received extracts were measured together with Coumarin 314 (standard 
program, see before) at the LTQ-Orbitrap for HR-MS quantification. The peak areas of cittilin 
were integrated and quantified by the Bruker QuantAnalysis software. The quantification is 
related to OD of the cultures. 
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Supplementary  
 
 
Supplementary figure 1:  The four plasmids: pSKII+ Cittilin short containing: leader, core peptide and ampilicilin 
resistance; pTOPO Cittilin long harbors: cittilin cluster, ampilicilin and kanamycin 
resistance; pSKII+ encloses: cittilin cluster and ampilicilin resistance; pCK Cittilin with: 
complete cittilin cluster, ampilicilin and kanamycin resistance. 
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Supplementary figure 2:  vector pSUMO ck4 
 
 
Supplementary figure 3:  vector pet-28a(+) (Novagen, picture Novagen) 
 
 
Supplementary figure 4:  UV spectrum of cittilin, UVmax = 290 nm. 
pSUMO3 ck4
5585 bp
lacIq
KanR
SUM O3
T7 term
T7 for
pBR322 ori
MunI (344)
Spe I (326)
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Supplementary figure 5:  1H spectrum of cittilin A in CD3OD at 500 MHz. 
 
Supplementary figure 6:  13C spectrum of cittilin A in CD3OD at 125 MHz. 
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Supplementary figure 7:  COSY spectrum of cittilin A in CD3OD at 500 MHz. 
 
 
Supplementary figure 8:  HSQC spectrum of cittilin A in CD3OD at 500 MHz. 
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Supplementary figure 9:  HMBC spectrum of cittilin A in CD3OD at 500 MHz. 
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Supplementary figure 10:  Genetic region around cittilin sequence  
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Cittilin cluster sequence in M. xanthus DK1622  
 
1        10        20        30        40        50        60        70 
|        |         |         |         |         |         |         | 
ATGGCGGGGCTGCTGAGCGCCCGCGCGCTCGCGGACCACTTCGAGAAAGTCGTCATCCTGGAGAGGGACTCGCTC
CCCGGCATGCACGCGGCGCGCAAAGGTGCTCCCCAGGGCACACACGTCCACGTGATGCTGGACGCGGGTCACCGC
CTCCTGGAGCGCTTCTTCCCCGGCCTCCTCCAGGACCTCCAGGACCAGGGGGCCGCGCTCATCGATTCGAGCCGG
GACGTCGCGTGGCACCACTTCGGCGTCTGGAAGTCGCGCGTCCCCCAAGGCCTTCCCCTGCTGGTGTGTACGCGT
CCCTTCCTGGAATGGCACGTGCTGCGCCGGGTGCTGGCGCTGCCCAACGTCGAGTTTCACGGCGGCGTCTCGGTC
GAAGGGCTGCTCACGGACGCCTCCCACCAGCGCGTCACCGGCGTGCGGTTGAAGAAGGCCGGCGTGGAGGAACCG
CTGGAGGCCGCGCTGGTGGTGGATGCCACGGGCCGGGGCTCGCGTGCGCCCCAGTGGCTGGAGGCCCTGGGCCAT
GCACGTCCCGACGAGGAACAGGTGCGGGTGGACCTCGCGTACACCACCCGCCTCTACGAACCTCCCGCGCACCGC
CAGGAGGACTGGAAGGTGCTCATGCAGTACCCGTGTCCGCCCGTGAACTGGCGCGCCGGCTTCATCTCCCGCGTA
GAGGGGGACCGCTGGATTGTCACCCTCAATGGGTACTTCGGCGAGCACGCGCCCGCGGACGACGAAGGCTTCCTC
GCGTTCGCCCGCTCACTGCCCCAGCCGGACCTGTACGCCTGCCTGCGGGAGGCCCGGCCGTTGGGGCCGCTCACC
CTGCACAAGGTGAAGGAGAGCCGCTGGCGGCACTATGAACGCCTCGCGCGCTTCCCGGAGAACTGGATCATCCTC
GGTGACGCCGTGTGTGCCTTCAACCCTGTCTTCGGCCAAGGCATGTCGGTGGCGGCCCAGGGCGCGGCGCAGCTC
CTCGCCTGCATCGAAGAGCAGGCCAGGCGCTTCCCCACGACGCTCGACGGACTCGCCCAGCGCTTCCGCAAGCGC
CTGTCCGACACCATCCGCCTGCCCTGGTTCATGGGCACGAACATCGACCTGCAGTACCCGAAGGCCGTCGGCCAG
CGGAAGCCCGGCGTGGGAGTGCTGCACTGGTACATCCGGCGGATGATGGAGCGCAGCTCCCGGGACGCCGCCGTG
CACCGGCAGTTCAACCGACTCCTGCACCTCCAGGCGGGGCTGGGCGCCGTCCTCCAGCCTTCGGTGGCCCTGCCA
GTGCTCGCGGACGGCGCCCGCGCGCTCTTCATGCCCCTGCATGCGCGGGCGAACACGGACATCCGCCCGGCCCCG
CCCTCCTCATCTCCATGACGGACCAGCGCGCCAATGCACGCAGCGGCCGAGCCGCTCCGCGAAGAAGTCGAACAG
ACTCACGTCCGTGAGCGCGCGGCCCAATGGCCGGATTCAAACAGCCGGTCTGGTGGCCGAAGCCCGGCGCGAAGG
ACCGCCCTGGAGCGAGACAGACTCAAGGGCAGCCGTCTCTCCCTTCAGAAGAAACACCCAGGCTTTGACGGTGCG
GACGTAAGCATCTATGATGCGAAACTGATTCGCAGAATCAAAATCACCCTTTCCAACGACTACCGTGAGTCCATC
CAACAGGCGTTCCCTTCCGCTCTTCGCCCTGCTTTCCGTCGTCGTCGTGCTGGCCGTCCTGTGGGTGGGCGTGAG
GTTCCAGCGCCCGGACGCCGCCGCGTCCACTCCCGCCGCGGAGGCTGCCGCGCCGGAGGGCCGGACGGTGACGCA
CGGACAAGGCACCACCGTCGTCCCGCTGAAGCCGCGGCGGGTGGTGGTGTTCGACCTGGTGGCGCTGGACATCCT
CCAGGCCCTGGAGGTGGACGTCCACGGCGTGGCGGGCGACATGTTCCCCCAGCACCTGACCCGGTTCCGGGACGC
GAAGTACCCGCGCATGGGCACCCTGTTCGAGCCTGACTACGAGGCACTCCAGGCCGCGAAGCCGGACCTCATCAT
CACCGGGGGCCGCTCCAGCGCGAAGTACTCGAACCTCTCCCGCATCGCGCCCACCATCGACGTGCCGATGAGCGG
CAAGGACTTCATCGCCTCGGTGATTGCCAACACGGAGATGCTAGCCAGCGTCTTTGGCAAGGAGGAGAAGGCGCG
CGGCCTGATTGAGGACCTGCGCAAGTCGGTGGCGGACCTCCAACAGATGACGGCGACACGCGGCAAGGGGCTGGT
CGTGCTCGTCACCGGAGGGCGCATGAGCGCCTATGGCCCGGGTTCGCGCTTTGGCGTCATCCATGGTGACTTCGG
CGTGCCCGAGGCCGTCGAGGGCCTGCGCACCTCGCTGCACGGCGAGTCCATCAGCGCGGAGTTCATCCGGGAGAA
GAATCCCGACTGGCTGTTCGTCATCGACCGGGACGCCGCCACCGGTCAGAAGGAAGGCAATGCCCGGCAGGTGCT
GGACAATGAATTGGTGCGGCAGACGACGGCCTGGCAGAAGAACCAGGTCATCTACCTGGACCCCGGCGTCACCTA
CCTGACCGGCGGCGGCATCCAGTCCGTCAAGCAGCTCCGCGACCAGGTCGCGAGCGCCTACACGCAGGCCCAGTA
GTCCCTCCCCACCGTGAAGCGCGCGTTCGCCGCCGCCGCCGTCCTCGTCACGTTGGCGGTGGTCAGCCTCCTGAT
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TGGCGCCAGTGACGTGTCCTGGCGCGCCCTCTTCGCTCCCGAGCCGGATGAGCGCGCCCTCCAGGTGCTGGTCAT
CAGCCGGCTGCCGCGCCTGTTCGCCGTCATGCTGGCGGGCACATCCCTGGGCGTCGCGGGCCTCATCATGCAGAT
GATTGCCCGCAACCGCTTCGTGGAGCCCACCACAGCGGGCACCGCGGAGTCCGCCAGCCTGGGCCTGCTGACCGC
CACCCTGCTGGCGCCTGGCCTTCCGGTGCTCGGGAAGATGATGGTGGCCACCGTCTTCGCCCTCGCGGGGACGGC
GCTGTTCCTGCTGGTGCTGCGGCGCATTCCCCTGCGCTCGGCCCTCATCGTCCCGGTGGTGGGCCTGATTCTGGG
CGGCATCATCGATTCGGCGACGACCTTCTTCGCCTACCGGTACGACCTGCTTCAGACGGTCAACGCGTGGACCAC
GGGTGACTTCTCCACCGTGCTTCGCGGCCGTTACGAGCTGCTGTGGGTGACGCTGGGCCTCACCTGCGCCGCCTA
CACTGCCGCGGACCGCTTCACCGTGGCCGGCATGGGCGAGACGTTCACCACCAACCTGGGGCTGAACTACCCGCG
CATCGTCGCGCTGGGGCTGGTCATCGTCGCCCTGGTCACCGCGATGGTGGTCGTCACGGTGGGCATGATTCCGTT
CCTGGGACTGATTGTCCCCAACCTGGTCAGCATGGTCATGGGCGACAACGCGCGCAGGTCCATTCCCTGGGTCGC
GGTGAGCGGCGCGGCCTTCGTGCTGCTCTGCGACATCGTGGGCCGCGTGGTGCGCCACCCGTATGAGATTCCCGG
AGGCACCATCGCCGGCGTCATCGGCAGCGTGCTCTTCCTGTACCTCCTGCTGAAGCGAGGCGCCCGTGCCGGCTA
ACGCCCCGCCCGTCAGCCCCCTGCGGCCCCTGCTCGTGCTGGGCTGCGTGGCCGTGGCCTTCATGGCCCTGTTCA
TGCTCGTCGACGTGAGCGGCCCGTGGGACTTCGTGCTGCCCTTCCGCGGGAAGAAGGTCGCCACCGCGTTGCTGG
TGGGCTACGCCGTCGCCGTCTCCACGGTGCTCTTCCAGACGGTGACGGGCAACCGCGTGCTGACGCCCGCCATCA
TGGGGTTCGACTACCTGTACGTGCTCATCCAGACGTGCCTGGTGTTCTTCCTGGGCTCCACCACCGTGGCGGGGC
TGGACCCCCGGTTCCTGTTCGGCGCGGAGGTCATCATCATGGTGGCCTTCTCCGCCATGCTGCACGGCTGGCTCT
TCGGCATGGCCCGGGGCAACGTCCACCTGCTACTGCTCACTGGCGTGGTGATGGGCGTGCTGTTCCGGAGCCTGT
CGTCGTTCGTCCAGCGCGTCATCGAACCCAACGAGTTCATCTTCCTGCAGGACCGCTTCTTCGCCAGCTTCAACG
ACCCGGAGCACGACCTGCTGCTGCTCTCCGCGGTGCTGACGCTGGGGGTCTCCGTGCTGGGCCTGCGGCTGCTGC
GCGCCTGTGACGTCCTGGTGCTGGGCCGGGAGGCCGCCATCAACCTGGGCGTGGACTACCAGCGGACGGTGTCAT
GGGTGCTGGCGCTGGTGGCCATCCTGGTCGCCGTGTCCACCGCGCTGGTGGGGCCCGTGACGTTCCTGGGGTTGC
TGGTGGCCAACATCGCCTACGCGGTGATGCGGACGTACCAGCACGCGTTCGTCCTCCCCGCCGCCGCGCTCATCG
CCGCCATCGCCCTGATCGCCGGGCAGTTCATGCTGGAGCGCGTCTTCCGCCTGGACACCAATCCACGGGTCATCA
TCGAGTTCGTCGGCGGGATGGTGTTCATCGCGATGCTCATGAGAAAGGCCACGAGATGATCGAGGCGAAGAACGT
CAGCAAGCGCTACGGTGAAACGCTGGTGGTGGATGGCGTCACCCTGAGCCTGCCCGTGGGCGGCGTCACCTCCAT
CATCGGCCCCAACGGCGCGGGCAAGTCGACCCTGCTGTCCATGATGAGCCGGGTGATGCCCATGTCATCGGGCAA
CGTTTGGGTGGACGGGCTGGACGTCACCACCACGCCGGGGGACACGCTCGCGAAGCGGCTGGCCATCCTCCGGCA
GGACAACCACATCTCCGCCCGGCTGACGGTGCGTGAGCTGGTGACCTTCGGCCGCTATCCGCACACCAAGGGCCG
CCCCACCGTGCAGGACCGCGAACACGTGGAGCGGGCCATCGAGCACATGGGGCTGAGCGCGCTCGCCGACCGCTT
CCTGGATGAGATGTCCGGCGGCCAGCGTCAGCGCGCCTTCGTGGCCATGGTGCTCTGCCAGGACACGGACCACGT
GCTGCTGGACGAGCCGCTCAACGGCCTGGACCTGAAACACGCGGTGTCCATGATGAAGCGGCTCCGGCACGCCGC
GGACACGCTGGGCAAGAGCTTCGTGCTGGTGCTGCACGACATCAACTTCGCCTCCTGCTACTCCGACCACATCGT
CGCCATGCGCGACGGCAAGGTCGCGTTCCAGGGCCGCCCGGAGGACATCATGCGCCCCGACGTCCTGCGCGCCAT
CTACGAGTTGGACATCTCCGTGCAGCAGATTGAAGGCGACTGGATTGCCACCCACTACCGGTGATGGCGCGGCGC
GCCAGCCTGGGATGCAAGGGGTTTCCACTAATCACAGACACTTGCACTGCCTTCTCAGGCTGTGCCACATTTCAC
CGCGCTGGCCATGACGTCAGCAGACAGCAAGACGCCACCACCTCAAACCAGGAGTTCGCCATGAAGAAGGCCCTG
TACTCTTTGGCTGTGCTGATGCGGTTTGCTCGCGCGGACAAGCTCTCCGCCCCGTATATCTATTACTAGTCAAAA
TCCGTCAGGCATTGAGCCCTGACGGTTGGGTCTCAAGAGCTGGTCGACGTGGGTGGAGCGCATGGTTCGCTCCAC
CTGCGCCAGCGGTAGTTCCCCCCTCCAGGACCCTTTCATGTCACAGGTGCGCCTTCCGCCGGGGCCCCAGGGCCA
CTTCATTGCTGGCAACCTGGTGGAGTTCTCCGAGGACCCGCTGGGGTTCCTCACCCGCTGCGCCAGGGAGTACGG
CGACGTGGTGCGCCTGGGGAAGCGCAACTTCCTCCTCAATCACCCGGACCTGATTGAACGCGTCCTGGTCAACGG
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CGACGGCAACTTTGTGAAGCTCGCCGGAGTGGGCCAAGGCAAGCGTCACAAAGGCGGCTTTCCCGAAGCGATGAT
GAACAGCGAGGGCGAGGACTGGCTGCGCAAGCGGCGCCTCGTCCAGCCCGCGTTCCATCGCAAGCACGTGGCCGC
GTGTGGTGACACCGTGGTGGCCCTCACCGAAACGATGCTCCAGACGTGGCGCCCGGGCGACGCGCGGGACGTGCA
CGCGGACGTGTCCGCGCTGGCGCTCGACATCGTCAGCCGATTCCTCTTCCACACGCCCATCGACGACGAGGCCCG
CCACGTGGCCGACGCCGTGGACGCTGTCATGCGGCACACCGACAGCCCCCTGCGGCCGCCCATCTGGGTGCCCAC
GCCCACCAACCTCCGCCTGCGCCGCGCCCTGGGCCGGCTCAACACGCTGCTCGCGACGCTCGTGCGCCGCTATCG
GGAGCAACCGGAGTCGCGCACGGACCTGCTCGCCCTGCTGCTGTCCGCTCCGGTCCCCCTCTCCGAGAATCAACT
GCGCGATGAGCTGGCGACGATGATCATGTCCGGGCACGAGACGACGGCGGACGCGCTCGTGTGGGCCTGGTACCT
GCTGGCCCAGCACCCGGAGGCCGAGGCCCGGCTGGTGGCGGAGCTGGAGACGGTGCTCGGGGGCCGGCTCCCTGG
CGCCGAGGACCTTCCTCGCCTGCGCTACACGGAGGCGGTGGTGAAGGAGGCCATGCGCCTGTACTCACCGGCGTG
GATCACCAGCCGGGAGGCGCTGCGCGACTGTGAGCTCGGCGGGTTCCACGTCCCAGCGGGAACGATGCTGGCGGT
GAGCCAGTGGGTCACCCACCGCGACGCGCGCTACTTCGACGCCCCCGAGTCCTTCCGTCCAGACCGCTGGCTGTC
CGAGGACGCCCAACGCATGCACCGGTACGTCTACTTCCCGTTCGGCGGCGGCCCCCGGTTCTGCATCGGCTCGGC
GCTGGCGATGATGGAGACGGTGCTCATCACCGCGTGCGTGGCACGGCGGTTCCGGCTGGAGCTGGCACCGGGCTG
CGTGGTGCGGCCCCGGCCGGCGCTCGCGCTCCAGCCGCTCGGGGTCTGGCTGATTCCGCGGCATCGCTCTCACAC
AACACAGGAAGGCGAGGTGCGGCATGCGGCGGGAGCATGAAGGGGCAGCGGTCCGGCGCGAGTTCTTCCGCTCGG
CATACCTGCTGGGCGCACCCTGGGACATCGGACGGCCCCAACAGGCCTTCGTCCAGTTGTGGGAGGCCGGCGCGA
TTTCCGGCGAGGTGCTCGACGTGGGCTGCGGCTTCGCGGAGAACGCCCTCTTTCTGGCGGCCAAGGGCCTGCCGG
TGTGCGGCGTGGACATGATGGAGCCGGCCATCCTGCGAGCACGCGAGACGGCCTCTCTGCGCGGGCTCGACGTGG
ACCTGCGTGTGGGCAACGCCCTGGAGCTGGCCACGCTGGGCCGGCGCTTCGACACCATCCTTGATTCGGCCCTGC
TCCACGTCTTCGAGCCTGGAGACCGGCCCGCGTTCGCCGCCAGCCTCGCGAGCGTGCTCCGGCCCGGCGGGCACT
ACCATGCGCTGTACTTCCGCGACGGACCGCGCGCCGTTCCACCGGAGGCACTGAACGCGACCTTCGGGGAAGGCT
GGCGCGTGAAGTCCATCCAGGAGGCGCACTACGAGCAGACCGACCCGGAGGGCGCGCAGGCCTGGCTCGCCACCA
TCGAACGGGTGCCTCCTTCGTCATCGACAGAGGACTGA 
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Chapter 2A 
 
The structure elucidation and biosynthesis of novel 
Myxoprincomides from Myxococcus xanthus DK897 
 
Abstract 
Myxococcus xanthus is a multiproducer of natural products. There are common secondary 
metabolites found in all M. xanthus strains, while others are only produced by a few strains. 
From M. xanthus DK897 extracts, novel myxoprincomides could be detected. 
Myxoprincomides are apparently produced by every M. xanthus strain analyzed to date, but 
two different types exist. The myxoprincomide family of peptides produced by M. xanthus 
DK897 comprises ten different derivatives which were isolated and characterized in this 
study. The biosynthetic genes were identified by transposon mutagenesis and the 
myxoprincomide gene cluster (mxp) was assembled using draft whole-genome sequence 
information. The mxp locus is largely similar to the related MXAN_3779 gene from 
M. xanthus DK1622, but distinct differences in the sequence exist which seem to lead to 
increased compound diversity. Interestingly, the structures of several myxoprincomides 
correspond well to intermediates expected to be formed on the NRPS-PKS assembly-line 
during myxoprincomide production. Thus, myxoprincomide biosynthesis is an intriguing 
example where release of intermediates from a giant biosynthetic multidomain enzyme can be 
observed, providing insights into the action of a biosynthetic assembly line in-vivo. 
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Introduction 
Myxobacteria are a potent source of secondary metabolites. More than 100 core structures and 
some 500 derivatives thereof have been identified. Most notable are the epothilones, whose 
semisynthetic analogue Ixabepilone was recently FDA approved for the US market as an 
anticancer drug. A huge number of myxobacterial natural products show remarkable 
biological activities. 
[16;204;205]
 These compounds are often products of polyketide synthases 
(PKSs) and nonribosomal peptide synthetases (NRPSs). In the case of myxobacteria 
NRPS/PKS hybrid synthetases are very common and frequently produce novel core 
structures.  
Often the large myxobacterial genomes harbor several biosynthetic gene clusters encoding for 
secondary metabolites. The bioinformatic analysis of whole-genome information from 
Myxococcus xanthus DK1622 for example suggests that its biosynthetic potential is much 
larger than expected on the basis of known secondary metabolites form this strain. DK1622 
was long time used as a model organism for studies of myxobacterial social motility and 
multicellular differentiation. 
[36]
 It was initially not even recognized as a producer of 
secondary metabolites, until analysis of its genome revealed 18 biosynthetic gene clusters 
encoding for PKS, NRPS and hybrids thereof. 
[91]
 Eight compound classes have since been 
assigned to biosynthetic gene clusters in DK1622: the DKxanthenes, the myxochromides, the 
myxalamides, the myxochelins, myxovirescins, myxoprincomides and two substances with 
unknown structure. 
[90;176;195;206-209]
  
Due to the striking discrepancy between numbers of genome-encoded biosynthetic pathways 
and known metabolites, it is most likely that more secondary metabolites can be isolated, not 
only in DK1622. Other M. xanthus strains are assumed to be secondary metabolite 
multiproducers as well. Hence a large chemical screening was performed on 98 M. xanthus 
strains isolated from locations worldwide, as well as several strains attained from single 
habitat. 
[51]
 The target was to find unknown metabolites, beside those already identified ones 
like DKxanthenes 
[209]
, myxochelin 
[83]
 from M. xanthus DK1622. The analysis was based on 
an HPLC-HR-MS screening, assisted by principal component analysis (PCA), a statistical tool 
to limit the manual effort. 
[210]
 PCA facilitates the analysis of multivariate data sets. To 
compare each data point in the HPLC-MS chromatogram with the received chromatographic 
data of other strains the computational methodology creates n-dimensional models based on 
molecular features. The software extracts significant information from complex data sets. The 
received information here resulting in outliers was verified by analyzing the raw LC-MS data. 
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With this method several potential novel secondary metabolite candidates have been detected 
in M. xanthus. 
[51]
 The next goal was on the one hand to isolate and characterize these 
supposedly metabolites and on the other hand to identify the genes underlying their 
biosynthesis. A detected group of candidates was isolated and correlated to their biosynthetic 
origin. We present the characterization of the myxoprincomide NRPS – PKS hybrid 
biosynthetic pathway in M. xanthus DK897. It is in charge of at least ten novel 
myxoprincomides which were structurally elucidated. Several of these structures are 
identified as biosynthetic intermediates of the myxoprincomide formation. The analysis of the 
mxp gene cluster in M. xanthus DK897 allows insights into an "imperfectly" working NRPS-
PKS biosynthetic assembly line with unusual biosynthetic features. 
 
Results and Discussion 
Screening for novel metabolites and their corresponding genes 
In a screening of M. xanthus strains 18 potential novel compounds beside myxochelin and 
cittilin were reported. 
[51]
 Apart from the known substance groups myxalamides, 
myxochromides, DKxanthenes, one novel group comprising three metabolites was detected in 
strain DK897, which is not produced by the model strain DK1622 (Figure 38).  
In order to correlate biosynthetic gene clusters to the potentially novel metabolites predicted 
from strain DK897, genes were randomly inactivated via transposon mutagenesis. The 
mutants were subsequently analyzed for the lack of these substances.  
In search for the corresponding gene cluster, an existing transposon mutagenesis library 
consisting of M. xanthus DK897 mutants was screened. Mutants have been cultivated in 
microtiter plates and 2000 mutants were analyzed by HPLC-MS by D. Krug and A. 
Sandmann. This analysis identified two knockout mutants deficient in production of the 
compounds with m/z = 382, m/z = 800 and m/z = 814. Transposon recovery was then 
performed to identify the inactivated genes in this mutant, followed by primer walking to 
obtain initial sequence information. Moreover, additional genetic information was acquired 
with the help of further knockout mutants and subsequent plasmid recovery. The recovered 
plasmids were sequenced; using this approach, a 10460 bp stretch was sequenced. 
Concurrently, the genome of DK897 was subjected to whole-genome sequencing, yielding 
more than 500 contigs. The partial cluster sequence as obtained from plasmid recovery was 
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aligned with these contigs. Five contigs were found with 100% identity to the partial gene 
cluster sequence (Figure 39). 
 
Figure 38:  HPLC-MS chromatograms of extracts of M. xanthus strains. Base peak (BPC) and 
extracted ion chromatogram (EIC) of the two strains DK1622 and DK897.  
 
 
Figure 39:  Order of the gene cluster sequence of transposon and plasmid recovery aligned to the 
contigs: contig1012 (950 bp), contig1009 (3947 bp), contig982 (860 bp) contig24 (2555 bp), 
contig32 (5276 bp) in total 15342 bp. 
To confirm that these contigs were definitely part of one gene cluster multiple PCRs were 
performed, and used to close the gaps by sequencing of the obtained amplified fragments. By 
combining the sequence information from contigs, transposon recovery plasmids and PCR 
products, altogether the sequenced region added up to 15342 bp. 
Next, the DK897 genome was subjected to paired-end sequencing to yield 139 scaffolds. The 
15 kbp sequence previously established was aligned with the new scaffolds of DK897. One 
large scaffold with a length of 26843 bp (scaffold 0024) containing the previously identified 
15 kbp segment was found (Figure 40). Gaps within this scaffold were closed by PCR and 
subsequent sequencing. 
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Figure 40:  Scaffold 0024 in comparison to the contigs and the known sequence from primer walking. 
 
Bioinformatic prediction of biosynthetic domains in the large reading frame spanning 
scaffold0024 revealed intriguing similarity to a different biosynthetic gene cluster in 
M. xanthus DK1622 (MXAN_3779), considering the order of domains and their predicted 
substrate specificity (Figure 41). MXAN_3779 encodes for a hybrid NRPS-PKS 
megasynthetase which consists of 13 modules. The loading module contains an acyl-CoA 
ligase domain and a PCP domain. Module 1 contains an N-methyltransferase, the A domain 
has predicted L-serine specificity. Four further NRPS modules are following with specificities 
for: an unknown amino acid, L-valine, L-serine and for another unknown amino acid. Module 
6 is a PKS module followed by a module containing an oxidation domain (Ox) within a 
presumed A domain. The assembly line continues with further NRPS modules.  
In the case of scaffold0024 from DK897 there is an N-methyltransferase, followed by five 
modules with similar specificity predictions as described for the DK1622 gene cluster. A PKS 
module and one module with an Ox domain within an A domain follow.  
 
 
Figure 41:  MXAN_3779 of DK1622 in comparison to scaffold 0024 of DK897. 
In a study concerned with identification of metabolites that correlate to the MXAN_3779 gene 
cluster in DK1622, a novel compound with m/z
 
[M+2H]
2+
 = 506 was identified (see chapter 
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2B). In the case of M. xanthus DK897 at the beginning three but up to date ten different 
derivatives could be correlated to the 800er cluster (c382, c683, c798, c800, c812, c814, c580, 
c581, c587 and c588). The largest product is m/z = 588
2+
. Therefore one can expect a larger 
gene cluster than in DK1622. 26.8 kb were known from the DK897 cluster, but comparison to 
the related cluster MXAN_3779 of DK1622, which has 42.8 kb, suggested that approximately 
half of the sequence was still missing. Therefore, a comparison of the MXAN_3779 gene 
from DK1622 followed to the 139 genomic scaffolds from DK897. The scaffolds were 
aligned with MXAN_3779 and additional matching parts of a postulated gene cluster could be 
found on four scaffolds: scaffold 00037, 00024, 00110 and 00036 (Figure 42).  
 
 
Figure 42:  Order of the four scaffolds of DK897 compared with the gmxorf2004.  
The gaps within these scaffolds could be estimated by using the MXAN_3779 sequence. PCR 
amplification and subsequent sequencing was used to connect the scaffolds with the missing 
sequence. Finally the gene cluster from DK897 consists of 46959 bp (Figure 43). 
 
 
Figure 43:  Myxoprincomide gene cluster in DK897 contains 14 predicted modules. 
The annotation of the DK897 cluster region revealed the presence of 14 modules starting with 
one acyl-CoA ligase (ACL) as hypothetical loading module, followed by 6 NRPS modules, 
one PKS module, continuing with another 6 NRPS modules and ends with a thioesterase (TE) 
domain. The domains were analyzed for their potential function and annotated accordingly. 
The substrate specificity of A domain was predicted whenever possible (Table 2). For 
analysis and prediction two web tools of J. Ravel et al. (A) 
[211]
 and T. Weber et al. (B) 
[212]
 
were used.  
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A-Domain Prediction with A 
[211]
 Prediction with B 
[212]
 
A1 Ser Ser 
A2 Orn Orn 
A3 No No 
A4 Hpg Val 
A5 Ser Ser 
A6 No No 
A7 No No 
A8 Ser Ser 
A9 No Tyr 
A10 Ahp Lys-b 
A11 No No 
A12 No Val 
Table 2:  A domain prediction using the web tools of A: J. Ravel et al. and B: T. Weber et al. (the 
substrate specificity code is depicted in Table 8). 
For the A domains three times serine, twice valine, one tyrosine, one lysine, one isoleucine 
and four unknown amino acids were predicted. If the structure was presumed to be collinear 
with domain organization, the predicted small molecule outcome should be similar to the 
structure depicted in Figure 44. Unknown amino acid residues are marked with R. However 
the chemical formula for this theoretical structure would be at least C51H83N13O18 which is not 
in agreement with the proposed molecular formula (based on high-resolution MS) of the 
largest detected molecule, calculated as C54H83N11O18. This indicates that two nitrogens are 
dispensable, and thus at least one module could possibly be inactive.  
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Figure 44:  Predicted structure if standard textbook biochemistry would be applied by gene cluster. 
The minimal sum formula would be C51H83N13O18. 
On protein level the different domains can be identified by highly conserved sequence motifs 
(core motifs or conserved regions). 
[102]
 Diverse domains have different numbers of core 
motifs (e.g. A domains have 10 and C domains 7). If such regions are missing it is often a 
reason for the inactivity of the domain. Therefore an attempt was made to predict directly 
from the sequence data which domain might be inactive through an alignment of the A 
domains (Supplementary figure 81); the 10 conserved regions were checked for major 
differences. In general all core motifs of the A domains are present. But in the case of A1 the 
core motifs are present but region 9 and 10 are located after the N-methyltransferase domain, 
like it is known from other NRPS clusters. 
[136;213]
 
Similar as with the A domains, the conserved regions of all C domains were also analyzed 
(Supplementary figure 82). 
[102]
 Some irregularity was located in module one and six; these 
condensation domains possess unusual C5 and C7 motifs. This might hint at no usage of 
module 1 and 6. Furthermore module eight exhibits an oxidation domain within the A domain 
and the PCP is lacking. That means module eight cannot function as a common module.  
The analysis of all PCPs revealed that the conserved motifs are present and intact 
(Supplementary figure 83). 
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Module 7 is a minimal polyketide synthase (PKS) module consisting of a ketosynthase (KS), 
an acyltransferase (AT) and an acyl carrier protein (ACP). The question for the PKS module 
is if it uses malonyl-CoA or methylmalonyl-CoA as substrate. For a prediction a phylogenetic 
tree of malonyl-CoA and methylmalonyl-CoA specific ATs of different myxobacterial PKS 
clusters was performed (Figure 45). The phylogenetic tree revealed that the AT domain of the 
myxoprincomide cluster groups slightly more with methylmalonyl-CoA specific ATs than 
with the malonyl-CoA specific ones, but it is still separate. Which might mean either that it is 
inactive or it is a novel type of AT where the type of substrate specificity cannot be predicted 
at the moment. 
To conclude, the domain analysis did not yield in striking information to make a reliable 
substance prediction. Therefore the compounds had to be isolated. 
 
Figure 45:  Phylogenetic tree of malonyl-CoA and methylmaloyl-CoA specific ATs domains of 
different myxobacterial PKS clusters compared the one AT in the myxoprincomide cluster 
(marked with arrow).  
Methylmalonyl-
CoA as  
substrate 
Malonyl- 
CoA as 
substrate 
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Substance characteristics 
At the beginning it was thought to be a structure class of only three derivatives (c382, c800, 
c814). But later two further compounds c580 and c587 could be correlated to the biosynthetic 
gene cluster (refer to Figure 46). Further depth comparison of wild type and mutant extracts 
revealed finally ten different derivatives produced by the mxpDK897 cluster: c382, c683, c798, 
c800, c812, c814, c580, c581, c587 and c588. The substances exhibit a typical peptide UV-
spectra. HR-MS measurements lead to the possible molecular formulas given in Table 3. To 
prove the accuracy of these formulae a reversed feeding experiment was carried out. The 
strain DK897 was cultivated in 
13
C / 
15
N background media. The extracts were analyzed with 
HR-MS, and compared to a mixture of the extracts of CTT with 
13
C, CTT with 
15
N, and a 
mixture of CTT, 
15
N and 
13
C. Using this technique all sum formulae could be confirmed by 
mass shifts depending on the number of carbons and nitrogens (Table 4). However, due to a 
very bad growth of the strain in the isotope background media (differs to the typical media 
composition for myxobacteria) only three myxoprincomides could be analyzed. 
 
Compound [m/z] Calculated [m/z] Sum formula 
c382 382.1963 382.1973 C18H27N3O6 
c683 683.3602 683.3610 C31H50N6O11 
c798 798.3879 798.3880 C35H55N7O14 
c800 800.4187 800.4036 C35H57N7O14 
c812 812.4035 812.4036 C36H57N7O14 
c814 814.4189 814.4193 C36H59N7O14 
c580 580.7949 580.7954* (1160.5834) C53H81N11O18 
c581 581.8027 581.8031* (1162.5990) C53H83N11O18 
c587 587.8028 587.8031* (1174.5990) C54H83N11O18 
c588 588.8107 588.8110* (1176.6147) C54H85N11O18 
Table 3:  Molecular formulas of myxoprincomides in DK897; * doubly charged. 
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Figure 46:  Extracted ion chromatograms of wild type and myxoprincomide knockout mutant 
showing that c800, c580, c587 and c587 are all compounds of the origin of one biosynthetic 
gene cluster.  
 
Compound [m/z] 
[m/z]  
13
C isotopes 
No.  
of C 
[m/z] 
15
N isotopes 
No.  
of N 
Sum formula 
c382 382.19735 400.25827 18 385.18881 3 C18H28O6N3 
c800 800.40381 835.51959 35 807,38257 7 C35H58O14N7 
c814 814.41965 850,53760 36 821,39923 7 C35H58O14N7 
Table 4:  Confimration of the molecular formulae of myxoprincomides in DK897 by incorporation 
of 13C and 15N. 
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In a next step the predicted A-domain specificity was checked. Therefore feeding experiments 
with the following amino acids were preformed: L-Methionine-(methyl-D3), L-Phenylalanine 
(-ring-
13
C6), L-Serine-(
13
C3, 
15
N), L-Valine-D8. The amino acids were added in small portions 
to the culture to a final concentration of 1 mM. The culture extracts were analyzed by HPLC-
MS. Valine is incorporated once, but with a mass shift of +7. Serine is incorporated several 
times but the exact amount was not clear as the mass shifts were not clearly defined for 
multiple incorporations. In contrast phenylalanine feeding showed a clear mass shift of 6 units 
that means exact one phenylalanine is embedded. The feeding of methionine resulted in a 
mass shift of +3. By feeding labeled methionine a labeled SAM pool is build which is then 
utilized for N-methylations. If methionine would be incorporated as whole amino acid the 
characteristic isotopic pattern would change because of the sulphur isotopes. Here only the 
methyl group of methionine is incorporated. The results of the amino acid feedings are shown 
in Table 5. The findings were in good agreement to the predictions for the A domains of the 
myxoprincomide gene cluster.  
 
Compound*
 
L-Methionine- 
(methyl-D3)
 
L-Phenylalanine 
(-ring-
13
C6) 
L-Valine 
(D8) 
L-Serine 
(
13
C3, 
15
N) 
c382 1 1 1 1 
c581 1 1 1 3 - 4 
c587 1 1 1 3 - 4 
c683 1 1 1 3 - 4 
c800 1 1 1 2 - 4 
c814 1 1 1 3 - 4 
Table 5:  Number of incorporated labeled amino acids in the myxoprincomides. Methionine is 
incorporated as N-methyl-D3. * Not every compound was produced. 
 
Purification procedure 
Since the compounds could not be predicted from the genes it was planned to isolate and to 
characterize them. But the first problem was to obtain sufficient material for compound 
purification and structural elucidation. Isolation of the myxoprincomides from an extract of a 
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70 L cultivation of DK897 was attempted. All isolation methods failed to yield measurable 
amounts of myxoprincomides. Reasons for that were the low production rate and the strong 
polarity of the substance. Major parts of the compound were not absorbed by the absorber 
resin XAD16. After extractions with ethyl acetate or butanol the myxoprincomides stayed 
mainly in the water phase.  
As soon as the complete sequence of the gene was established and it was known that the 
megasynthetase is encoded by a single gene, production of the new compounds could be 
improved by introducing a promoter upstream of the gene. A promoter was inserted upstream 
of the gene by a single cross over experiment resulting in the mutant called 
DK897_800erstart. The chosen promoter was known to increase the production rate in 
myxobacteria. The same techniques as used by N. Socorro Cortina et al. were employed. 
[176]
 
The clones were tested for their production by HPLC-MS. The promoter insertion yielded in a 
high production of myxoprincomides. 
Beside that different media (like TS, CYE, M) were tested for improved myxoprincomide 
yield. Furthermore the addition of Fe(III)-EDTA was used to reduce the amount of produced 
myxochelin as it coelutes in the same range as the targeted compound. Using these conditions 
some of the myxoprincomides could be detected in the MS-BPC which was never possible in 
the wild type before. That means that the production rate was significantly increased. 
Therefore the DK897_800erstart mutant was cultivated in a 300 L fermenter.  
 
The obtained XAD was transferred into a big glass column, extracted with water, followed by 
a mixture of water / MeOH (1:1), and pure MeOH. Major parts of the compound 
myxoprincomides were detected in the methanol water mixture and in the first pure methanol 
fractions. The solvent was removed, diluted in MeOH and defatted with n-heptane. The crude 
methanol extract was dissolved in water and portioned with ethyl acetate. The remaining 
crude extract was loaded onto a methanolic Sephadex
®
 LH-20 column. 
The fractions positive for myxoprincomides were further purified using a preparative HPLC-
MS system equipped with an Xbridge C18 OBD column (Waters). First purification round 
using methanol / water eluent (pH = 3), second round same eluent but pH = 9.4 and a last 
purification step with acetonitrile as eluent (pH = 3). Impure fractions were further separated 
via a methanol Sephadex
®
 LH-20 column to obtain pure substances of c382, c683, c798, 
c800, c812, c814, c582 and c587. 
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Structure elucidation of the myxoprincomides 
For structure elucidation one and two dimensional NMR spectra were generated (spectra 
depicted in Supplementary figure 11 to Supplementary figure 71). The structure was solved 
step by step through identifying each single amino acid in the peptide chain. COSY and 
TOCSY spectra were used for spin system analysis. The correlations are depicted in Figure 
47. CH correlations were received from HSQC spectra. For long range C - H correlations 
HMBC data were used (Figure 48). All experiments were carried out in d6-DMSO. The 
detailed NMR-data for the myxoprincomides are shown in Supplementary table 1 to 
Supplementary table 8. 
 
As all ten peptides have similar core structure their structure elucidation is exemplified by 
c800 (43) as the best NMR data were obtained here; data shown in Table 6. In total seven 
amino acids (AA1 to AA7) could be identified for 43: 
 
AA1: The myxoprincomide structure begins with a methylated serine (NMeSer). In this spin 
system of NMeSer two protons are connected to a hydroxylated carbon atom. Next to that 
group a single proton is bound to a carbon with a shift of 64.4 ppm which shows an HMBC 
correlation (Figure 48) to a methyl group with a chemical shift of 33.1 ppm indicating an N-
methyl group. 
 
AA2: Adjacent to AA1 a β-oxidized valine (OH-Val1) is bound. This is reflected in two 
methyl groups showing a singlet in the proton spectra. These methyl groups are in the 
neighborhood of a quaternary carbon with a shift of 71.7 ppm. A chemical shift of 71.7 ppm 
indicates a hydroxyl group linked to a carbon. This carbon displays a HMBC correlation 
(Figure 48) to the α-proton of the amino acid and the two methylgroups mentioned before. 
 
AA3: After OH-Val1 (AA2) an amino acid with an aromatic spin system follows in the 
peptide sequence. This amino acid exhibits five aromatic protons showing a characteristic 
coupling pattern of a phenyl ring. These protons are in the neighborhood of a CH2 group 
followed by an α-proton. Hence it could be identified as a phenylalanine.  
 
AA4: Similar shifts to the ones of AA2 appear in the next amino acid, it is another β-oxidized 
valine (OH-Val2). 
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AA5: The α-proton of the next spin system shows a COSY correlation to a CH2 group. This 
carbon has a chemical shift of 62.0 ppm which originates from a connected hydroxyl group. 
Thus this amino acid is a serine.  
 
AA6: The subsequent spin system in the COSY spectrum contains two methyl groups and 
three CH groups in a row. The first CH carries the two methyl groups to build an isopropyl 
unit. This isopropyl group is linked to a CH which is further connected to nitrogen atom and 
the third CH group. The latter is neighbored to a hydroxyl group, and a carbonyl verified by 
HMBC correlations (Figure 48). That means this amino acid is 3-amino-2-hydroxy-4-
methylpentanoic acid (2OH-β-Val). 
 
AA7: The last amino acid in the structure of c800 (43) shows further characteristic shifts of a 
serine like AA5. 
 
Figure 47:  COSY correlations in c800. 
The amino acid sequence of the peptide was determined by correlations from the carbonyl 
groups to the nitrogen protons and the α-protons of the amino acids (HMBC correlations, 
depicted in Figure 48). Beside that NOESY correlations were used, too. The outcome of the 
above described NMR analysis was the structure of c800 (43) as depicted in Figure 47 to 
Figure 49. 
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Figure 48:  HMBC correlations of myxoprincomide c800; only important ones are shown. 
Myxoprincomides c382 (40) and c683 (41) are smaller fragments of c800 (43). Therefore the 
chemical shifts are similar and could be compared to c800 (43). c382 (40) consists out of the 
first three amino acids NMeSer, OH-Val1 and Phe (AA1 to AA3). c683 (41) is a hexapeptide, 
it consist of the same first five amino acids (AA1 – AA5) which are part of c800 (43) while 
the last amino acid is a normal valine instead of 2OH-β-Val. The valine is reflected by two 
methyl groups which show a COSY correlation to a CH group that is connected to the α-CH 
of the amino acid. 
Myxoprincomide c798 (42) has two protons less than c800 (43). The reason for that is a 
diketo group in (AA6). Here the 2-hydroxy group of 2OH-β-Val is oxidized to a keto group, 
resulting in 2-oxo-β-Leu. 
 
Beside those four myxoprincomides five larger ones were isolated: c812 (44), c814 (45), c581 
(46), c582 (47), c587 (48) and c588 (49). In c812 (44) and c814 (45) the pentanoic amino acid 
(AA6) is extended by one CH2 unit to result in 3-amino-2-hydroxy-5-methylhexanoic amino 
acid and 3-amino-5-methyl-2-oxohexanoic amino acid respectively. 
c581 (46), c582 (47), c587 (48) and c588 (49) are decapeptides. The amino acid sequence of 
c800 (43) continues with a tyrosine (AA8). Here the aromatic spin system shows a para 
disubstituted phenyl ring connected to the peptide backbone. Tyrosine is followed by a β-
lysine (AA9) which is identified by the analysis of a spin system containing eight different 
proton signals bound to five different carbons. The final spin system (AA10) shows a methyl 
group neighbored to the α-proton of an amino acid. The chemical shifts are characteristic for 
an alanine.  
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The differences between c581 (46) and c582 (47) are again the variation of the oxidized stage 
in the pentanoic acid (AA6; 2OH-β-Val vs. 2-oxo-β-Leu).  
While c587 (48) and c588 (49) consist out of a hexanoic acid at AA6, instead of a pentanoic 
acid. The difference is once again the oxidation stage of AA6, although c588 (49) could not 
be isolated in sufficient amounts for complete NMR analysis, but its mass indicates the keto 
hydroxyl form of 48.  
Chapter 2A: DK897 Myxoprincomides 
 
 
86 
 
Figure 49:  Structure of the myxoprincomides in DK897: 40 = c382, 41 = c683, 42 = c798, 43 = c800, 
44 = c812 
Chapter 2A: DK897 Myxoprincomides 
 
 
87 
 
Figure 50:  Structures of the myxoprincomides from DK897: 45 = c814, 46 = c581, 47 = c582, 48 = 
c587, 49 = c588 
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 δC δH (J in Hz) HMBC 
 NMeSer 
   
1 169.3     
2 64.4 3.53 m 1, 3 
3 61.1 3.62 m 1, 2, NMe 
    3.55 m 1, 2 
NH    * 
 
NMe 33.1 2.31 s 2 
OH-Val1 
   
1 170.2     
2 55.9 4.28 m 1, 3, 4, 5, 1NMe 
3 71.8     
4 26.0 1.05 s 3, 5 
5 25.9 0.98 s 3, 4 
NH   8.47 m 2 
Phe 
   
1 170.4     
2 54.8 4.58 m 1, 3, 1´ 
3 37.7 3.01 m 1, 2, 1´, 2´, 6´  
    2 75 m 2, 1´, 2´, 6´  
1´ 138.0     
2´, 6´ 128.8 7.17 m 3, 1´, 3´, 4´, 5´ 
3´, 5´ 129.7 7.17 m 1´, 2´, 4´, 6´ 
4´ 127.0 7.11 m 1´, 3´, 5´ 
NH   8.42 d (8.0) 1OH-Val1 
OH-Val2 
   
1 171.9     
2 61.0 4.31 m 1, 3, 4, 5, 1Phe 
3 72.0     
4 27.6 1.09 s 2, 3, 5 
5 27.9 1.00 s 2, 3, 4 
NH   8.09 d (8.0) 1 
Ser1 
   
1 170.3     
2 55.9 4.27 m 3 
3 62.0 3.49 m 1 
    3.49 m 1 
NH   8.20 d (5.9) 1 
2OH-β-Val 
   
1 172.9     
2 70.9 4.09 m 1, 3, 4 
3 57.5 3.79 m 4, 6, 1Ser1 
4 29.7 1.75 m 3, 6 
5 20.2 0.84 d (6.4) 3, 4, 6 
6 19.9 0.76 d (6.4) 3, 4, 5,  
NH   7.68 d (6.3) 1Ser 
Ser2 
   
1 174.4     
2 56.9 3.86 m 1, 3 
3 62.8 3.58 m 1, 2 
    3.58 m 1, 2 
NH   7.78 d 1, 1 2OH-β-Val 
Table 6:  NMR data of myxoprincomide c800 measured at 500 MHz in DMSO (* = not assigned). 
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By NMR experiments the structure was determined, but not the absolute configuration of the 
peptide. The absolute configuration of amino acids can be determined by different methods. 
One commonly used method is the Mosher ester technique; it identifies the absolute 
configuration of unknown sterogenic center of secondary alcohols or amines by NMR. 
[214;215] 
Mosher's acid (α-methoxy-α-trifluoromethylphenylacetic acid (MTPA)) reacts with an alcohol 
or amine to form an ester or amide. Here one uses the fact that the protons display different 
chemical shifts depending on an R or S configuration. 
An alternative would be NMR measurements using the coupling constants and using NOESY 
or ROESY data. But even here one stereo center has to be known before. It is possible to 
determine the configuration by the combined analysis of homonuclear (H-H) and 
heteronuclear (C-H) 
2,3
J couplings and NOEs. 
[216] But as the observed myxoprincomide 
spectra were already complicated due to signal overlapping it would be hard and probably not 
possible to assign the configuration for all stereo centers. Therefore NMR structure 
elucidation was only used for the identification of the amino acids and for determining the 
amino acid sequence. But the stereochemistry of the amino acids remained to be solved after 
the NMR analysis. To determine if the amino acids had L- or D- configuration the 
myxoprincomides were hydrolyzed and amino acids were assigned by advanced Marfey’s 
method. 
[217-221] 
The advanced Marfeys reagent (D/L-FDLA) reacts with the amino acid and 
depending on its configuration it results in a LL or LD configuration and DL or DD, 
respectively (Figure 51). The diasteromers LL and RR elute in HPLC analytic at one retention 
time, same for DL and LD. The amino acids are derivatized once with D-FDLA and once 
with L-FDLA. With the knowledge of the configuration from the Marfeys reagent it possible 
to assign the amino acid configuration (Table 7). All amino acids in the myxoprincomides are 
L-amino acids. 
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Figure 51:  Marfeys reagent reacts with the amino acid to the LL- of LD-diasteronmer. 
 
Component 
Mass of derivatized 
 amino acid 
Retention time of 
L-FDLA + L-aa 
Retention time of 
D-FDLA + L-aa 
L-Alanine 384.2 11.7 12.5 
L-Tyrosine 476.3 11.9 12.4 
L-Valine 412.3 12.4 13.7 
L-Phenylalanine 460.3 13.1 14.2 
Met-Ser 414.2 10.5 10.7 
OH-Val 428.2 11.1 12.2 
2OH-β-Val 442.2 12.1 12.9 
2OH-β-Leu 456.2 12.2 13.9 
Table 7:  Retention times of the amino acids in the myxoprincomides with the Marfeys reagent.  
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Biosynthesis of the myxoprincomides 
Knowing the structure of the myxoprincomides, the biosynthesis can be further analyzed and 
inactive modules can be assigned. The complete biosynthesis is schematically shown in 
Figure 53. 
Based on the structure the biosynthesis begins with module 1 instead of starting with the 
loading module. A reason for it might be as described before, that the C domain in module 1 
has deviations in its core motifs possibly rendering it inactive. The metabolite starts with L-
serine which is methylated by the N-methyltransferase of module 1. In the next step the amino 
acid is condensed with a β-hydroxylated L-valine (module 2). Alternatively it is condensed 
with a valine which is hydroxylated later on during biosynthesis. An incorporation of L-
phenylalanine and a chain extension by another β-hydroxylated L-valine or rather valine with 
later hydroxylation follows (modules 3 and 4). The prediction for the A domains in module 2 
and 4 did expect ornthine and hydroxyl-phenyl-glycine and not valine or rather the 
uncommon β-hydroxylated L-valine. Module 5 extends the intermediate by an L-serine as 
predicted. The following three modules are special. For c683 (41) module 6 connects the 
intermediate with a valine. But for the longer metabolites at this position there is a hexanoic 
or a pentanoic amino acid. If the pentanoic or rather the hexanoic amino acids are directly 
attached by module 6 then module 7 and 8 would be inactive. This is very unlikely because 
the substrate specificity of the A domain of module 6 would be uncommonly wide it would be 
able to accept at least five different amino acids. From the genetic point of view the PKS 
module (module 7) seems to be active and the NRPS module 8 exhibits an oxidation domain 
within the A domain and no PCP. Such embedded oxidation domains within A domains are 
described for example for the biosynthesis of myxothiazol in MtaD 
[119]
 and for epothilone in 
EposP 
[222;223]
. The Ox domain are located between the A8 and A9 motifs of an A domain. 
[224]
 
A suggestion for the involvement of module 7 and 8 is made for the myxoprincomide 
biosynthesis of DK1622 (see chapter 2B). 
[176]
 In this proposal both modules are active. The 
PKS module (module 7) adds a malonyl-CoA to the intermediate (refer to Figure 52). And the 
oxidation domain of module 8 possibly performs an alpha oxidation of the acetyl group. The 
obtained functional groups tautomerise and are attacked by the serine introduced by module 9. 
During this process a CO is lost. Parts of the intermediates are further oxidized (by module 9) 
to built a diketo group; others remain as 1-keto-2-hydroxy group. This is a very unusual step 
and not fully understood. But feeding experiments of different 
13
C-labeled acetates in 
DK1622 supported the above described hypothesis because of an incorporation of one 
13
C-
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labeled carbon (see chapter 2B). 
[176]
 The mechanism will be further addressed in chapter 
2B 
[176]
.  
After the unusual building block the assembly continues according to textbook NRPS 
biosynthesis. The amino acids: L-serine, L-tyrosine, beta-lysine, and L-alanine are added by 
module 9 to 12. The specificity for serine, tyrosine and beta-lysine was predicted before. 
Module 13 can be assumed to be inactive as the PCP domain has some proline residues in the 
sequence that are not present in other PCP domains of the assembly line. These proline 
residues could have an effect on the proper folding of the domain and leads to inactivity. 
From the last module only the TE domain is needed. It is in charge of releasing the final 
product. For the release of the intermediates a bail out of the intermediates directly from the 
assembly line is imaginable. For such event normally a type II TE is needed. Typically these 
trans-acting TEs remove aberrant intermediates on biosynthetic assembly lines. 
[225]
 Here such 
a TE was not identified so far, therefore it might be possible that there is a product release 
with unknown mechanism or a hydrolytical spontaneous release. 
[225]
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Figure 52:  Proposed mechanism for the α-hydroxy moiety formation or rather α-keto intermediate 
formation (only modules 6 to 10 are shown). 
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Figure 53:  Scheme for the biosynthesis of the myxoprincomides in M. xanthus DK897 exemplified 
with the final structure of c581. 
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Comparison of the mxp biosynthetic pathways from DK897 and DK1622 
The comparison of the two different myxoprincomide structures of DK897 and DK1622 
(Figure 54) already suggests a biosynthetic relationship. 7 amino acids out of 9 are identical 
and in the same amino acid order. A view at the two biosynthetic pathways (Figure 53 and 
Figure 55) reveals that the two mxp clusters of the M. xanthus strains are very close relatives. 
As the domain order in the clusters is similar, apart from one additional module. Probably one 
module was inserted or lost during an evolutionary process.  
 
 
Figure 54:  Structures of myxoprincomides of DK897 (c582) and of DK1622 (c506). 
That the A domains in both biosynthetic gene cluster are very similar to each other can be 
shown by a phylogenetic tree (Figure 56). Each A domain has exactly one very close relative 
from the other strain, except the A domain A2 of mxpDK897. 
The A domain specificities within the cluster of DK1622 
[176]
 and DK897 were compared 
(Table 8). Domains A2 (extra), A3 and A6 of DK897 have some differences to the 
corresponding A domain of DK1622 but a prediction by the residues was not possible. 
Chapter 2A: DK897 Myxoprincomides 
 
 
96 
 
Figure 55:  Comparison of the myxoprincomide clusters of DK897 and DK1622. 
 
 
Figure 56:  Phylogenetic tree of A-domains from myxoprincomide cluster of DK1622 and DK897 
Furthermore every domain was aligned to its possible analogue of the other strain (Table 9). 
The identity is always above 87 % except for PCP3 (47.9%), C4 (82.4%), C5 (80.5%) and the 
domains of module 2 of DK897 which do not have an analogue in DK1622. That means here 
are the major differences on protein level between the two clusters.  
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To conclude, the gene cluster of DK897 exhibits one additional module (module 2) which 
incorporates an OH-Val or rather a valine with subsequent oxidation. While module 3 
employs a phenylalanine instead of a leucine. Hence these two modules are in charge of the 
structural differences of the myxoprincomide of DK897 and DK1622. 
A-Domain 
Analysis with web  
tools of J. Ravel et al. 
[211]
 
Analysis with web  
tools of T. Weber et al. 
[212]
 
residues pred. residues pred. 
A1 DK1622 DVWHVSLV ser DVWHVSLVD- ser 
A1 DK897 DVWHVSLV ser DVWHVSLVD- ser 
A2 DK1622 DVVLMGAT no DVVLMGATMK no 
A2 DK897 DVGELVSI orn DVGEIGSIDK orn 
A2 DK1622 DVVLMGAT no DVVLMGATMK no 
A3 DK897 DVILLGGT no DVIVLGGTMK no 
A3 DK1622 DALWLGLG hpg DALWLGGTFK val 
A4 DK897 DALWLGLG hpg DALWLGGTFK val 
A4 DK1622 DVWHVSLV ser DVWHVSLVDK ser 
A5 DK897 DVWHVSLV ser DVWHVSLVDK ser 
A5 DK1622 DGMHNVGI no DGMHNVGIIK no 
A6 DK897 DGMHHVGI no DGMHHVGIIK no 
A6 DK1622 Mono-oxygenase no Mono-oxygenase no 
A7 DK897 Mono-oxygenase no Mono-oxygenase no 
A7 DK1622 DVWHVSLV ser DVWHVSLVDK ser 
A8 DK897 DVWHVSLV ser DVWHVSLVDK ser 
A8 DK1622 DG-DVAAV no DGEDVAAVCK tyr 
A9 DK897 DG-DVAAV no DGEDVAAVCK tyr 
A9 DK1622 DTENVGTA ahp DTENVGTAVK lys-b 
A10 DK897 DTENVGTA ahp DTENVGTAVK lys-b 
A10 DK1622 DG-DFGVV no DGEDFGVVCK ile 
A11 DK897 DG-DFGVV no DGEDFGVVC- no 
A11 DK1622 DV-DLAAV no DVDDLAAVYK val 
A12 DK897 DV-DLAAV no DVDDLAAVYK val 
Table 8:  Analysis of the A domains of the DK897 cluster and gmxorf2004 of DK1622; differences in 
the residues are marked in bold  
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DK897 Identity [%] DK1622 
 
DK897 Identity [%] DK1622 
ACL 98.0 ACL 
 
KS1 98.4 KS1 
ACP1 100.0 ACP1 
 
AT1 97.3 AT1 
C1 97.7 C1 
 
ACP2 96.9 ACP2 
A1 94.9 A1 
 
C7 91.9 C6 
M 98.0 M 
 
A7 97.8 A6 
PCP1 100.0 PCP1 
 
C8 87.6 C7 
C2 90.8 C2 
 
A8 95.3 A7 
A2 50.1 A2 
 
PCP8 100.0 PCP7 
PCP2 47.9 PCP2 
 
C9 97.7 C8 
C3 87.6 C2 
 
A9 97.3 A8 
A3 89.1 A2 
 
PCP9 95.4 PCP8 
PCP3 47.9 PCP2 
 
C10 98.2 C9 
C4 82.4 C3 
 
A10 96.3 A9 
A4 90.0 A3 
 
PCP10 100.0 PCP9 
PCP4 92.3 PCP3 
 
C11 98.2 C10 
C5 80.5 C4 
 
A11 98.1 A10 
A5 94.5 A4 
 
PCP11 97.0 PCP10 
PCP5 95.4 PCP4 
 
C12 96.6 C11 
C6 91.7 C5 
 
A12 97.1 A11 
A6 97.3 A5 
 
PCP12 100 PCP11 
PCP6 98.5 PCP5 
 
TE 97.2 TE 
Table 9:  Identity between the domains of mxpDK897 and mxpDK1622. 
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Conclusion  
To conclude, novel myxoprincomides 
I
 have been discovered in M. xanthus DK897. 
Structurally the myxoprincomides are interesting due to numerous striking features like 
unusual amino acids and other rare structural elements. Up to now, ten compounds, which 
were correlated to the DK897 myxoprincomide gene cluster, were detected: c382 (40), c683 
(41), c800 (43), c812 (44), c814 (45), c581 (1160) (46), c582 (1162) (47), c587 (1174) (48) 
and c588 (1176) (49). The last four are probably products of the complete assembly line, 
while the others are possibly chunk products, released early from the assembly line. It is likely 
that further intermediates of the myxoprincomide family, like a tetra, penta, octa or nona 
peptides, are produced but not detected up to date. However it is a fascinating example of an 
NRPS-PKS assembly line, which releases several intermediates. With its 39 catalytic domains 
mxp897 is the largest myxobacterial biosynthetic gene identified so far. Furthermore it is 
particular exciting due to its analog in M. xanthus DK1622. The analysis of 98 M. xanthus 
strains revealed that either the myxoprincomide type of DK897 or the variants of DK1622 are 
built, but never both. 
[51]
 That means, either the strains possess the DK897 gene cluster or the 
DK1622 one. Therefore the myxoprincomides must exhibit a fundamental role for the 
M. xanthus strains. 
The characterization of the biosynthetic machinery revealed, that it does not follow the 
biosynthetic textbook model. Several deviations of in silico predictions were identified. It 
shows once again that textbook biochemistry cannot always be applied for myxobacteria.  
 
 
Methods 
Cultivation:  
Myxococcus xanthus DK897 and mutant strains were grown in CTT medium (1 l water, 10 g 
Casitone (Difco), 10 ml 1 M Tris-HCl pH = 8.0, 10 ml of 0.8 M MgSO4, 1 ml K2HPO4 pH = 
7.6, final pH adjusted to 7.6). For mutant strains kanamycin sulfate was added (50 µg / ml). 
Cultures were grown in 50 ml CTT medium containing 2 % amberlite XAD-16 resin (Sigma-
Aldrich). Cultures were grown for 72 h at 180 rpm, 30 °C in 300 ml Erlenmeyer flasks. 
Cultures were harvested by centrifugation (10 min, 8000 rpm). The XAD / cell pellet was 
                                                 
I
 The name myxoprincomide is derived from myxobacteria (myxo-), its discovery by principal (-prin-) 
component (-co-) analysis and the amide (-mide) bond. 
Chapter 2A: DK897 Myxoprincomides 
 
 
100 
extracted with methanol (2 x 50 ml), dried in vacuo. For HPLC-MS (and HR-MS) analysis it 
was resuspended in 1 ml methanol.  
 
MS analysis:  
HPLC-HR-MS: Accela UPLC system coupled to a TriVersa NanoMate (Advion) ion source 
and a LTQ Orbitrap (Thermo Scientific). Separation: RP-18 column (50 mm x 2.1 mm, 
particle size 1.7 µm; Waters Acquity BEH), mobile phase was water (A) and acetonitrile B 
(each plus 0.1 % formic acid), flow rate of 400 μl / min, gradient: 0 min 1 % B; 1 min 1 % B; 
10 min 99 % B; 12 min 99 % B; 12.5 min 1 % B; 14 min 1 % B.  
HPLC-MS: Positive / negative mode, m/z = 100-1100, auto MSn, runtime 24 min, column 
Luna C18 2.5µm, T = 32 °C, flow rate = 0.400 ml/min, solvent A: water with 0.1 % formic 
acid, B: acetonitrile with 0.1 % formic acid. The different gradients are depicted in Table 10 
to Table 12. 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
0 95 5 
1 95 5 
16 5 95 
18 5 95 
19 95 5 
24 95 5 
Table 10:  Gradient of 1STDKURZ 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
0 95 5 
2 95 5 
22 5 95 
25 5 95 
27 95 5 
32 95 5 
Table 11:  Gradient of 1Std_neu 
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Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
0 95 5 
2 95 5 
32 5 95 
36 5 95 
39 95 5 
44 95 5 
Table 12:  Gradient of 1STDLANG 
Gene inactivation: 
A fragment of ~550 bp was amplified using Taq polymerase (Fermentas). The resulting PCR 
product was cloned into pCR2.1-TOPO (Invitrogen). E. coli (DH10b) cells were used for 
cloning. The colonies were selected on Luria–Bertani (LB)-agar containing kanamycin sulfate 
(50 µg / ml), single colonies were cultivated in LB medium (1.5 ml, with Kan 50 µg / ml). 
From these cultures plasmid was isolated using the Nucleospin plasmid kit (Macherey & 
Nagel). The obtained plasmid was transformed into M. xanthus DK897 (650 V, 400 Ω, 25 µF, 
creation of M. xanthus mutants described previously [195-198]). 
 
Transposon-mutagenesis and transposon recovery: 
The plasmid pMycoMar 
[226]
 was used for transposon mutagenesis. It contains the mini -
transposon magellan4, kanamycin resistance and the oriR6K. Because of the TA dinucleotide-
recognition sequence it is able to integrate randomly into several host genomes. 45000 clones 
were obtained, 2688 of them were cultivated (each clone in 250 µl CTT-media containing 
kanamycin, in microtiter plates at 30 °C for 3 days). For HPLC-MS analysis the clones were 
cultivated under the same conditions together with XAD resin for 72 h. The cultures were 
centrifuged and the precipitate was extracted with methanol. The obtained extract was then 
analyzed by HPLC-MS. The extracts were screen for the lack of c382, c800, c814. In mutant 
5D9 these compounds were missing. For transposon recovery the chromosomal DNA was 
isolated (Puregene™ DNA Purification Kit), digested with SmaI, re-ligated, transformed in 
E coli DH5α-λpir. Plasmids were isolated and sequenced with primers (K388 and K390 for 
the kanamycin resistance gene). For obtaining further sequence information new primers were 
subsequently designed to obtain the complete sequences information of the plasmid. For 
obtaining more sequence information a TOPO plasmid (Invitrogen) was integrated at the end 
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of the known sequence of the myxoprincomide cluster in DK897. DNA was isolated, digested 
with HindIII, relegated, and transformed into E. coli DH5α-λpir, followed by plasmid 
isolation and again subsequent sequencing of the plasmid. By this method 10460 bp of 
sequence information were gathered. This information was later on used when contigs of the 
strain were available, to identify contigs which were part of the gene cluster.  
 
Contigs: 
A PCR at 65 °C with Phusion polymerase (Finnzymes) was performed between the gaps of 
the contigs. Primers:  
1012_e_1for = CTGGGGGCTGAGGACTTCGTG 
0024_a_1rev = GACGCGAGGCGCTGGGAGCAC 
1012_a_1rev = GTAGCCGTTCACCAGCCCCAC 
0032_e_1for = CAACTCGCCGGGCATGCCGAG 
0032_a_1rev = GTCTTCGCGAACCACGGCGAC 
0982_e_1for = CTGGACTTGCTGGTGGGCCTG 
0982_a_1rev = GTTGACGAAGAAGCCAATGAG 
0024_e_1for = GAGGTGACCATCCACGCGCTG 
1009_e_1for = GAACGAGACGTCGAAGATC 
1009_a_1rev = GTCCCGCGGTCAGTAGCGCCAAG. 
The resulting amplificates were cloned into the pJet vector (Fermentas), electroporated into 
E.coli (DH10b) and the plasmids were sequenced. The missing gap could be closed between 
1009 and 1012 (324 bp), between 0982 and 0024 (639 bp), between 1009 and 0982 (236 bp), 
for the fourth gap there was no correct clone and it has to be repeated. 
 
Scaffolds: 
High quality genomic DNA was prepared (because of several PCR problems) and primers 
were designed to amplify these regions:  
scaf37_1f = CGTTCGAGTCAGAGCGGCTGA 
scaf37_2f = GAGCTCATCGAAGCGCAAGTC 
scaf37_3f = TGACCACCCTGCCGTTGATG 
scaf24_1r = CATCAACGGCAGGGTGGTCA 
scaf24_2r = CACGTCTCCGGTGCGGTACAG 
scaf24_3r = CACCCAACTCGATGCGGAAGC  
A2_1f = ATCACGCCGCATCAGCGCGGT 
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A2_2f = GCTGACACCACCGTCCATCA 
A2_3f =CTGGATGCGAGGGCCAACCA  
A2_1r = TGCTGCATCTGCTCGAAGAGT  
A2_2r =CGATGGACACGGAGTCACCCAC 
A2_3r = AGGCCCGAAGGGATTGGGCAC  
A4_1f = TGCACCGGGGCCTGGACTTGCTG  
A4_2f = CTCAGTGCGCTGCCCATGATG 
A4_1r = TGAGGTGCGAACCGGCGGGCAG 
A4_2r = CACGAAGCGAGAGCCGATGAG 
A?_1f = CTCGGAGCGCATCTCCCGGTTG  
A?_2f = CTGGAGTACGCCACCGAGCTG  
A?_1r = GACACCCCAGAGGACGGCCAG 
A?_2r = CTCCAGCGCGTCCTCCACATGG  
A?2_1f = CTGGGAACGGAGGTCCTGCTC  
A?2_2f = CTCATCGACTTCGGCCTGGACAC  
A?2_1r = GGAAGTTGGAGCCGTTGTTGTAC  
A?2_2r = GACCTCGTGCCGCTTCACCAC 
A6_1f = CTGCAACGTGTCGCCATCCTCTC  
A6_2f = CTCCAAGTTCGACCTGAGCCTG 
A6_3f = CACTTCGGGTCAGGAGGACTTCG  
A6_1r = GTGCGCGGAGCGACGTAGAG 
A6_2r = TCGCGTCTCCTCACGCACCAC  
A6_3r = GACACCCAGGTGAACGAAGGTC  
A9_1f = GGACGCTTTCAGTGGACAGC 
A9_2f = GAGCTGTGCATCGCGGGAGAAGG  
A9_3f = CCTTCAACGTCTACGGCCCGAC 
A9_1r = GACCGACTGGAAGGCCGCGAG  
A9_2r = GTTCACGAAGAAGCCGATGAG  
A9_3r = GTCCAGGCTCAGCTCGAACAG  
A10_1f = GATGCTGGCGTGGCTGGAGCA  
A10_2f = CGTCATCTACACGTCCGGCT 
A10_1r = GAGCCGCAGCTCGAGCCCATC  
A10_2r = CTTGCGGTCCACCTTTCCAC 
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The obtained fragments (Supplementary figure 84 and Supplementary) were ligated into the 
pJet-vector (Fermentas), plasmid DNA was isolated and send for sequencing. 
 
Annotation: 
Using the PKS / NRPS analysis software of http://nrps.igs.umaryland.edu/nrps/index.html 
[211]
 
annotations of the clusters were performed. For the substrate prediction of A domains the 
NRPSpredictor software (http://www-ab.informatik.uni-tuebingen.de/software/NRPS 
predictor) 
[212]
 was used. The published genome sequence of the M. xanthus DK1622 is 
available under http://ncbi.nlm.nih.gov.  
 
Reverse feeding: 
The Casitone in the CTT media was exchanged against the enriched 
15
N respectively 
13
C 
powder (ISOGRO). 0.5 ml of DK897 CTT culture were centrifuged, the pellet was washed, 
and dissolved in 5 ml 
15
N / 
13
C media. Each sample was grown in 25 ml flasks, in duplicates 
as well as the control with CTT media. After 3 days the culture have been harvested and 
extracted and analyzed as described before.  
 
Feeding of labeled amino acids: 
The amino acids were dissolved in water and added in small portions to the culture, every 
morning and every evening to end with a final concentration of 1 mM in 25 ml. The cultures 
were extracted and measured in the hct and in the Orbitrap and compared to the control. In the 
hct only the 580.8 could be detected. In the Orbitrap measurements small traces of 800 and 
814 were found, too.  
 
Promoter insertion: 
The first 804 bp of the gene cluster were amplified with Phusion (Finnzymes) polymerase 
using the following primers:  
start800_1f = CGCGCTCATATGCACGAGACTCCGCGAAC 
stop800_1r = CTCGAATTCGAAGTTGGGTCCACCGCTGATG 
58 °C, GC buffer (Finnzymes). The PCR product and the pSBtn5Kan plasmid 
(Supplementary figure 79) were digested with NdeI and EcoRI and ligated. The resulting 
plasmid (pSBtn5Kan-800erstart) was transformed into the strain DK897. The plasmid should 
integrate directly in front of the cluster which is then under the control of the tn5 promoter 
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and has a RBS directly before the start codon. After confirmation of the appropriate 
integration by PCR the strain was cultivated in large scale. 
 
Large scale fermentation: 
The mutant DK897_800erstart was cultivated for 144 h in a 300 l fermenter with PS medium 
(10 g / l Casein Peptone Type S (Marcor), 2 g / l MgSO4, 80 μg / ml Fe(III)EDTA , and 4 g / l 
starch) pH = 7.1). After 72 h, 2 % XAD-16 resin was added. At the end XAD and the cells 
were separated from the liquid medium. The fermentation was performed by W. Kessler. 
 
Purification: 
The XAD (2 kg) was transferred into a big glass column, extracted with water (2.5 l), a 
mixture of water / MeOH 1:1 (2.5 l), MeOH extraction (6 l). The cells (200 g) were extracted 
twice with MeOH and once with CHCl3. The different fractions were analyzed for their 
compounds. Myxoprincomides were obtained in different fractions see Table 13. 
Substance c382 c580 c588 c683 c800 c814 
Retention time [min] 6.8 7.9 8.2 8.0 7.7 8.3 
H2O + - - + + - 
H2O / MeOH + + + + + + 
MeOH 1 + + + + + + 
MeOH 2 - + - + + + 
MeOH 3 - + - + - - 
MeOH 4 - - - - - - 
Cells 1 + + + + + + 
Cells 2 + + + + + + 
CHCl3 - - - - - - 
Table 13:  Myxoprincomide fractions after elution from XAD. 
The solvent was removed; the H2O / MeOH and MeOH 1 fraction was again diluted in MeOH 
and extracted against heptane to get rid of fats. MeOH removal and dissolving in water, 
partition with ethyl acetate, here mayor parts of the DKxanthenes stayed. The obtained 
fraction had high concentration of myxoprincomides. Next step was methanolic Sephadex
®
 
LH-20 column. Myxoprincomide fractions were dried and dissolved in a water methanol 
mixture 1:1 and injected into the Waters Auto Purification System. Preparative LC runs were 
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performed using an Xbridge Prep C18 OBD column (19 x 150 mm, 5 μm particle size). As 
mobile phase water with 0.1 % formic acid (A) and methanol with 0.1% formic acid (B) were 
used. The following gradient was used: 
Time [min] A % B % 
0 73.0 27.0 
3.00 73.0 27.0 
9.00 50.0 50.0 
9.50 5.0 95.0 
12.50 5.0 95.0 
13.00 73.0 27.0 
16.00 73.0 27.0 
Table 14:  Gradient used at the Waters Auto Purification System. 
Detection was performed by a 3100 Mass Detector (Waters) and fractions were collected on a 
2767 Sample Manager (Waters) and concentrated afterwards.  
Second purification was run at the same system, same gradient using different solvent system 
A2: H2O + NH4CO2 50 mM, pH = 9.4, B2: MeOH + H2O 5% + NH4CO2 50 mM, pH = 9.4. 
Third purification was done with acetonitrile as solvent again under acidic conditions pH = 3, 
gradient: 
Time [min] A % B % 
0 95 5 
2 95 5 
9.00 65 35 
9.50 5.0 95.0 
10.50 5.0 95.0 
11.00 95 5 
14.00 95 5 
Table 15:  Gradient used for third purification step at the Waters Auto Purification System. 
Still impure fractions were further separated via a methanol Sephadex
®
 LH-20 column. 
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NMR: 
The pure substances were measured with the microprobe at 500 MHz Bruker Avance NMR 
spectrometer in DMSO-d6.  
 
Marfey: 
The myxoprincomides were hydrolyzed by 5 M HCL at 100 °C over night. The solvent was 
removed, redissolved in 100 µl water and split into two portions. 30 µl of NaHCO3 and 200 µl 
of D- or L-FDLA were added. The solution was kept on 37 °C for 1 h. 800 µl of acetonitrile 
was added, centrifuged and injected into the HPLC.  
 
Production kinetics: 
In 100 ml Erlenmeyer flasks 25 ml of CTT with 0.5 % XAD were inoculated with 50 μl 
preculture (washed with CTT media before). At certain time points triplicates were harvested 
until 99 h after inoculation. The cultures were centrifuged and cell / XAD pellet was separated 
from the supernatant, samples where frozen at -20 °C. The pellet was extracted with 50 ml 
MeOH and the supernatant was freeze dried, the residue was resumed in MeOH. 
 
Supplementary 
13C-NMR was recorded at 125 MHz with DMSO-d6; reference at ppm δ 39.51. 1H-NMR 
was recorded at 500 MHz with DMSO-d6; reference at ppm δ 2.50 ppm. Protons assigned in 
HMBC correlate to indicated carbon. Allocated NOESY protons showing correlation to 
indicated proton.  
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δC δH (J in Hz) HMBC NOESY 
NMeSer 
    
1 169.2       
2 64.6 3.45 m 1, 3, N-Me   
3 61.1 3.57 dd (6.3, 11.4) 1, 2   
    3.66 dd (4.2, 11.6) 1, 2   
NH    * 
 
  
NMe 33.3 2.33 s 2   
     
OH-Val1 
    
1 169.7       
2 60.9 4.21 m 3, 4, 5, 1   
3 71.8       
4 27.6 1.05 s 2, 3, 5   
5 25.7 1.03 s 2, 3, 4   
NH   8.27 d (9.7)     
     
Phe 
    
1 174.6       
2 56.1 4.23 m 1, 3, 1´ NH 
3 37.6 3.08 dd (4.3, 13.9) 1, 2, 1´, 2´, 6´  3 
    2.82 dd (8.6, 13.5) 1, 2, 1´, 2´, 6´  3 
1´ 139.1       
2´, 6´ 129.7 7.17 m 3, 1´, 3´, 4´, 5´   
3´, 5´ 128.4 7.18 m 1´, 2´, 4´, 6´   
4´ 126.4 7.13 m 1´, 3´, 5´   
NH   7.64 d (7.8)   2OH-Val 
* not assigned 
Supplementary table 1:  NMR Spectroscopic data for c382 (DMSO-d6) 
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δC δH (J in Hz) HMBC 
 NMeSer 
   
1 171.2     
2 66.4 3.04 m 1, 3, N-Me 
3 61.9 3.54 m 1, 2 
    3.40 dd (7.3, 10.7) 1, 2 
NH    * - 
NMe 34.4 2.15 s 2 
    
OH-Val1 
   
1 167.7     
2 59.6 4.27 m 1 
3 71.7     
4 27.7 1.02 s 2, 3, 5 
5 25.3 0.97 s 2, 3, 4 
NH   7.34 m   
    
Phe 
   
1 171.2     
2 54.3 4.59 m   
3 37.3 3.05 m 2, 1´, 2´, 6´  
    2.77 dd (10.4, 13.8) 1, 2, 1´, 2´, 6´  
1´ 138.0     
2´, 6´ 129.3 7.21 m 3, 1´, 3´, 4´, 5´ 
3´, 5´ 128.2 7.18 m 1´, 4´, 
4´ 126.4 7.11 m 2´, 6´ 
NH   8.55 m 1OH-Val2 
    
OH-Val2 
   
1 170.1     
2 60.5 4.40 d (9.0) 1, 3, 4, 5, 1Phe 
3 71.9     
4 28.2 1.10 s 2, 3, 5 
5 25.0 1.10 s 3 
NH   8.10 m 1Phe 
    
Ser1 
   
1 167.7     
2 55.9 4.27 m 3 
3 61.9 3.65 dd (5.4, 10.7) 1, 2 
    3.54 m 1, 2 
NH   8.06 m   
    
Supplementary table 2:  NMR Spectroscopic data for c683 (DMSO-d6); * not assigned 
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δC δH (J in Hz) HMBC 
Val    
1 174.9     
2 59.9 3.87 dd (4.9, 8.6) 1, 3, 4, 5, 1Ser 
3 30.8 1.95 m 1, 2, 4, 5 
4 19.8 0.76 t (7.2) 2, 5 
5 18.3 0.76 t (7.2) 3, 4 
NH   7.52 m 2, 1Ser 
Supplementary table 2:  continued 
 
 
δC δH (J in Hz) HMBC NOESY 
 NMeSer 
    
1 170.7       
2 66.0 3.12 m 1, 3, NMe 1, 3, NMe 
3 61.7 3.54 m 1, 2 2, 3 
    3.43 dd (6.8, 10.5) 1, 2 2, 3 
NH 
 
*     
NMe 34.2 2.19 s 2 2 
     
OH-Val1 
    
1 170.2       
2 60.4 4.46 m 1, 3, 5   
3 72.3       
4 28.0 1.12 s 2, 3, 5 2 
5 24.7 1.06 s 2, 3 5 
NH   8.07 m 1Phe   
     
Phe 
    
1 171.3       
2 54.2 4.59 m 1, 1AS,  3 
3 37.4 3.05 m 1, 2, 1´, 2´, 6´ 2, 3 
    2.77 dd (10.3, 14.0) 1, 2, 1´, 2´, 6´ 2, 3 
1´ 138.0       
2´, 6´ 129.3 7.20 m 3, 3´, 5´   
3´, 5´ 128.3 7.18 m 1´, 2´, 6´   
4´ 126.4 7.11 m 2´, 6´   
NH   8.49 d (8.5)     
Supplementary table 3:  NMR Spectroscopic data for c798 (DMSO-d6); * not assigned 
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δC δH (J in Hz) HMBC NOESY 
OH-Val2     
1 *       
2 59.8 4.27 m 3 4, 5, 1Ser1 
3 71.8       
4 27.7 1.01 s 2, 3, 5 2 
5 25.6 0.97 s 2, 3, 4 2 
NH   8.11 m     
     
Ser1 
    
1 *       
2 55.7 4.31 m   3 
3 63.3 3.67 m   3 
    3.59 m 2 3 
NH   8.67 d (7.8) 170.2   
     
Val 
    
1 *       
2 *       
3 57.7 5.06 m     
4 34.9 2.12 m     
5 19.6 0.83 d (6.8) 3, 6   
6 19.6 0.78 d (6.8) 3, 5   
NH   8.14 m     
     
Ser2 
    
1  *       
2 56.6 3.88 m     
3 61.7 3.63 m 2   
    3.54 m     
NH   8.18 m / 8.00 m     
Supplementary table 3:  continued 
  
Chapter 2A: DK897 Myxoprincomides 
 
 
112 
 
δC δH (J in Hz) HMBC 
 NMeSer    
1 169.3     
2 64.4 3.53 m 1, 3 
3 61.1 3.62 m 1, 2, NMe 
    3.55 m 1, 2 
NH    * 
 
NMe 33.1 2.31 s 2 
    
OH-Val1 
   
1 170.2     
2 55.9 4.28 m 1, 3, 4, 5, 1NMe 
3 71.8     
4 26.0 1.05 s 3, 5 
5 25.9 0.98 s 3, 4 
NH   8.47 m 2 
    
Phe 
   
1 170.4     
2 54.8 4.58 m 1, 3, 1´ 
3 37.7 3.01 m 1, 2, 1´, 2´, 6´  
    2 75 m 2, 1´, 2´, 6´  
1´ 138.0     
2´, 6´ 128.8 7.17 m 3, 1´, 3´, 4´, 5´ 
3´, 5´ 129.7 7.17 m 1´, 2´, 4´, 6´ 
4´ 127.0 7.11 m 1´, 3´, 5´ 
NH   8.42 d (8.0) 1OH-Val1 
    
OH-Val2 
   
1 171.9     
2 61.0 4.31 m 1, 3, 4, 5, 1Phe 
3 72.0     
4 27.6 1.09 s 2, 3, 5 
5 27.9 1.00 s 2, 3, 4 
NH   8.09 d (8.0) 1 
        
Ser1 
   
1 170.3     
2 55.9 4.27 m 3 
3 62.0 3.49 m 1 
    3.49 m 1 
NH   8.20 d (5.9) 1 
Supplementary table 4:  NMR Spectroscopic data for c800 (DMSO-d6); * not assigned 
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δC δH (J in Hz) HMBC 
2OH-β-Val 
   
1 172.9     
2 70.9 4.09 m 1, 3, 4 
3 57.5 3.79 m 4, 6, 1Ser1 
4 29.7 1.75 m 3, 6 
5 20.2 0.84 d (6.4) 3, 4, 6 
6 19.9 0.76 d (6.4) 3, 4, 5,  
NH   7.68 d (6.3) 1Ser 
    
Ser2 
   
1 174.4     
2 56.9 3.86 m 1, 3 
3 62.8 3.58 m 1, 2 
    3.58 m 1, 2 
NH   7.78 d 1, 1βVal 
Supplementary table 4:  continued 
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δC δH (J in Hz) HMBC 
 NMeSer    
1 169.4     
2 65.2 3.19 m   
3 61.0 3.61 m 1 
    3.47 m   
NH   7.96 m / 8.05 m / 8.15 m / 8.63 m*   
NMe 33.5 2.26 s 2 
    
OH-Val1 
   
1 169.8     
2 59.8 4.40 d (9.3) 1, 3 
3 70.9     
4 27.0 1.06 s 2, 3, 5 
5 24.9 1.02 s 2, 3, 4 
NH   8.15 m 1NMe 
    
Phe 
   
1 170.6     
2 53.7 4.67 m 1, 1OH-Val1 
3 36.8 3.07 m 1, 1´, 2´, 6´ 
    2.82 m 1, 1´, 2´, 6´ 
1´ 137.2     
2´, 6´ 128.8 7.24 m 4,2´, 4´, 6´ 
3´, 5´ 127.6 7.22 m 1´, 3´,5´ 
4´ 125.8 7.15 m 2´, 6´ 
NH   8.20 m   
    
OH-Val2 
   
1 169.1     
2 59.4 4.49 d (9.9) 1, 3 
3 71.3     
4 27.4 1.11 s 2, 3, 5 
5 25.1 1.08 s 2, 3, 4 
NH   7.96 m / 8.05 m / 8.15 m / 8.63 m*   
    
Ser1 
   
1 170.0     
2 54.8 4.33 d (9.0) 1, 1OH-Val2 
3 60.8 3.71 m   
    3.62 m   
NH   7.96 m / 8.05 m / 8.15 m / 8.63 m*   
Supplementary table 5:  NMR Spectroscopic data for c812 (DMSO-d6); * not assigned 
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δC δH (J in Hz) HMBC 
β-Leu 
   
1 *     
2 *      
3 51.5 / 52.1 5.14 m / 4.10 m   
4 37.0 1.37 m   
    1.23 m   
5 23.4 1.53 m   
6 23.7 0.79 d (6.5) 4, 5, 7 
7 21.4 0.84 d (6.5) 4, 5, 6 
NH   8.17 m   
    
Ser2 
   
1 169.2     
2 55.9 4.19 m   
3 60.8 3.66 m   
    3.66 m   
NH   7.96 m / 8.05 m / 8.15 m / 8.63 m*   
Supplementary table 5:  continued 
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δC δH (J in Hz) HMBC NOESY 
 NMeSer 
    
1 170.6       
2 66.4 2.97 dd (4.5, 7.1) 1, 3, NMe 1 
3 61.7 3.54 m 1 1 
    3.39 dd (7.2, 10.8) 1, 2 1 
NH   *     
NMe 34.2 2.15 s 2   
     
OH-Val1 
    
1 170.0       
2 59.2 4.26 m   1, 1Phe 
3 71.1       
4 27.3 1.03 s 2, 3, 5   
5 24.8 0.97 s 2, 3, 4   
NH   7.98 d (7.7)     
     
Phe 
    
1 171.0       
2 53.8 4.62 s   1, 1OH-Val1 
3 36.7 3.06 dd (3.7, 14.2) 2, 1´, 2´, 6´ 1 
    2.78 dd (10.3, 14.2) 1, 2, 1´, 2´, 6´ 1 
1´ 137.9       
2´, 6´ 128.9 7.24 m 3, 3´, 4´, 5´   
3´, 5´ 127.9 7.19 m 1´, 3´, 5´   
4´ 126.0 7.13 m 2´, 6´   
NH   8.47 d (8.6) 1OH-Val1 1OH-Val1 
     
OH-Val2 
    
1 170.1       
2 60.1 4.35 m 1, 3, 5, 1Ser1 1, 1Phe 
3 71.0       
4 27.3 1.11 s 2, 3, 5   
5 25.1 1.08 s 2, 3, 4   
NH   8.15 m 1Phe 1Phe 
     
Ser1 
    
1 169.4       
2 54.8 4.24 m   1 
3 61.4 3.54 m 1 1 
    3.47 m 1 1 
NH   8.14 m 1OH-Val2   
Supplementary table 6:  NMR Spectroscopic data for c814 (DMSO-d6); * not assigned 
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δC δH (J in Hz) HMBC NOESY 
β-Leu     
1 171.7       
2 72.0 3.85 d (2.9) 1 1, 1Ser1 
3 49.6 4.12 m   1 
4 39.7 1.35 m 3, 7   
    1.25 m 3, 7   
5 23.8 1.53 m     
6 23.2 0.8 d (6.5) 5, 7   
7 21.7 0.8 d (6.5) 5, 6   
NH   7.61 d (9.0) 1Ser1   
     
Ser2 
    
1 172.8       
2 55.4 3.82 m 1 1 
3 62.3 3.58 m 1, 2 1 
    3.49 m 1, 2 1 
NH   7.69 d (6.8) 1, 1βLeu 1, 1β-Leu 
Supplementary table 6:  continued 
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δC δH (J in Hz) HMBC 
 NMeSer    
1 168.4     
2 64.2 3.52 m NMe 
3 60.9 3.67 m   
    3.57 m 1, 2 
NH   8.29 m   
NMe 32.9 2.35 s 2 
    
OH-Val1 
   
1 170.0     
2 60.2 4.34 m 1, 3, 4, 5, 1NMe 
3 71.6     
4 27.5 1.07 s 2, 3, 5 
5 25.5 1.04 s 2, 3, 4 
NH   7.84 m / 8.59 m   
    
Phe 
   
1 171.3     
2 54.4 4.66 m 1, 3 
3 37.4 3.05 m 2, 1´, 2´, 6´ 
    2.81 m 2, 2´, 6´ 
1´ 137.8     
2´, 6´ 129.4 7.23 m 1´, 2´, 6´ 
3´, 5´ 128.3 7.21 m 1´, 3´, 5´ 
4´ 126.5 7.15 m 2´, 6´ 
NH   8.24 m 1OH-Val1 
    
OH-Val2 
   
1 *     
2 60.1 4.34 m   
3 72.1     
4 28.1 1.15 s 2, 3, 5 
5 24.9 1.10 s 2, 3, 4 
NH   7.84 m / 8.59 m   
        
Ser1 
   
1       
2 60.3 4.48 m    
3   3.72 m   
    3.54 m   
NH   7.66 m   
Supplementary table 7:  NMR Spectroscopic data for c581 (DMSO-d6); * not assigned 
Chapter 2A: DK897 Myxoprincomides 
 
 
119 
 
δC δH (J in Hz) HMBC 
2OH-β-Val 
   
1 170.5     
2 196.7     
3 57.9 5.15 m 1, 2, 4, 5, 6 
4 29.6 2.16 m 5, 6 
5 19.5 0.85 m 3, 4, 6 
6 17.9 0.78 m 3, 4, 5 
NH   8.03 m   
    
Ser2 
   
1  *     
2 55.4 4.38 m   
3 61.8 3.71 m   
    3.60 m   
NH   8.21 m   
    
Tyr 
   
1  *     
2 55.2 4.33 m   
3 36.8 2.93 m   
    2.70 m   
1´ 128.2     
2´, 6´ 130.3 7.00 m 3, 2´, 3´, 4´, 5´, 6´ 
3´, 5´ 115.2 6.62m 1´, 3´, 4´, 5´ 
4´ 156.1     
NH   8.36 m   
    
β-Lys 
   
1 169.7     
2 40.9 2.21 m   
    2.21 m   
3 45.9 4.05 m   
4 30.7 1.52 m   
    1.36 m   
5 23.8 1.53 m   
    1.53 m   
6 38.8 2.74 m 4, 5 
    2.74 m 4, 5 
NH   7.89 m   
    
Ala 
   
1 175.7     
2 48.9 4.09 m 1, 3, 1β-Lys 
3 18.2 1.22 d (6.6) 1, 2 
NH   7.94 m 1β-Lys 
Supplementary table 7:  continued 
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δC δH (J in Hz) HMBC NOESY 
 NMeSer     
1 169.7       
2 65.9 3.11 m   NMe 
3 61.7 3.59 m 1   
    3.45 m     
NH    *     
NMe 34.2 2.22 s 1,2   
     
OH-Val1 
    
1 170.0       
2 59.4 4.28 m 1, 4 5 
3 71.5       
4 25.3 1.01 s 2, 3, 5 2 
5 27.5 1.05 s 2, 3, 4 2 
NH   8.03 m 1NMe   
     
Phe 
    
1  *       
2 54.1 4.65 m   3, NH 
3 37.2 3.05 m 2´, 6´ 2, 3 
    2.78 m 2, 2´, 6´ 2, 3 
1´ 137.9       
2´, 6´ 129.3 7.23 m 2´, 4´, 6´   
3´, 5´ 128.1 7.21 m 1´, 3´, 5´ 2, 3 
4´ 126.4 7.15 m     
NH   8.20 d (6.9) 1 OH-Val1 2, 3 
     
OH-Val2 
    
1 170.0       
2 60.1 4.40 d (9.1) 1, 3, 5, 1Phe NH 
3 71.8       
4 27.8 1.13 s 2, 3, 5   
5 24.9 1.10 s 2, 3, 4 2 
NH   8.09 m   2Phe, 3Phe 
     
Ser1 
    
1         
2 55.6 4.31 m     
3 61.7 3.59 m     
    3.54 m     
NH   8.10 m     
Supplementary table 8:  NMR Spectroscopic data for c582 (DMSO-d6); * not assigned 
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δC δH (J in Hz) HMBC NOESY 
2OH-β-Val 
    
1 173.3       
2 70.5 4.12 m   NH, 4, 5, 6 
3 57.2 3.80 m   NH, 4, 5, 6 
4 29.2 1.80 m     
5 19.9 0.90 d (6.1) 3, 4, 6 NH, 2, 3, 4, 6  
6 19.4 0.82 d (6.1) 3, 4, 5 NH, 2, 3, 4, 5 
NH   7.63 d (8.4)   3, 4, 5, 6 
     
Ser2 
    
1 170.0       
2 55.1 4.19 m 1 NH 
3 61.7 3.59 m   NH 
    3.48 m 1   
NH   7.89 m 12OH-β-Val   
     
Tyr 
    
1 170.7       
2 55.0 4.32 m 1 NH, 3, 2´, 6´ 
3 36.4 2.96 m   2, 3, 2´, 6´, NH 
    2.75 m 2´, 6´ 2, 3, 2´, 6´, NH 
1´ 128.1       
2´, 6´ 130.1 7.00 d (8.4) 3, 2´, 4´, 6´ 2, 3, 3´, 5´, NH 
3´, 5´ 115.1 6.63 d (8.4) 1´, 3´, 4´, 5´ 2´, 6´ 
4´ 155.9       
NH   8.10 m 1, 1AS 2 
          
β-Lys 
    
1 169.6       
2 40.8 2.22 m   4 
    2.16 m     
3 45.6 4.04 m   2, 4, 6, NH 
4 30.4 1.51 m   3 
    1.34 m   4 
5 23.6 1.48 m     
    1.52 m   6 
6 38.6 2.74 m 4 4 
NH   7.73 d (9.1)     
     
Ala 
    
1 175.4       
2 49.0 4.03 m 1, 3, 1β-Lys 3, NH 
3 18.2 1.21 d (7.6)   2, NH 
NH   7.86 m 1β-Lys 3 
Supplementary table 8:  continued 
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δC δH (J in Hz) HMBC 
 NMeSer 
   
1  *     
2 59.9 4.46 m   
3 64.7 3.39 m   
    3.39 m   
NH    *   
NMe 33.2 2.31 s 3 
    
OH-Val1 
   
1 169.8     
2 59.8 4.51 m 1, 3 
3 71.8     
4 24.6 1.13 s 2, 3, 5 
5 24.9 1.10 s 3, 4 
NH   8.10 m   
        
Phe 
   
1  *     
2 54.3 4.64 m   
3 37.3 3.04 m 2, 1´, 2´, 6´ 
    2.79 m   
1´ 137.7     
2´, 6´ 129.3 7.22 m 3, 2´, 4´, 6´ 
3´, 5´ 128.2 7.20 m 1´, 3´, 5´ 
4´ 126.4 7.15 m 2´, 6´ 
NH   8.23 m 1OH-Val1 
    
OH-Val2 
   
1  *     
2 59.9 4.46 m   
3 71.4     
4 27.5 1.06 s 2, 3, 5 
5 25.6 1.03 s 2, 3, 4 
NH    *   
        
Ser1 
   
1  *     
2 64.5 3.42 m   
3 61.0 3.63 m   
    3.52 m 2 
NH    *   
Supplementary table 9:  NMR Spectroscopic data for c587 (DMSO-d6); * not assigned 
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δC δH (J in Hz) HMBC 
β-Leu 
   
1 169.8     
2 52.0 5.09 m   
3 59.9 4.46 m   
4 38.4 3.31 m   
5 28.3 1.45 m   
6 24.0 0.79 m 5, 7 
7 21.3 0.84 m 4, 6 
NH   8.06 m   
    
Ser2 
   
1 168.9     
2 59.9 4.30 m 1, 1β-Leu 
3 61.6 3.70 m   
    3.58 m   
NH   8.27 m   
    
Tyr 
   
1  *     
2 55.1 4.33 m   
3 36.8 2.91 m 2´, 6´ 
    2.69 m 2´, 6´ 
1´ 127.6     
2´, 6´ 130.2 6.99 m 3, 2´, 3´, 4´, 5´, 6´ 
3´, 5´ 115.1 6.63 m 1´, 3´, 4´, 5´ 
4´ 155.9     
NH   8.33 m   
        
    
β-Lys 
   
1 169.3     
2 40.7 2.20 m   
    2.20 m   
3 45.9 4.03 m   
4 30.5 1.50 m   
    1.35 m   
5 23.7 1.51 m   
    1.51 m   
6 38.6 2.74 m 4, 5 
    2.74 m 4, 5 
NH   7.84 m   
Supplementary table 9:  continued 
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δC δH (J in Hz) HMBC 
Ala 
   
1 175.3     
2 48.9 4.08 m 1, 3, 1β-Lys 
3 18.0 1.22 d (6.9) 1, 2 
NH   7.97 m 1β-Lys 
Supplementary table 9:  continued 
 
 
The NMR spectra of the isolated myxoprincomides from DK897 are depicted in the following 
figures: 
 
Supplementary figure 11:  1H NMR spectrum of myxoprincomide c800 in DMSO-d6. 
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Supplementary figure 12:  COSY spectrum of myxoprincomide c800 in DMSO-d6. 
 
 
Supplementary figure 13:  TOSY spectrum of myxoprincomide c800 in DMSO-d6. 
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Supplementary figure 14:  HSQC spectrum of myxoprincomide c800 in DMSO-d6. 
 
 
Supplementary figure 15:  HMBC spectrum of myxoprincomide c800 in DMSO-d6. 
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Supplementary figure 16:  13C spectrum of myxoprincomide c800 in DMSO-d6. 
 
 
Supplementary figure 17:  DEPT135 spectrum of myxoprincomide c800 in DMSO-d6. 
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Supplementary figure 18:  NOESY spectrum of myxoprincomide c800 in DMSO-d6. 
 
 
Supplementary figure 19:  1H NMR spectrum of myxoprincomide c382 in DMSO-d6. 
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Supplementary figure 20:  COSY spectrum of myxoprincomide c382 in DMSO-d6. 
 
 
Supplementary figure 21:  HSQC spectrum of myxoprincomide c382 in DMSO-d6. 
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Supplementary figure 22:  HMBC spectrum of myxoprincomide c382 in DMSO-d6. 
 
 
Supplementary figure 23:  13C spectrum of myxoprincomide c382 in DMSO-d6. 
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Supplementary figure 24:  NOESY spectrum of myxoprincomide c382 in DMSO-d6. 
 
 
Supplementary figure 25:  1H NMR spectrum of myxoprincomide c683 in DMSO-d6. 
 
  
Chapter 2A: DK897 Myxoprincomides 
 
 
132 
 
 
Supplementary figure 26:  COSY spectrum of myxoprincomide c683 in DMSO-d6. 
 
 
Supplementary figure 27:  HSQC spectrum of myxoprincomide c683 in DMSO-d6. 
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Supplementary figure 28:  HMBC spectrum of myxoprincomide c683 in DMSO-d6. 
 
 
Supplementary figure 29:  13C spectrum of myxoprincomide c683 in DMSO-d6. 
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Supplementary figure 30:  1H NMR spectrum of myxoprincomide c798 in DMSO-d6. 
 
 
Supplementary figure 31:  COSY spectrum of myxoprincomide c798 in DMSO-d6. 
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Supplementary figure 32:  TOCSY spectrum of myxoprincomide c798 in DMSO-d6. 
 
 
Supplementary figure 33:  HSQC spectrum of myxoprincomide c798 in DMSO-d6. 
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Supplementary figure 34:  HMBC spectrum of myxoprincomide c798 in DMSO-d6. 
 
Supplementary figure 35:  13C spectrum of myxoprincomide c798 in DMSO-d6. 
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Supplementary figure 36:  NOESY spectrum of myxoprincomide c798 in DMSO-d6. 
 
 
Supplementary figure 37:  ROESY spectrum of myxoprincomide c798 in DMSO-d6. 
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Supplementary figure 38:  1H NMR spectrum of myxoprincomide c812 in DMSO-d6. 
 
 
Supplementary figure 39:  COSY spectrum of myxoprincomide c812 in DMSO-d6. 
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Supplementary figure 40:  TOSY spectrum of myxoprincomide c812 in DMSO-d6. 
 
 
Supplementary figure 41:  HSQC spectrum of myxoprincomide c812 in DMSO-d6. 
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Supplementary figure 42:  HMBC spectrum of myxoprincomide c812 in DMSO-d6. 
 
 
Supplementary figure 43:  NOESY spectrum of myxoprincomide c812 in DMSO-d6. 
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Supplementary figure 44:  1H NMR spectrum of myxoprincomide c814 in DMSO-d6. 
 
 
Supplementary figure 45:  COSY spectrum of myxoprincomide c814 in DMSO-d6. 
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Supplementary figure 46:  TOSY spectrum of myxoprincomide c814 in DMSO-d6. 
 
 
Supplementary figure 47: HSQC spectrum of myxoprincomide c814 in DMSO-d6. 
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Supplementary figure 48:  HMBC spectrum of myxoprincomide c814 in DMSO-d6. 
 
 
Supplementary figure 49:  13C spectrum of myxoprincomide c814 in DMSO-d6. 
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Supplementary figure 50:  NOESY spectrum of myxoprincomide c814 in DMSO-d6. 
 
 
Supplementary figure 51:  1H NMR spectrum of myxoprincomide c581 in DMSO-d6. 
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Supplementary figure 52:  COSY spectrum of myxoprincomide c581 in DMSO-d6. 
 
 
Supplementary figure 53:  TOSY spectrum of myxoprincomide c581 in DMSO-d6. 
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Supplementary figure 54:  HSQC spectrum of myxoprincomide c581 in DMSO-d6. 
 
 
Supplementary figure 55:  HMBC spectrum of myxoprincomide c581 in DMSO-d6. 
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Supplementary figure 56:  13C spectrum of myxoprincomide c581 in DMSO-d6. 
 
 
Supplementary figure 57:  NOESY spectrum of myxoprincomide c581 in DMSO-d6. 
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Supplementary figure 58: 1H NMR spectrum of myxoprincomide c582 in DMSO-d6. 
 
 
Supplementary figure 59:  COSY spectrum of myxoprincomide c582 in DMSO-d6. 
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Supplementary figure 60:  TOSY spectrum of myxoprincomide c582 in DMSO-d6. 
 
 
Supplementary figure 61:  HSQC spectrum of myxoprincomide c582 in DMSO-d6. 
  
Chapter 2A: DK897 Myxoprincomides 
 
 
150 
 
 
Supplementary figure 62:  HMBC spectrum of myxoprincomide c582 in DMSO-d6. 
 
 
Supplementary figure 63:  13C spectrum of myxoprincomide c582 in DMSO-d6. 
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Supplementary figure 64:  NOESY spectrum of myxoprincomide c582 in DMSO-d6. 
 
 
Supplementary figure 65:  1H NMR spectrum of myxoprincomide c587 in DMSO-d6. 
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Supplementary figure 66:  COSY spectrum of myxoprincomide c587 in DMSO-d6. 
 
 
Supplementary figure 67:  TOSY spectrum of myxoprincomide c587 in DMSO-d6. 
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Supplementary figure 68:  HSQC spectrum of myxoprincomide c587 in DMSO-d6. 
 
 
Supplementary figure 69:  HMBC spectrum of myxoprincomide c587 in DMSO-d6. 
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Supplementary figure 70:  13C spectrum of myxoprincomide c587 in DMSO-d6. 
 
 
Supplementary figure 71:  NOESY spectrum of myxoprincomide c587 in DMSO-d6. 
 
From the myxoprincomides MS
2
 experiments were measured (Supplementary table 10) and 
the spectra are depicted in Supplementary figure 72. The main fragments of the double 
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charged compounds are listed in Supplementary table 11 and the spectra are shown in 
Supplementary figure 73. 
c814 c800 c798 c683 c382 
814.5 800.5 798.5 683.4  
796.5 782.4 780.4 665.4 364.1 
778.5 764.5 762.4 647.4 346.2 
768.5 754.4    
756.5 742.4 740.5 625.4  
738.5 724.4 722.4 607.4  
720.6 706.4 704.4 589.3  
681.5 667.4 667.4   
 663.4    
663.4 649.3    
598.3 584.3 582.4 467.3 166 
 566.4 564.3 566.3  
580.4 538.4    
566.4 530.3 530.2 530.3  
548.3 520.4 524.3 548.3  
540.4 513.4 513.3 513.3  
522.3 508.4 508.3 508.3  
513.3 503.3    
508.3 496.3  495.2  
499.3 490.3 490.3 490.3 189 
495.2 479.3 479.3 479.4  
490.4 472.3 472.3 472.3 171.1 
479.3 461.3 461.3 461.3  
473.2 455.3  454.3  
461.3 437.2 443.3 443.3  
451.2 437.3 435.3 437.2  
443.3 433.2  431.2  
433.3 421.1 421.3 421.2 120 
421.2 414.3 417.3 409.2  
 403.2 403.3   
415.3 401.2 399.2   
403.2 394.1  403.2  
391.2 385.3 385.2 391.2  
373.1 364.2 364.1 364.2  
364.1 345.1 345.1 345.2  
345.1 332.1 332.1 332.1  
332.1 322.2 320.1 328.1  
 312 306.1 306  
318.1 304.1 302 292.1  
300.1 286 284 263.1  
291 279   291.1 
 274   281.1 
283 269.3    
273.4 262   263 
259.1 245 245 245  
 240.8  234.9  
249 235.1 233 217 217 
241.1 227  199 199 
Supplementary table 10:  MS2 comparison of 814, 800, 798, 683, and 382. 
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c580 c582 c587 
944.4 946.5 960.5 
797.4 799.4 813.4 
682.3 684.3 698.3 
571.8 572.8 579.8 
551.7 552.8 559.8 
472.7 473.8 480.7 
346.2 346.2 346.2 
306.1 306.1 306.1 
Supplementary table 11:  Fragmentation pattern of C580, c582, c587, blue = double charged. 
Chapter 2A: DK897 Myxoprincomides 
 
 
157 
 
Supplementary figure 72:  MS and MS2 spectra of c814, c800, c798 and c683. 
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Supplementary figure 73:  Chromatogram and fragmentation pattern of c581, c582 and c587. 
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MS spectra of feeding studies are displayed in Supplementary figure 74 to Supplementary 
figure 78. 
 
 
Supplementary figure 74:  Isotopic pattern of c580 without labeled amino acid feeding. 
 
 
Supplementary figure 75:  Isotopic pattern of c580 after feeding with isotopic labeled valine. 
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Supplementary figure 76:  Isotopic pattern of c580 after feeding with isotopic labeled serine. 
 
 
 
Supplementary figure 77:  Isotopic pattern of c580 after feeding with isotopic labeled phenylalanine. 
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Supplementary figure 78:  Isotopic pattern of c580 after feeding with isotopic labeled methionine. 
Supplementary figure 79:  pSBtn5Kan-800erstart plasmid for promoter activation of the 800er cluster. 
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The obtained clones were analyzed by colony PCR with following primers:  
800startkon_1r = GAGGGTTCGCGGAGTCTCGTG 
800startkon_1f = CGATTAAGTTGGGTAACGCCAGG 
 
Supplementary figure 80:  Control gel of two DK897start clones and WT, 100 bp marker, expected size 288 bp. 
 
Supplementary figure 81:  Alignment of A domains from the 800er cluster (For domain A1 the core motif A9 and 
A10 show differences but they are located directly after the N-Met sequence). 
Clone 1, Clone 2, DK897, marker          
Marker 
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Supplementary figure 82:  Alignment of C domains from the 800er cluster. 
 
 
Supplementary figure 83:  Alignment of PCP domains from the 800er cluster. 
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Supplementary figure 84:  Gel after PCR with Phusion, GC buffer, 58 °C and primers for closing the gaps in the 
800er cluster sequence. 
 
Supplementary figure 85:  Gel after PCR with Phusion, GC buffer, 63 °C and primers for closing the gaps in the 
800er cluster sequence. 
 
Production kinetics 
To identify the optimal time point for compound isolation a production kinetic was 
performed. At defined time points triplicates were harvested until 99 h after inoculation. The 
samples were analyzed and quantified by HPLC-MS. 
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Figure 57:  Growth curve of M. xanthus DK897. 
The cell maximum is somewhere between 82 h and 91 h afterwards the culture begins to die 
(Figure 57).  
 
Figure 58:  Production curve of cittilin A and c800 compared to cell growth. 
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Bioactivity tests of fractionated crude extracts 
20 mg of extract of the strains DK897 with a 25 min long gradient at the waters machine. 48 
fraction of each 11 ml (0.44 min) volume were collected. The solvent was removed and the 
remaining solid was transferred into a 48 well plate. Each fraction has been analyzed at the 
Orbitrap refer to section HPLC-HR-MS. Fractions were sent to Riken in Japan for following 
bioassays: 
1. HL-60: Growth inhibition of human leukemia cell line, HL-60 for 48 h. 
2. K562: Growth inhibition of human leukemia cell line, K562 for 48 h. 
3. tsFT210: Growth inhibition of mouse cdc2 mutant cell line, tsFT210 for 48 h. 
4. tsNRK: Morphological change of temperature-sensitive Rous sarcoma virus-infected NRK 
cells, tsNRK for 72 h. 
5. E. coli: Growth inhibition of Escherichia coli (HO141 strain) for 6 h. 
6. Yeast: Growth inhibition of Saccharomyces cerevisiae (MIC30M strain) for 18 h. 
7. M. oryzae: Growth inhibition of Magnaporthe Oryzae (Kita strain) for 48 h. 
8. p38: p38 MAP kinase inhibitor screening method using growth recovery of E. coli 
BL21(DE3) transformed by His-p38 expression plasmid as an index. 
9. PDI: Enzymatic inhibition of insulin reductase activity of PDI for 3 h. 
10. Heparanase: Enzymatic inhibition of heparan sulfate degradation assay for 24 h. 
11. Plk1-PBD: Inhibition of polo box domain (PBD) of polo like kinase 1 (Plk1) dependent 
protein–protein interaction. 
12. Plk3-PBD: Inhibition of polo box domain (PBD) of polo like kinase 3 (Plk3) dependent 
protein–protein interaction. 
 
The following fractions showed activity (++: moderate activity; +++: strong activity), when 
possible it was correlated to masses. 
1. DK897 (04) inhibited the growth of HL-60 (++) and K562 (+++) cells. 
 No clear MS peaks detected. 
2. DK897 (15) inhibited heparanase activity (++). 
 Possible candidates: m/z = 421, 485, 997, 800, 652, 417, 613, 576 
3. DK897 (24) inhibited PDI activity (++). 
 Possible candidates: m/z = 602, 647, 552, 363, 289 
4. DK897 (37) inhibited the growth of E. coli (++). 
 Possible candidates: Myxalamides and m/z = 344, 332, 358, 649 
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5. DK897 (38) inhibited the growth of M. oryzae (+++). 
 Possible candidates: m/z = 346, 334, 360  
6. DK897 (39) inhibited the growth of several cells (++ ~ +++) and inhibited Plk1/PBD 
and Plk3/PBD interactions (++). 
 No clear MS peaks detected 
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Chapter 4 
 
Natural evolution in the laboratory:  
Spirangien C – F produced by a spontaneous mutant of 
Sorangium cellulosum So ce90 
 
Abstract 
Four new spirangiens C – F were isolated from extracts of a spontaneous mutant of 
Sorangium cellulosum So ce90. The novel structures were elucidated by NMR spectroscopy. 
All four compounds contain a shortened conjugated chromophore compared to the known 
spirangien. The mutation of the strain occurred during investigations of spirangien 
biosynthesis. To verify the mutated sequence region in the biosynthetic gene cluster of the 
spirangien a cosmid library was prepared. Sequence analysis revealed that the second last 
module exhibits mutations which might lead to module skipping. The results give further 
insights into spiroacetal formations. 
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Introduction 
A vast number of natural products are produced by microorganisms. Within this huge amount 
of secondary metabolites there is enormous structure diversity. Many of these substances 
possess biological activity and show for example antibacterial of cytotoxic effects. 
[1-4]
 Hence 
natural products serve as lead structures in medicinal chemistry 
[4]
 but often natural 
compounds are a challenge for synthetic chemistry. 
[227]
 To obtain new derivatives of natural 
products combinatorial biosynthesis can be employed. 
[93]
 In nature novel substances emerge 
by evolutionary processes, each compound passed through a pre-selection for biological 
activity. 
[18]
 Here it is reported from some kind of evolutionary process in Sorangium 
cellulosum which took place in the laboratory and conducted in novel secondary metabolites. 
The Sorangium species produces several different kinds of bioactive compounds: antifungals 
such as soraphens 
[228]
 antibacterials like sorangicins 
[75]
 or cytotoxic substances like 
ratjadons 
[229]
. Here the strain Sorangium cellulosum So ce90 was addressed. It produces 
famous anti cancer drug epothilone 
[173;174]
 but it also generates another interesting compound 
which acts antifungal and is also highly cytotoxic, the spirangien A (50) (IC50 7 ng / mL 
against L929) and B (51). 
[174;230]
 To date the mode of action still remains unknown 
[231]
. The 
natural producer builds only small amounts of Spirangiens. The metabolites are sensitive 
towards UV light, oxygen and heat. 
The spirangiens have a polyketide backbone with a spiroketal core structure. The structure of 
Spirangien contains 14 stereo centers, a conjugated pentaenic chromophore with a terminal 
carboxylic acid. On the other side of the molecule it ends with is a single double bond. At that 
position there is the difference between 50 and 51. 50 ends with a methyl and 51 with an ethyl 
group. The absolute stereo chemistry was determined by chemical degradation and GC 
analysis. 
[230]
 Furthermore a crystal structure of the spiroacetal fragment led to the relative 
configuration. The final absolute configuration was determined by total synthesis. 
[232;233]
  
 
Figure 66:  Structures of spirangien A (50; left), spirangien B (51; right). 
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Results and Discussion 
The wild type strain So ce90 produces spirangien A (50) and B (51), but during conjugation 
experiments for the identification and the analysis of the its biosynthetic genes a spontaneous 
mutant (BFA3KO) appeared which exhibits the production of novel spirangien 
derivatives. 
[175]
 The phenotype of the mutant differed from the wild type strain by the 
spirangiens. Compared to it the BFA3KO mutant produced no 50 and 51 but instead four new 
derivates with lower masses (Figure 67).  
 
Figure 67:  HPLC-MS chromatogram extract of wild type BPC- (top) and UV chromatogram (upper 
middle), BFA3KO-3 mutant BPC- (lower middle) and UV chromatogram (bottom). 
High resolution mass spectrometry indicated molecular formulae as follows: C38H62O9 
(measured m/z = 663.44653, calculated m/z = 663.4467, spirangien C), C39H64O9 (measured 
m/z = 677.46187, calculated m/z = 677.4623, spirangien D), C38H62O8 (measured m/z = 
647.45166, calculated m/z = 647.4517, spirangien E) and C39H64O8 (measured m/z = 
661.46619, calculated m/z = 661.4674, spirangien F). In contrast to 50 and 51 it appeared that 
these compounds lost one C3H4 unit plus one non-hydroxylated position (loss of O) in the 
case of spirangien E and F. Furthermore the UV-maxima exhibited a hypochromic shift of 
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30 nm (Figure 68) which indicates that conjugation to one double bond is lost in the 
unsaturated chain. 
[234]
 
 
Figure 68:  UV-spectra of spirangien A and of new derivatives spirangien C and E (order right to 
left). 
To proof this hypothesis of a shortened chromophore the new derivatives had to be isolated. 
The BFA3KO mutant was fermented in large scale (by K. Gerth, Helmholtz Centre for 
Infection Research (HZI), Braunschweig) and the obtained crude extract was used for 
spirangien isolation. As the spirangiens are very sensitive to light and oxygen, the purification 
process was performed under light and oxygen exclusion. Crude extract of BFA3KO mutant 
was extracted with ethyl acetate. The received mixture was fractionated on a Sephadex
®
 
LH-20 (MeOH) column. The obtained fractions were separated by reverse phase HPLC to 
lead to the isolation of spirangien C, E and F.  
The pure substances were used for NMR experiments. Their NMR spectra (see 
Supplementary figure 86 to Supplementary figure 102) showed a lack of one double bond 
compared to the published data of spirangien A and B. 
[230]
 The NMR-spectra revealed the 
presence of 10 sp
2
-hybridized carbons whereof two are already assigned for C-30 and C31. 
Therefore only four double bonds are left for the chromophore region which is in good 
agreement with the shift of 30 nm in the UV-spectra (Figure 68). 
 
Figure 69:  COSY fragments were assigned (marked in black); HMBC correlations as arrows (only 
fundamental ones); R1 = -OH or -H; R2 = -CH3 or -CH2CH3. 
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Spirangien F has a shift at position C-20 from 71.5 ppm to 37.5 ppm, suggesting here a lack 
of oxygen. COSY and HMBC spectra proofed that the spiroketal backbone is unchanged 
(Figure 69). The single double bond at position C-30 was verified by HMBC-correlations. In 
an analogous manner the methyl ether at position C-23 (78.6 ppm) is attested and the methyl 
group at position C-14 is present at 1.11 ppm. In contrast to that no hydroxyl methyl was 
found at position C-3.  
To identify which of the double bonds of the chromophore is lacking compared to the original 
spirangien, the coupling constants of the conjugated double bonds were analyzed (Figure 70). 
By using them it is possible to decide if it is a Z or E double bond. Only C-4 / C-5 and C-8 / 
C-9 have large coupling constants of 14 to 15 Hz which is indicative of trans configuration. 
Hence the shortened spirangiens have an order of Z, E, Z and E double bonds, respectively. 
The known spirangien has a Z, E, Z, E, Z configuration. Aware of the existence of the methyl 
group at C-14 and biosynthetic consideration the double bond of C-12 / C-13 of the common 
spirangien is missing in the novel derivatives. 
 
Figure 70:  Double bond region of the 1H-NMR-spectra of shortened spirangien. 
Four new spirangien derivatives could be isolated; three of them could be characterized 
completely by NMR. Their final structure is depicted in Figure 71, the NMR data are listed in 
Table 19 to Table 21 and the spectra are shown in Supplementary figure 86 to Supplementary 
figure 102. 
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Figure 71:  Shortened spirangien derivatives, left side: spirangien C (R = Me) and spirangien D (R = 
Et); right side: spirangien E (R = Me) and spirangien F (R = Et). 
As further proof of the structures feeding experiments with L-[methyl-3D]-methionine to the 
BFA3KO mutant and to the wild type have been executed (by B. Frank). L-methyl-
methionine is needed for the SAM pool, which is used for methylation of hydroxyl groups. 
After feeding of L-[methyl-3D]-methionine the spirangien of the wild type showed a mass 
shift of + 3 and + 6, the spirangiens of the mutant in contrast had only a mass shift of + 3. 
This result indicates that one methyl group is lost; this is in agreement with the NMR 
structure elucidation. 
 
To identify the reason for the shortened spirangiens one has to observe the biosynthetic gene 
cluster of spirangien. It is 88 kb in size, encodes seven polyketide synthases spiD to spiJ and 
six further genes (spiA, spiB, spiC and spiK, spiL and spiZ) refer to Figure 72. 
[235]
 The 
function and the domains of each gene are given in Table 17. And a biosynthetic scheme for 
the spirangien assembly by Frank et al. is depicted in Figure 73. 
[235]
 
 
Figure 72:  Biosynthetic gene cluster of spirangien; seven polyketide synthases (green) flanked on 
both sides by adjacent genes (blue).  
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Gene Function Protein Domains 
spiA Thioesterase TE 
spiB Methyltransferase Me 
spiC 
Cytochrome P450 
monooxygenase 
P450 
spiD PKS 
ACP, KS, AT, AT, DH, KR, ACP, KS, AT, DH, ER, 
KR, ACP 
spiE PKS KS, AT, KR, ACP, KS, AT, DH, KR, ACP 
spiF PKS KS, AT, KR, ACP 
spiG PKS 
KS, AT, KR, ACP, KS, AT, DH, ER, KR, ACP, KS, 
AT, KR, ACP 
spiH PKS 
KS, AT, KR, ACP, KS, AT, KR, ACP, KS, AT, 
DH,KR, ACP 
spiI PKS KS, AT, KR, ACP,KS, AT, DH, KR, ACP 
spiJ PKS KS, AT, DH, KR, ACP, KS, AT, KR,ACP, TE 
spiK Methyltransferase Me 
spiL 
cytochrome P450 
monooxygenase 
P450 
spiZ sigma-24 factor ∑ 
Table 17:  Biosynthetic genes of spirangien and their function. AT (acyl transferase), KS 
(ketosynthase), ACP (acyl carrier), KR (ketoreductase), DH (dehydratase), ER (enoyl 
reductase), TE (thioesterase). 
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Figure 73:  Biosynthesis model of Spirangien A according to Fank et al. AT (acyl transferase), KS 
(ketosynthase), ACP (acyl carrier), KR (ketoreductase), DH (dehydratase), ER (enoyl 
reductase), TE (thioesterase), L (linker regions). 
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The BFA3KO mutant (= BFR-J40) occurred during inactivation experiments of a gene 
encoding putative transcription factor (deoRB) in S. cellulosum So ce90. 
[175]
 It is unlikely that 
this inactivation altered the metabolites as it is assumed that deoRB is not directly involved in 
the disappearance of spirangien and in the production of new derivatives of that compound. It 
is more likely that a mutation or a deletion in the sequence of the biosynthetic gene cluster of 
the spirangien took place. Knowing the structures of the shortened spirangiens one can 
assume that the sequence in gene spiJ in module 14 differs compared to the one described in 
Figure 73. In order to identify any change in the sequence of the spirangien gene cluster 
during deoRB inactivation, the assumed region of spiJ was tried to be amplified but several 
attempts failed presumably because of extensive sequence repeats in the respective region. 
Furthermore, a comparative Southern blot analysis of genomic DNA of the mutant and the 
wild type indicates that no deletion of a larger region took place in the mutant (details in PhD 
thesis of B. Frank 
[175]
). A further test to generate a double mutant and subsequent vector 
recovery failed because the respective construct (pRK415 derivative with thiostreptone 
resistance gene) could not be cloned. One way of getting information what exactly happened 
in the cluster was the generation of a cosmid library from the mutant genome and subsequent 
screen by PCR / Southern hybridization. Alternatively, cloning of the cluster by redET-
technology could be performed. 
[236-238]
 But finally a cosmid library of the BFA3KO mutant 
was generated by S. Rachid to re-sequence the gene cluster.  
To screening the cosmid library, hybridization with homologous DNA fragments from the 
ketosynthase enzyme of the module 9 of the known spirangien gene cluster as well as a 
fragment of the thioesterase in spiJ gene was carried out by S. Rachid (Figure 74). Primers 
BF_SH1 and BF_SH9 were used for amplification of a DIG-labeled KS probe, and BFST1 
and CFST2 were used to generate a DIG-labeled fragment of the spirangien TE. 
 
Figure 74:  Hybridization of the BFA3KO cosmid library membrane with a KS probe of the module 
9 (left) and with a TE probe from the spiJ gene, resulted in identification of B:P6 cosmid. 
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It has been confirmed by a PCR, that the cosmid B:P6 carries the 3’ end of the gene cluster, 
the KS encoding gene and the TE region. Thus the insert of the cosmid was sequenced on 
both strands (Maren Scharfer, HZI Braunschweig), by using a shotgun library with DNA 
fragments of approximately 1.5 – 2.0 kb in length. Sequence analysis showed an insert length 
of 36053 bp. The sequence was aligned with the wild type sequence. Each difference in the 
sequence compared to the wild type was re-sequenced. Finally the alignment showed several 
mutated regions or point mutations in the sequence of spiJ, module 15, in an acyltransferase 
(AT). As these mutations occur at the same time it could be possible that there are some 
sequencing mistakes in the original wild type sequence. In the DNA sequence of the spiJ 
seven regions within the second AT domain with either nucleotide substitution, nucleotide 
deletion or insertion have been observed (Figure 75, latest status of ongoing investigations of 
S. Rachid). 
 
 
 
Figure 75:  Alignment of the spirangien cluster and of the mutated cluster in cosmid B:P6. Only 
regions with differences in spiJ are shown. 
Such a genetic modifiaction might have caused a module skipping. Module skipping means to 
bypass the utilization of a complete module or of a single domain of a biosynthetic 
pathway. 
[239]
 The biosynthetic intermediate is directly transferred from a module to the after 
next one that means a complete module with all its enzyme activities is mistreated. 
[240]
 In 
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another case the ACP of the module is involved but the other domains are skipped and no 
extender unit is added to the intermediate due to an inactive AT domain. 
[207]
 
The mutations here might have resulted in the inactivation of the AT domain of SpiJ and it 
can be assumed that a module skipping occurred within the final PKS extension module to 
lead to a production of shorter spirangiens.  
The production of shorter derivatives without the hydroxyl group at position C-20 
demonstrates that the substrate recognition for SpiL is tough, as spirangien C and D are 
oxidized in contrast to spirangien E and F. The lack of the oxidation here also sheds light onto 
the spiroketal formation. The biosynthetic spiroacetal formation is poorly understood as 
intermediates are often unstable and responsible enzymes were difficult to identify. 
[241]
 For 
the spiroketal monensin it is described; it is formed by an SN2 reaction catalyzed by an 
epoxide-hydrolase/cyclase enzymes. 
[242]
 In contrast to that Osada et al. recently identified 
two responsible enzymes (RevG and RevJ) which are involved in the spiroacetal formation of 
reveromycin. 
[241]
 RevG (a dihydroxy ketone synthase) conducts the dehydrogenation and 
RevJ (a spiroacetal synthase) accomplishes the cyclization. 
The spiroacetal formation of avermectin 
[243]
 and tautomycin is explained via a dehydrative 
cyclization mechanism as it is suggested for spirangien, too. Frank et al. describe two possible 
ways for the construction of the spiroketals (Figure 76). 
[235]
 In the one case first the oxidation 
of C-21 takes place then spiroketal formation follows and the hydroxylation at C-20 occurs at 
the end. Alternatively C-20 is oxidized at first, then C-21 and afterwards the first ring is 
closed followed by the second ring closure. But the presence of non-hydroxylated derivatives 
at C-20 indicates that this last proposed pathway has to be wrong and that the hydroxyl group 
is not essential for spiroketal formation. Therefore, the left pathway of Figure 76 has to be the 
correct mechanism and the other hypothetical pathway can be excluded. 
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Figure 76:  Proposed spiroketal formation during the biosynthesis of spirangien; ketogroup at C-21 
shown as hydrated form. 
To summarize some kind of evolution imitated accidental in the lab occurred to the strain 
So ce90. Spontaneous mutations appeared within the biosynthetic gene cluster of spirangien 
as a consequence novel spirangien derivatives emerged. It might be seen as evolution in the 
lab in front of the researches eye. Seven variabilities have occurred in the sequence of the 
second AT domain in spiJ. At least one of those mutations apparently caused a module 
skipping. As result of the skipping shorter spirangien derivatives have been produced by the 
“natural” mutant. These were isolated and characterized by NMR analysis. Their structure fits 
perfectly to the genetic modifications within the biosynthetic gene cluster. Furthermore it 
shows that methyltransferase (SpiK) has very tight substrate specificity as no further methyl 
ether occurs. The cytochrome P450 (SpiL) still accepts the novel derivatives but the error 
ratio is high as not the complete spirangien E and F are converted.  
The evidence of the structure spirangien E and F and the interpretation of their biosynthesis 
contributes to the understanding of the spiroketal formation.  
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Experimental Section 
Purification process of the spirangien derivatives 
The BFKO mutant of So ce90 was cultivated together with XAD in a 9 l fermenter (K. Gerth), 
for cultivation details see Frank et al. 
[235]
. As the spirangien especially the shorten derivatives 
are light sensitive the whole work up process was performed with dimmed light, whenever 
possible under nitrogen and stored in MeOH at -20 °C. The XAD was eluted in an open glass 
column with MeOH (1.25 l). The organic solvent was removed; some brine was added to the 
water phase and extracted three times with ethyl acetate. The ethyl acetate contained 2.02 g of 
extract which was dissolved in MeOH and a partition (2 x) against heptane reduced the extract 
to 1.88 g. The crude extract was placed on a MPLC column (MeOH / H2O (85 : 15), 50 mM 
K2HPO4 / NaH2PO4, pH = 7, flow rate = 50 ml / min, d = 10 cm, 10 bar) this led to six 
fractions which contained mainly: epothilone A, epothilone B, spirangien C, spirangien D, 
spirangien E and spirangien F. The MeOH was removed and the water phase extracted with 
ethyl acetate (3 x), the combined ethyl acetate was extracted against water, the solvent was 
dried with Na2SO4. The spirangien containing fractions were purified with preparative HPLC 
(16 x 250 mm Nucleodur C18 Machery – Nagel, MeOH / H2O (85:15), 50 mM K2HPO4 / 
NaH2PO4, pH = 7, flow rate = 15 ml / min, detection: 320 nm). The appropriate peaks were 
collected, the MeOH was removed and the water phase extracted (3x) with EE which then 
was distributed against water and dried over Na2SO4. Four novel spirangien derivatives were 
isolated: spirangien C (2.1 mg), spirangien D (less than 1 mg), spirangien E (12.4 mg), 
spirangien F (7.6 mg).  
 
Structure analysis 
The structure analysis was performed by NMR spectroscopy in CD3OD using a Bruker 
Avance 500 instrument. 
1
H-, 
1
H,
1
H COSY-, HSQC-, HMBC- spectra were measured and 
when it was possible 
13
C spectra. The data are listed Table 19, Table 20 and Table 21. 
Bioactivity 
The three spirangien derivatives were tested against following cell lines: L929, Sw480 and 
U037. The new derivatives showed IC 50 values between 0.0007 to 0.005 µg / ml (see  
Table 18. The biological assay were performed by Y.A. Elnakady. 
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Spirangien C 
IC50 [µg / ml] 
Spirangien E 
IC50 [µg / ml] 
Spirangien F 
IC50 [µg / ml] 
L929 0.005 0.002 0.002 
Sw480 not available 0.003 0.003 
U937 0.0007 0.002 0.001 
Table 18:   IC50 values for the new spirangien derivatives. 
 
Creation of cosmid library  
Chromosomal DNA of So ce90 BFA3KO was isolated and partially digested with Sau3AI, 
dephosphorylated and subsequently ligated into SuperCos1 (Stratagene) pre-treated with 
XbaI, dephosphorylated, and restricted with BamHI. Packaging of the ligation mixture with 
Gigapack III Gold (Stratagene) packaging extract and transducing the resulting phages into 
E. coli HS699 generated a genomic library consisting of 2304 clones.  
All single colonies were transferred into 384-well microtiter plates, grown in LB medium 
overnight, and replicated twice. Glycerol (10 %) was added to one copy of the library, and the 
plates were frozen at - 80 ºC. For colony hybridization, the colonies of the second copy were 
transferred twice onto a 22.2 x 22.2 cm nylon membrane (Biodyne B, Pall) with a Qbot robot 
(Genetix). The creation of the cosmid library was done by S. Rachid. 
 
Identification of the B:P6 cosmid  
Primers BF_SH1 (5’-CGGAGATCGCATCGATGTC-3’), and BF_SH9 (5’-GTTCGGGACC 
GTGATCCC-3’) were used to amplify a 952 bp DIG-labeled KS probe, and primers BFST1 
and CFST2 (sequence by B. Frank) were used to generate a 576 bp DIG-labeled fragment of 
the TE (Supplementary figure 103).   
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No. 
1
H [ppm]   J [Hz] 
13
C [ppm] H-H-COSY HMBC 
1 - - - 174.6 - - 
2 2.51 d 6.4 43.1 3 1, 3, 4 
3 4.60 m - 69.8 2, 4 1, 2, 4 
4 5.77 dd 6.2, 14.8 136.7 3, 5 2, 3  
5 6.80 dd 11.5, 14.8 126.8 4, 6 6 
6 5.99 t exp. dd 11.1 129.6 5, 7, 8 4, 5, 7 
7 6.09 t exp. dd 11.5 131.0 6, 8 6, 8, 9 
8 6.74 dd 11.5, 14.3 129.3 7, 9 7, 9 
9 6.57 t exp. dd 11.8 14.3 130.4 8, 10, 11 7, 8, 10 
10 6.16 t exp. dd 11.0 129.9 9, 11 9 
11 5.62 t exp. dd 10.6 134.3 10, 14 9, 14 1 4Me, 15 
14 2.94 m - 35.8 11, 14Me, 15 10, 11, 14Me 
14 Me 1.11 d 6.9 19.7 14 11, 14, 15 
15 3.55 dd 2.2, 9.7 76.4 14, 16 11, 14, 16, 17 
16 1.61 m - 39.8 15, 16Me, 17 15, 16Me, 17 
16 Me 0.79 d 6.9 9.3 16 15, 16 
17 3.59 m - 74.8 16, 18 15, 16, 16Me 
18 1.91 m - 25.4 18Me, 19ab 17, 18Me 
18 Me 0.75 d 6.7 17.9 18 17, 18, 19 
19 1.73 m - 37.5 18, 18Me, 20 18, 20 
19b 1.67 m - 37.5 18, 18Me, 20 20, 21 
20a 3.38 m - 71.0 19ab 18, 19 
20b - - - - - - 
21 - - - 99.5 - - 
22a 2.04 m - 33.7 22b, 23 21, 23, 24 
22b 1.37 m - 33.7 22a, 23 21, 23 
23 3.65 m - 78.6 22a, 22b, 24 23oMe, 24Me 
23 OMe 3.36 s - 55.1 - 23 
24 2.12 m - 32.5 23, 24Me, 25 22, 23, 24Me 
24 Me 0.77 d 7.0 3.9 24 23, 24, 25 
25 3.63 m - 72.3 24, 26 23, 24Me, 26, 27 
26 1.82 m - 37.6 25, 26Me, 27 25, 26Me 
26 Me 0.79 d 7.0 7.9 26 25, 26, 27 
27 3.68 m - 75.9 26, 28 25, 26Me, 28, 29 
28 1.73 m - 35.1 29ab, 27 27, 28Me, 29 
28 Me 0.71 d 6.7 15.5 28Me 27, 28, 29 
29a 2.66 m - 45.6 31, 29b, 28 28, 28Me, 30 
29b 1.60 m - 45.6 29a, 31 28, 30 
30 - - - 135.4 - - 
30 Me 1.60 m - 14.7 - 29, 30, 31 
31 5.21 q 6.5 120.9 29ab, 32 29, 30Me 
32 1.58 m - 13.4 31 30, 31 
33 - - - - - - 
Table 19:  NMR Spectroscopic data of the spirangien C (500 MHz, methanol-d4), for better 
comparison to spirangien A and B the same numbering [230] is use, therefore C-12 and C-
13 do not exist.  
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No. 
1
H  
[ppm] 
  J [Hz] 
13
C  
[ppm] 
H-H-COSY HMBC 
1 - - - 175.2 - - 
2 2.50 d 6.8 43.3 3 1, 3 
3 4.60 m - 69.5 2, 4, 5 1, 2, 4, 5 
4 5.77 dd 6.3, 15.1 136.8 3, 5, 6 2, 3, 6 
5 6.82 dd 11.2, 15.0 127.0 3, 4, 6, 7 3, 6  
6 5.99 t exp. dd 11.0 129.6 5, 7 4, 5, 8 
7 6.09 t exp. dd 11.0 131.0 5, 6, 8 5, 6, 8 
8 6.74 dd 11.8, 14.7 129.2 6, 7, 9 9 
9 6.56 t exp. dd 11.2, 14.2 130.3 8, 10, 11 7, 10, 11 
10 6.15 t exp. dd 11.4 129.8 9, 11 9, 14 
11 5.62 t exp. dd 10.3 134.1 9, 10, 14 10, 14, 14Me, 15 
14 2.93 m - 35.7 11, 14Me, 15 11, 14Me 
14 Me 1.11 d 6.7 19.7 14 14, 15, 17 
15 3.54 dd 2.0, 9.9 76.6 14, 16 11, 14Me, 17 
16 1.61 m - 40.3 15 ,16Me, 17 15, 16Me 
16 Me 0.74 d 4.4 9.5 16 15, 16, 17 
17 3.60 d 9.8 75.4 16, 18 16, 16Me, 18Me, 19, 21 
18 1.51 m - 32.3 17, 18Me, 19 17, 19 
18 Me 0.78 d 5.9 18.4 18 17, 18, 19 
19 1.56 m - 29.9 18, 20ab 18, 18Me, 20, 21 
19b 1.56 m - 29.9 18, 20ab 18, 18Me, 20, 21 
20a 1.65 m - 37.5 19, 20b 18, 19, 21 
20b 1.49 m - 37.5 19, 20a 18, 19, 21 
21 - - - 98.1 - - 
22a 1.72 m - 38.0 22b, 23 21, 23, 24 
22b 1.43 m - 38.0 22a, 23 21, 23 
23 3.66 m - 78.6 22ab, 24 21, 23 
23 OMe 3.32 s - 55.5 - 23 
24 2.12 m - 33.1 23, 24, 25 23, 24Me, 26 
24 Me 0.77 d 6.7 4.2 24 23, 24, 25 
25 3.64 m - 72.2 26 24Me, 26 
26 1.85 m - 38.0 24, 26 25, 26Me, 27 
26 Me 0.81 d 7.0 8.2 26 25, 26, 27 
27 3.70 m - 76.3 26, 28 25, 26, 28, 29 
28 1.73 m - 35.6 27, 28Me, 29ab 28Me, 29 
28 Me 0.72 d 4.1 15.7 28 27, 28, 29 
29a 2.68 m - 46.2 28 28, 30 
29b 1.60 m - 46.2 28 28 30 
30 - - - 134.8 - - 
30 Me 1.61 m - 16.1 - 28, 30, 31 
31 5.16 t 6.8 129.6 29ab, 32 29, 30Me, 32 
32 2.03 m - 22.4 31, 33 30, 31, 33 
33 0.96 t 7.1 14.9 32 31, 32 
Table 20:  NMR Spectroscopic data of the spirangien F (500 MHz, methanol-d4), for better 
comparison to spirangien A and B the same numbering [230] is use, therefore C-12 and C-
13 do not exist.  
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No. 
1
H  
[ppm] 
  J [Hz] 
13
C  
[ppm] 
H-H-COSY HMBC 
1 - - - 174.9 - - 
2 2.51 d 6.7 43.4 3 1, 3, 4 
3 4.60 q exp. dt 6.4 70.0 2, 4, 5 1, 2, 4, 5 
4 5.77 dd 6.4,14.9 137.0 3,5,6 2, 3, 5 
5 6.81 dd 11.7, 14.8 127.0 3, 4 ,6, 7 3, 6, 7 
6 5.99 t exp. dd 11.1 129.9 5, 7 4, 5, 7, 8 
7 6.09 t exp. dd 11.1 131.3 6, 8 5, 9 
8 6.73 dd 11.7, 14.2 129.5 7, 9 6, 7, 9 
9 6.76 t exp. dd 11.3 130.6 8, 10 7, 8, 10, 11 
10 6.15 t exp. dd 11.3 130.1 9, 11 8, 9, 11 
11 5.62 t exp. dd 10.4 134.5 9, 10, 14 10, 14, 14Me, 15 
14 2.82 m - 36.2 11, 14Me, 15 10, 11, 14Me 
14 Me 1.11 d 7.0 19.6 14 11, 14, 15 
15 3.54 d exp. ddd 1.7, 10.1 76.8 14, 16 11, 14, 14Me, 16, 17 
16 1.61 - - 40.2 15, 16Me, 17 15, 16, Me 
16 Me 0.72 m - 9.5 16 15, 16, 17 
17 3.60 m - 75.4 16, 18 15, 16, 16Me, 18, 18Me 
18 1.49 m - 32.3 18Me 17, 19 
18 Me 0.78 d 5.1 18.4 18 17, 18, 19 
19 1.55 m - 29.8 18, 20ab 17, 18, 20, 21 
19b 1.55 m - 29.8 18, 20ab 17, 18, 20, 21 
20a 1.65 m - 37.4 19, 20b 19, 21 
20b 1.48 m - 37.4 19, 20a 19, 21 
21 - - - 98.1 - - 
22a 1.70 m - 38.0 22b, 23 21, 23 
22b 1.41 m - 38.0 22a, 23 21, 23 
23 3.66 m - 78.6 22a, 24 24, 23OMe 
23 oMe 3.32 s - 55.5 - 23 
24 2.12 m - 32.9 23, 24Me, 25 24Me 
24 Me 0.76 d 6.6 4.3 24 23, 24, 25 
25 3.65 m - 72.2 24, 26 23, 24, 24Me, 26, 27 
26 1.84 m - 37.8 25, 26Me, 27 25, 26Me 
26 Me 0.80 d 7.1 8.7 26 25, 26, 27 
27 3.70 m - 76.2 26, 28 25, 26, 28, 28Me, 29 
28 1.72 m - 35.6 29ab, 27 27, 29 
28 Me 0.71 m - 15.6 28 27, 28, 29 
29a 2.66 m - 46.1 31, 29b, 28 28, 28Me, 30 
29b 1.63 m - 46.1 29a, 31 28, 28Me, 30 
30 - - - 136.1 - - 
30 Me 1.61 m - 16.0 31 29, 30, 31 
31 5.22 q 6.4 121.2 29, 32 29, 30Me, 32 
32 1.59 m - 13.6 31 30, 31 
33 - - - - - - 
Table 21:  NMR Spectroscopic data of the spirangien E (500 MHz, methanol-d4), for better 
comparison to spirangien A and B the same numbering [230] is use, therefore C-12 and C-
13 do not exist.  
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The cosmid C4L22 carrying the spirangien gene cluster of the So ce90 wild type was used as 
template DNA for the PCR amplifications. Hybridization of the southern membrane of the 
mutant (So ce90 BF3AKO) with each probe was performed under stringent condition (68 °C).  
PCR analysis of the cosmid B:P6: to test whether B:P6 carry the 3’ end of the gene cluster a 
PCR amplification of the KS encoding gene (952 bp) in module 9, and TE region (576 bp) 
was performed using BF_SH1, and BF_SH9 and BFST1 and CFST2, respectively 
(Supplementary figure 103). The cosmid sequencing was done by M. Scharfer and the 
identification was performed by S. Rachid therefore it is not further described in details. 
  
Chapter 4: Spirangien 
 
 
269 
Supporting Information 
 
Supplementary figure 86:  1H spectrum of spirangien C in methanol-d4. 
 
 
Supplementary figure 87:  13C spectrum of spirangien C in methanol-d4. 
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Supplementary figure 88:  COSY spectrum of spirangien C in methanol-d4. 
 
 
Supplementary figure 89:  HSQC spectrum of spirangien C in methanol-d4. 
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Supplementary figure 90: HMBC spectrum of spirangien C in methanol-d4. 
 
 
Supplementary figure 91:  1H spectrum of spirangien D in methanol-d4. 
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Supplementary figure 92:  1H spectrum of spirangien E in methanol-d4. 
 
 
Supplementary figure 93:  13C spectrum of spirangien E in methanol-d4. 
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Supplementary figure 94:  COSY spectrum of spirangien E in methanol-d4. 
 
 
Supplementary figure 95:  HSQC spectrum of spirangien E in methanol-d4. 
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Supplementary figure 96:  HMBC spectrum of spirangien E in methanol-d4. 
 
 
Supplementary figure 97:  1H spectrum of spirangien F in methanol-d4. 
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Supplementary figure 98:  13C spectrum of spirangien F in methanol-d4. 
 
Supplementary figure 99:  COSY spectrum of spirangien F in methanol-d4. 
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Supplementary figure 100:  HSQC spectrum of spirangien F in methanol-d4. 
 
 
Supplementary figure 101:  HMBC spectrum of spirangien F in methanol-d4. 
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Supplementary figure 102:  TOCSY spectrum of spirangien F in methanol-d4. 
 
Supplementary figure 103:  left: Dig-labeled PCR fragments of KS (lane 1 and 2), and TE fragment (lane 4 and 5). 
Lane 3 is DNA marker. Right: PCR analysis showing generation of a KS fragment 
(lane 1), and TE fragment (lane 3) using B:P6 as DNA template. 
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Discussion 
1. Biosynthetic pathways 
Bacteria utilize several different biosynthetic pathways for the production of secondary 
metabolites. The present work discusses biosynthetic pathways based on PKS / NRPS 
mechanisms on the one side and a highly unusual ribosomal pathway on the other side. In this 
thesis the PKS biosynthesis is represented by spirangien, while myxoprincomide and 
chondrochloren are a result of a PKS–NRPS hybrid systems. In contrast to that, the 
tetrapeptide cittilin is produced by a ribosomal pathway. 
While PKS, NRPS and hybrid NRPS-PKS biosynthetic pathways are commonly known as 
biosynthetic routes for natural compounds of myxobacteria, 
[45;49]
 the ribosomal production of 
a secondary metabolite is proven here for the first time from that order. Various ribosomal 
biosynthetic pathways are known from other bacteria; the class of bacteriocins 
[146;147]
 is 
known since long for example, but recently more and more other ribosomal secondary 
metabolites are being published. 
[156;157]
 
In the last decade the methodology for identification and characterization of secondary 
metabolite biosynthetic pathways changed dramatically due to the availability of whole 
genome sequence information. More and more bacterial genomes are deciphered and 
bioinformatic analysis reveals the presence of secondary metabolite biosynthetic pathways. 
Astonishingly the number of known natural products (NP) is often much lower than the 
genetic capacity of the organism. 
[97;204]
 Thus, the discovery of novel NP from genetically 
proficient organisms currently constitutes a bottleneck, rather than obtaining the sequence 
information for a biosynthetic gene cluster. 
For detection and functional analysis of biosynthetic genes, bioinformatic tools have been 
developed which are able to perform the annotation of biosynthetic pathways in genomes 
routinely. However, knowing the gene cluster does not automatically mean that the 
corresponding metabolite can be identified. Particular if the biosynthesis does not conform to 
the so called textbook biosynthetic model (described in the introduction). In some cases the 
biosynthesis follows the colinearity rule where each module is performing one function, but 
often biosynthesis in myxobacteria does not follow this model. 
[97]
 Frequently in silico 
analysis alone is not able to predict the final product from its genes, like in the case of the 
myxoprincomides. 
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2. Structure and biosynthesis of cittilin 
Cittilin is a common substance for M. xanthus, since 69 strains of 98 various strains form 
differing locations worldwide are producing it. 
[51]
 The biological function for the bacteria is 
not clear as an antibiotic or antifungal activity has not been found. Nevertheless cittilin B is 
medicinally interesting as it has been described as a neurotensin antagonist (neurotensin 
receptor from guinea pigs IC50 = 30 mg / mL). 
[170;172]
 Such antagonists are useful for treating 
depression, psychoses, Alzheimer and Parkinson diseases. Therefore RP-66453 which is 
structurally identical to cittilin B was patented by Rhone-Poulenc in 1995. The company used 
it as a lead structure for the development of antipsychotic pharmaceuticals. Chemical 
modification at the structure ended with the discovery of potent neurotensin antagonists. 
[244]
 
The two aryl crosslinks between the tyrosine residues are the characteristic features of the 
cittilin tetrapeptide. The carbon - carbon bond together with the ether connection of phenyl 
rings are known from a small number of other natural compounds. The most famous example 
is vancomycin where both types of connections are present. Same structural features are 
known from teicoplanin (52) 
[245]
, balhimycin 
[178]
, kistamine 
[179]
, and chloropeptin 
[180]
, too. 
Structures with the existence of only an ether bridge between two tyrosine rings are K 13 (54), 
deoxybouvardin (55), aceroside IV (56) and the structures of the RA family (for example 
RA VII (53), it is an anti – tumor agent) [246]. Endo aryl-aryl bonds exist in many bioactive 
macrocycles like biphenomycin (57) and acerogenin K (58). Biphenomycin B is highly potent 
antibiotic against Gram-negative and β-lactam-resistant microorganisms. It was isolated from 
Streptomyces griseorubiginosus (NO. 43708) culture. 
[247;248]
 These compounds demonstrate 
that aryl - aryl connections as present in cittilin are employed by different organisms for 
diverse structures. 
From the chemical point of view the synthesis of such complex aryl - aryl architecture was a 
challenge. The synthesis of vancomycin for instance led to numerous impetuses in the 
development of synthetic methodologies. 
[249] 
In the case of cittilin B the total synthesis solved 
its long time unknown absolute configuration. 
[182-185]
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Figure 77:  Cittilin, teicoplanin (52), RA VII (53), K 13 (54), deoxybouvardin (55), aceroside IV (56), 
biphenomycin A (57), acerogenin K (58). 
The biosynthesis for the NRPS product vancomycin was well studied, too. Here the aryl - aryl 
connections are build by different cytochrome P450 enzymes. Each linkage is performed by a 
specialized P450 enzyme (further details see cittilin chapter). 
[181]
 In contrast to vancomycin 
cittilin is not a NRPS product it is build by a ribosome-dependent pathway. For both, the 
ribosomal and the NRPS pathway there are enzymes which are able to modify the peptide 
core structures. These modifying enzymes of the ribosomal biosynthesis are similar to NRPS 
post modifying enzymes. 
[194]
 However definitely more NRPS than ribosomal secondary 
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metabolites are known. But frequently natural peptides are thought to be of nonribosomal and 
not of ribosomal origin. 
[144;152;155;162]
 After isolation cittilin was presumed to be an NRPS 
product, too. And therefore a search within the genome for typical NRPS A-domains with 
tyrosine and isoleucine specificities was performed. Only the lack of them led to the discovery 
of the encoding precursor peptide sequence. 
Ribosomal peptide encoding sequences, like the one of cittilin, can be very short and are hard 
to discover in the course of routine secondary metabolite gene cluster analysis as such 
sequences do not need to be within large operons. Cittilin for instance is inside of an open 
reading frame which is only 231 base pairs long. Up to date the core peptide and the 
modifying enzymes of the cittilin gene cluster are identified. A signal peptide and a 
recognition sequence are not present or not verified so far. The exact length and the function 
of the leader peptide are not known but leader peptides often differ for each ribosomal 
peptide. 
[145]
 Furthermore the backbone ring closure of cittilin is unusual; it is not like in the 
case of the patellamides where the first amino acid is connected with the final one, to close 
the ring. And the ring closure is not similar to the lantibiotic ring formation. 
[145;148]
 There, 
cysteine threonine and serine residues are used for cyclization. Lantibiotic cyclization 
happens in two sequential steps. At first threonine or serine are dehydrated. In a second step 
the dehydroxylated group is linked with a thiol group of a cysteine. Both processes are 
performed by a bifunctional synthetase LanM (refer to introduction chapter). 
[190]
 In contrast 
to lantibiotics and patellamides, the cittilin rings are formed by a post-translational P450 
enzyme. Involvement of the P450-dependent oxygenase in cittilin biosynthesis was 
unambiguously confirmed by construction of its oxygenase knockout mutant, which showed 
lack of cittilin production. Such P450 enzymes are implemented in the biosynthesis of 
vancomycin. There the C-C connections are build by two P450 enzymes (OxyA and OxyB) 
while OxyC, another P450, is in charge of the phenolic coupling. 
[181;189]
 
Except for the modifying enzymes cittilin biosynthetic pathway is a promising system for a 
genetic library by site directed mutagenesis of the encoding sequence by PCR. By simple 
mutagenesis in the heterologous expression construct novel cittilin derivatives were 
generated. A similar approach was used by Schmidt et al. in a study with the patellamides, 
demonstrating that it is possible to create a peptide library by mutating the encoding sequence 
by PCR. 
[143]
 But with the cittilin system even the obtained peptides are further modified. In 
ribosomal systems structural variation can be made easily compared to NRPS ones. For NRPS 
machineries such library creation is very difficult and only possible under high effort. Here 
complete A domains have to be exchanged / created, which then have to be able to interact 
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with the other domains / modules. But the domains are encoded in huge protein sequences and 
not in the three letter code for one amino acid like in the case of the ribosomal biosynthesis. 
To further increase the diversity of the cittilin derivatives by site directed mutagenesis the 
core ring system could be changed. This is only possible if the N and C terminal sequences 
are not necessary for the recognition or the processing for the modifying enzymes. If so it is 
likely that it is even possible to produce a pentapeptide or a multipeptide instead of the 
tetrapeptide, although the exact role of the precursor peptide is not known. Furthermore the 
P450 might not accept the pre-cittilin as substrate if one of the tyrosines is exchanged. 
However for all these modifications it looks like if the ABC transporter system is present the 
production rate is higher, even if the exact function could not be clarified, this should be 
addressed in further studies. 
To conclude, the work presented in the cittilin chapter, revealed that myxobacteria are using 
their ribosomal machinery, beside the typical described PKS and NRPS pathways, for the 
production of secondary metabolites. 
Cittilin is the first known myxobacterial representative for which the biosynthetic machinery 
could be shown to rely on a ribosomal mechanism. There is a number of other recently 
published secondary metabolites from other bacteria which are produced via ribosomal 
pathways like the patellamides 
[144]
, the microviridins 
[157;160]
 and the cyanobactins 
[156;157]
. As 
more and more ribosomal peptides are identified form other bacteria it looks most likely that 
further interesting substances are as well built in ribosomal manner by myxobacteria. To 
increase the body of knowledge of ribosomal secondary metabolites further ribosomal 
pathways should be analyzed. 
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3. Myxoprincomides of Myxococcus xanthus DK1622 and DK897 
The myxoprincomides are novel secondary metabolites produced by the M. xanthus. Two 
different types of myxoprincomides were isolated, one structure type from DK897 and the 
other one from DK1622. In the screening of 98 M. xanthus strains every strain produces 
myxoprincomides, 
[51]
 only the type varies, either the DK1622 type or the DK897 variants are 
present. 73% of the screened strains produced the DK897 type of myxoprincomides (at least 
one of the 10 compounds was detected). While the DK1622 myxoprincomide variant (c506) 
was found in 36 strains. But both types are always produced in very small amounts. The 
biological function of the myxoprincomides remains elusive so far. In general the range of 
biological activities from known myxobacterial secondary metabolites is wide. 
Chondrochloren produced by Chondromyces crocatus Cm c5 for example shows weak anti-
bacterial and anti-fungal activity. 
[77]
 Spirangien a secondary metabolite of Sorangium 
cellulosum So ce90 is cytotoxic and anti-fungal. 
[230]
 For M. xanthus secondary metabolites 
diverse biological activities have been reported, too. Cytotoxic effects for example are 
described form myxochromides 
[85]
 while the myxalamides 
[82]
 are acting anti-fungal. Anti-
bacterial activity is known from myxovirescin [84] and myxochelin 
[83]
. The later is a 
siderophore which has as well antiviral activity. Furthermore the above discussed cittilin is 
described as neurotensin antagonist. 
[170;172]
 In the case of the myxoprincomides, no detectable 
antifungal, antibiotic or cytotoxic function was found. But as every M. xanthus strain 
produces myxoprincomides its role should be significant for the producing organism. It might 
be something which it is normally not tested and hard to detect for instance like in the case of 
the DKxanthenes which play an important pheromone-like role for sporulation. 
[86;196]
 Roles 
in microbial differentiation or function that are related between primary and secondary 
metabolism are often difficult to identify. Hence it is problematic to demonstrate competitive 
advantage to the producer. 
 
At the beginning of the thesis the myxoprincomides of DK897 and DK1622 have been run as 
different projects, as the biosynthetic cluster of DK897 was not known. Therefore no 
correlation between the two clusters was obvious. Furthermore the masses and mass 
fragments of the myxoprincomides and of course the strains were different. During the 
ongoing process and the finish of the genome sequencing of DK897, it became more and 
more obvious that the biosynthetic machinery and as well the substances are close relatives. 
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But the strategy of correlating the biosynthetic genes to the compound was completely 
different. 
In the case of DK987 first no genome information was available. Therefore a transposon 
mutagenesis was performed and the obtained transposon mutants were screened by LC-MS 
for lacking myxoprincomide production. Here approximately 2000 mutants were screened to 
identify the gene metabolite correlation. While for DK1622 the complete genome was known 
and a targeted mutagenesis was used to inactivate potential biosynthetic gene clusters. The 
comparatively low number of created mutants were screened for lack in production of any 
possible compound. In this approach the discovery of novel secondary metabolites from 
genome sequenced strain has been assisted by modern analytical techniques, combined with 
statistical tools to reduce manual efforts. And targeted mutagenesis experiments led to the 
correlation of novel compounds. Gene inactivation studies have been merged with liquid 
chromatography coupled to high resolution mass spectrometry (LC-HR-MS) analysis. The 
metabolome has been analyzed with principal component analysis (PCA). Yielding in statistic 
findings which point at differences between wild type and mutant strains. Manual comparison 
of LC-MS data would be very tedious, and failed before to assign novel metabolites. The 
huge amount of data including media-derived signals, low abundance of compounds make it 
impossible to detect any novel substance produced in trace amounts manually. Here 
implementation of statistical tools is a necessary assistance. 
After confirmation of the gene metabolite correlation the gene cluster could be analyzed in 
silico and a substance isolation procedure was started. But in the event of DK897 a transposon 
recovery of the non myxoprincomide producing clone was carried out. Followed by 
subsequent plasmid sequencing to obtain first biosynthetic gene cluster information. That 
means to assign the myxoprincomide gene cluster in DK897 an older strategy was applied. In 
the case of the genome sequenced strain DK1622 the myxoprincomides and the correlating 
gene cluster have been detected with a novel approach, the “secondary metabolome mining”.  
For DK1622 18 biosynthetic gene clusters (PKS, NRPS and hybrids thereof) have been 
located but only five of them were correlated to a natural product (at the beginning of this 
thesis). 
[90;195;206-209]
 But in an evaluation it was found out, that at the transcriptomic and 
proteomic levels 13 gene clusters are active under laboratory conditions. 
[89;90]
 The high 
number of unassigned biosynthetic gene clusters in DK1622 translates into a resource of 
novel natural products which should be exploited. Here three novel classes of secondary 
metabolites have been detected and connected to genes. With the discovery of the cittilin 
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biosynthetic genes, a cluster which is not NRPS or PKS based, in total 9 secondary 
metabolites of M. xanthus DK1622 are correlated to their genes. 
However the genes revealed that there have to be more unknown compounds in the bacterial 
extracts. One possibility for not detecting them is that the products of these none correlated 
biosynthetic routes might be produced early and degraded during the life cycle of M. xanthus. 
From Sorangium cellulosum So ce56 such a case (chivosazol) has been observed. 
[88]
 
Chivosazol production can be detected in So ce56 after 100 h of growth. Further accumulation 
follows for further 200 h then the degradation process is faster than the chivosazol 
production. 
[250]
 Similar cases could be investigated by a kinetic study involving harvesting 
and measuring of samples at different time points. Another factor might be a weak stability of 
the natural products. Furthermore a problem can be the adsorption characteristics with regards 
to the XAD-16 adsorber resin. Or if the metabolites do not have UV absorption and are very 
poorly ionizing it would be a detection problem. 
Assuming that the molecules are present in the bacterial extracts it would be a matter of 
identification within the extract. Small quantities (under laboratory conditions) or low 
abundance at all may make their detection difficult. This means that the bottleneck is the 
analytical discovery of the secondary metabolites. It is an analytical challenge to solve this 
difficulty. To overcome this problematic the “secondary metabolome mining” approach has 
been developed (refer to chapter 2B). 
[176]
  
 
The myxoprincomide structure shows several rare and unprecedented features beside common 
amino acids very uncommon structural elements are incorporated. For instance either (2S,3S)-
3-amino-2-hydroxy-5-methylhexanoic acid (59) or (2S,3S)-3-Amino-2-hydroxy-4-methyl-
pentanoic acid (60) are part of the myxoprincomides. Alternatively there is the diketo variant 
of 59 and 60 ((S)-3-amino-5-methyl-2-oxohexanoic acid (62) and (S)-3-amino-4-methyl-2-
oxopentanoic acid (63)). An α-keto-valine building block is known from the structures of 
oriamide 
[251]
, cyclotheonamides 
[252]
, keramamides 
[253]
 and scleritodormin 
[254]
 which are all 
marine natural products. 59 is known from the structure of amastatin isolated from a 
streptomyces species. 
[255-257]
 Beside that it is present in several synthetic derivatives of 
natural compounds. 
Another uncommon part is (S)-Hydroxy-valine or (2S)-2-Amino-3-hydroxy-3-methylbutanoic 
acid (OH-Val; 61). It is twice inside the structure of the long myxoprincomides of the DK897 
type and only once in the DK1622 type. It occurs in nature as single amino acid 
[258]
 or as 
glycerin ether 
[259]
. Therefore it is likely that no oxidation domain for the oxidation of a valine 
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is needed within the corresponding modules. 61 is part of the natural compounds zorbamycin 
[260]
, luzopeptin 
[261], and yaku’amides [262]. Furthermore it is known from the myxobacterial 
compound myxovalargin 
[76]
.
 
The fourth unusual amino acid is β-lysine. As secondary metabolite component it has been 
described within the structure of the antibiotics viomycin 
[263]
 and nourseothricin 
[264]
. 
 
 
59   60    61 
 
 
62    63 
Figure 78:  Structures of (2S,3S)-3-amino-2-hydroxy-5-methylhexanoic acid (59), (2S,3S)-3-Amino-2-
hydroxy-4-methylpentanoic acid (60), (2S)-2-Amino-3-hydroxy-3-methylbutanoic acid, 
(S)-3-amino-5-methyl-2-oxohexanoic acid (62) and (S)-3-amino-4-methyl-2-oxopentanoic 
acid (63). 
All these striking features reveal once again, that myxobacterial biosynthetic pathways often 
do not follow the textbook biochemistry. 
[97]
 Furthermore it is typical for myxobacteria to 
produce a large family of metabolites by several variations during biosynthesis. 
[45]
 From the 
evolutionary point of view such diversity of structures generated by one biosynthetic pathway 
is called as the ‘screening hypothesis’ meaning to produce different compounds at low costs. 
[265]
  
The incorporation of these unusual building blocks makes in silico structure prediction nearly 
impossible. Further deviations from the textbook biochemistry are the missing of domains and 
the lacking of conserved motifs which might have the consequence of module skipping (refer 
to section module skipping; later on) which makes analysis even more complicated.  
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Otherwise such uncommon metabolites like the myxoprincomides are a thrilling occasion to 
explore unusual building blocks and their biosynthetic routes. One can assume that there are 
still a significant number of secondary metabolites which needed to be explored. 
 
 
Figure 79:  Structures of myxoprincomides in strain DK897 (top) and DK1622 (bottom), differences 
marked in circles.  
The structural differences of the DK897 type of myxoprincomides and the DK1622 variants 
are depicted in Figure 79. The major disparities are two varying amino acids. One is an 
additional phenylalanine in the DK897 type of myxoprincomides. And another variation is the 
second amino acid. The DK897 variants exhibit an OH-Val at this position while the DK1622 
types contain a leucine. Despite differences in one amino acid and an extra one, the molecular 
core structure and the amino acid order are the same.  
 
The structural distinctions of the two myxoprincomide types are reflected in the biosynthetic 
gene clusters, too. The myxoprincomide gene is 42.8 kb (DK1622) respectively 46.9 kb 
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(DK897) in size. It consists of 13 (DK1622) or rather 14 (DK897) modules, and ends with a 
thioesterase domain. mxp897 is the largest myxobacterial biosynthetic gene exhibiting 39 
catalytic domains. And in DK1622 its length is unique, too, as it encodes the largest single 
and continuous hybrid enzyme. Remarkably, the myxoprincomide gene cluster in DK897 has 
one module more which is in charge of an incorporation of one OH-Val. Furthermore there is 
an incorporation of one phenylalanine instead of a leucine. This might give insights into the 
evolutionary development of the biosynthetic gene clusters. Whereas at that point it is not 
possible to say which of the existing gene cluster was present at first. Either a module deletion 
took place or a module insertion. Another possibility would be that both gene clusters 
developed from one antecessor. In general there are different settings discussed in literature 
for the origin of a gene cluster. 
[266]
 One described possibility is the duplication of existing 
gene cluster. 
[267]
 Another explanation is the establishment of a novel cluster by relocation of 
scattered genes within the genome. 
[268]
 The third way is the horizontal gene transfer from one 
genome to another 
[267;269]
 but this still does not really answer the question how the gene 
cluster developed in the donor species. If not the complete cluster is from foreign origin single 
parts of a cluster might have their origin in horizontal gene transfer. The KS domain of 
module epoB in the biosynthesis of epothilone for instance has its origin in horizontal gene 
transfer. 
[270]
 This might be the case for the extra module in the DK897 myxoprincomide 
biosynthesis, too. 
However in both gene clusters, the PKS module and the following one show novel and to date 
unexplained biochemistry. Furthermore the assembly line has a broad intermediate acceptance 
as 62 and 63 and maybe even 59, 60 are incorporated, if no oxidation of 59 and 60 is 
performed. It is not clear if some intermediates are further oxidized by oxidation domain in 
the module which follows the PKS one or if different amino acids are incorporated. The 
enzymatic machineries apparently tolerate a wide range of intermediates. Otherwise partly the 
intermediates are released from the assembly before the final product is reached. However, 
the final results are several intermediates and four different end products build by one single 
gene cluster.  
At this point the premature release from the assembly line is not clear, it could be a 
spontaneous hydrolytical, or alternatively an enzyme catalyzed release, for instance by a 
thioesterase (TE). A TE domain (type I) is normally located at the end of the assembly line 
and it usually cleavages of the full-length product. For this final product release there are two 
major mechanisms. 
[225;271]
 One possibility, catalyzed by the TE, is the intermolecular release 
by hydrolysis. Here water acts as nucleophile to release a linear product. This occurs for 
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example in the biosynthesis of vancomycin 
[9]
 or in chondrochloren 
[133]
. In the latter the pre-
chondrochloren (refer to chapter 7) is build before it is further modified by CndG into the 
final product. 
[134]
 The second major TE-catalyzed mechanism is the intramolecular release by 
macrocyclization; represented for example by the biosynthesis of epothilone or erythromycin 
6-DEB. Here the hydroxyl (or in other cases the amino group of the peptidyl-acyl-chain) 
reacts as internal nucleophile to release a macrocyclic product. 
Beside these two release mechanisms there are also several others. 
[225]
 Indanomycin for 
instance is a TE-less clusters where probably an extra module, containing a cyclase domain, 
releases the product. 
[272]
 Furthermore there are unknown release mechanisms where the 
release method is not obvious and not investigated so far. 
[225]
 For myxobacteria unusual 
release mechanisms are common, examples are the biosynthesis of melithiazol 
[273]
 
stigmatellin 
[274]
 and aurafuron 
[275]
. 
Intermediates which are stuck on the chain due to biosynthetic errors are typically removed by 
type II TE 
[225]
 but such a domain is not present in the myxoprincomide cluster. It is more 
likely that the release of the myxoprincomide intermediates is similar to the one of the 
pikromycin biosynthesis. There is a directly offload of an intermediate by the terminal TE 
domain. 
[276]
 The intermediates must either be passed through the modules to the terminal TE 
domain without undergoing extension, or directly transferred to the terminal TE domain. In 
the last case a conformational flexibility is needed to directly offload the diverse 
intermediates. To understand the release mechanisms deeper analysis or molecular studies are 
necessary.  
 
Another open question in the biosynthesis of myxoprincomide is the PKS module and the 
subsequent one. Here a proposal for the DK1622 biosynthesis has been made where the 
intermediate is extended by a malonyl-CoA. Followed by an alpha oxidation of the acetyl 
group performed by the oxidation domain of the proceeding module. In this proposal an α-
keto functional group is formed by tautomerization. This functional group is nucleophilically 
attacked by the amino group of the subsequent serine resulting in a loss of CO and a C-1 unit 
originating from a malonyl-CoA. This mechanism has been supported by 
13
C-labeled acetate 
feedings. Furthermore different myxoprincomide derivatives with different oxidation stages 
have been isolated in DK897. There are the alpha-hydroxy variants (59 / 60) and the diketo 
forms (62 / 63); both exist with two different amino acid residues. 
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To conclude, the myxoprincomides constitute a novel group of natural compounds identified 
from M. xanthus. Myxoprincomide production seems to be a characteristic feature of the 
species M. xanthus with at least two different types. Their structure contains unusual features 
which is typical for myxobacterial biosynthesis as the biosynthetic machineries most 
frequently do not follow the “textbook” model. It shows once again that in silico prediction of 
the compound`s structure does not function correctly for the complete molecule. 
[97]
 The 
specificities could not be predicted in every case and missing conserved motifs and missing 
domains seem to result in module skipping. The detailed characterizations of such 
biosynthetic routes are necessary to improve biosynthetic predictions. Beside that 
myxoprincomide biosynthesis is very fascinating as several intermediates and end products 
are released during the NRPS-PKS assembly of the myxoprincomide pathway.  
Moreover a novel mechanism for the formation of diketo groups in peptide chains has been 
suggested. Here a C1 unit originating from acetate is incorporated by a PKS module. 
Oxidation and further tautomerization with subsequent extension of another amino acid leads 
to a loss of CO and formation of an α-hydroxy intermediate. This can further be oxidized into 
an α- keto moiety.  
The myxoprincomide biosynthetic gene clusters in DK897 and DK1622 are slightly different 
but both contain several unusual modules which are in charge of this interesting biosynthesis. 
Two different strategies were applied to identify the compound gene correlation. Furthermore 
it could be demonstrated, that the ability of connecting biosynthetic gene clusters to its 
metabolite assists its isolation. As the natural abundance of the myxoprincomides is very low, 
genetic manipulation was used to create optimized producer strains. 
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4. Module skipping increases chemical diversity 
Some of the reported biosynthetic assembly lines are deviations from textbook biochemistry. 
Such exceptions made it difficult to predict the final product of biosynthetic assembly lines 
from the primary sequence. In theory each module performs one discrete elongation step. And 
the order of different steps is given by the module sequence. More and more exceptions of the 
text book biochemistry are discovered 
[108]
; especially from myxobacteria 
[45]
; therefore this 
cannot be considered as individual case. For example there are reports of occasions of 
stuttering of modules (a module is used multiple times for chain extension) or module 
skipping. 
[277]
 These things might have been relevant for the evolution of PKSs, 
[278]
 as such 
stuttering increases the diversity of natural compounds. The biochemical knowledge of 
stuttering, if fully understood, can be used for engineering of metabolic assembly lines to 
create novel unnatural natural products. 
[277]
 Examples for module stuttering are stigmatellin 
and borellidin. For stigmatellin ten condensation cycles are necessary and these cycles are 
performed by nine PKS modules. 
[274]
 For borellidin eight condensation steps are necessary 
for the final product, but the biosynthetic assembly line contains only six extension modules. 
[279]
 
Module skipping is to bypass the utilization of a single domain or a complete module of a 
biosynthetic assembly. 
[239]
 When a complete module is skipped, the biosynthetic intermediate 
is directly transferred from one module to the after next one. That means that a complete 
module with all its enzyme activities is ignored. 
[240]
 Alternatively the ACP or PCP of the 
skipped module is still involved, but no extender unit is added to the intermediate because the 
AT or rather A domain is inactive. 
[207]
 Such module skipping can be irregular or 
programmed. For the aberrant skipping the epothilone derivative K is an example. 
[280]
 A well 
investigated example of such module skipping was reported by Leadlay et al. 
[278]
 They report 
of a hybrid tetraketide synthase of erythromycin containing a foreign module of rapamycin 
which resulted in different products: triketides as major product and tetraketides as minor 
products. 
Programmed skipping is known from pikromycin synthase from Streptomyces venezuelae. 
Depending on the cultivation conditions either the full-length product or a truncated version is 
build. 
[281]
 Myxobacterial examples with intentional module skipping are myxochromide S 
[207]
, disorazol 
[282]
 and chivosazol 
[283]
.  
For a NRPS-PKS hybrid system module skipping was shown by site-directed mutagenesis 
experiments in vivo in the biosynthesis of leinamycin. 
[284]
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In this work such skipping is reported for NRPS-PKS hybrid product myxoprincomide. Here 
module 13 (DK897) or rather module 12 (DK1622) is skipped. 
Another skipping example in this thesis is the PKS product spirangien. Here point mutations 
lead to module skipping. A spiroketal compound described in literature with module skipping 
is nemadectin (Figure 80). 
[108]
 Here the penultimate methylmalonyl-CoA extender unit is not 
always incorporated by the PKS. This skipping leads to nine additional products. 
 
Figure 80: Nemadectin (top left) and products that result from module skipping 
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5. Pre-chondrochloren, last intermediate in chondrochloren 
biosynthesis 
The strain Chondromyces crocatus Cm c5 is a very potent secondary metabolite producer; it 
generates at least six distinct classes. It is known to produce the highly antifungal ajudazols 
which inhibit the mitochondrial electron transport. 
[285]
 Another interesting metabolite is the 
macrolide thuggacin, it acts against tuberculosis. The biosynthesis of both metabolites is well 
discussed in the thesis of K. Buntin. 
[286]
 
The biosynthesis of chondrochloren 
[77]
 which is also generated by Chondromyces crocatus 
Cm c5 was described by Rachid et al. 
[133]
. Particularly the post-assembly enzymatic 
reactions, the chlorination and the oxidative decarboxylation (by CndG), are very interesting. 
CndG operates post-PKS / NRPS and it attains the biological activity of the chondrochloren. 
Decarboxylations are widespread in nature; they specifically modify the substrates. 
[287;288]
 
Three different enzyme classes are known which are distinguished by their used cofactors. 
One decarboxylase group uses the cofactors: biotin, flavin, and NAD
+ 
/ NADP
+
. 
[289-291]
 The 
second class employs inorganic cofactors. 
[292]
 And enzymes without a known cofactor build 
the third group. 
[287;293]
 
The oxidative decarboxylase (CndG) of the chondrochloren gene cluster was heterologously 
expressed in Escherichia coli by S. Rachid. To show that CndG is FAD-dependent; the pre-
chondrochloren was needed as substrate to convert it by the enzyme into chondrochloren. A 
knockout of CndG leads to a carboxylated and saturated derivative of chondrochloren A and 
B, named as pre-chondrochloren. It is the last intermediate within the biosynthesis of 
chondrochloren. To proof the hypothesis of the pre-chondrochloren the mutant was cultivated 
in larger scale to isolate the novel created metabolite. 
 
Biological activity tests of pre-chondrochloren revealed that the decarboxylation is essential 
for the bioactivity. This shows how important each single step in biosynthesis can be. In the 
case of the shortened spirangien variants structural variations did not exhibit strong difference 
in comparison to the normal spirangiens. 
But it demonstrates that evolution which leads to structural differences makes sense for the 
bacteria. As huge structural diversity by small variations in the structure might lead to strong 
differences in bioactivity. That is also the reason why natural products are used as leads 
structures for drugs. 
[4]
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6. Spirangien and spiroketal formations 
Spirangien is only one of several interesting secondary metabolites of Sorangium cellulosum 
So ce90. Epothilone 
[173;174]
 is the most famous representative of that strain. Small 
modifications to its structure led to the development of a new anticancer drug, 
Ixabepilone
®
. 
[5]
 
Spirangien is a product of pure PKS machinery. One common characteristic of type I PKS is 
the colinearity of the gene cluster with its structure. But in the described spirangien chapter a 
spontaneous mutant occurred which lead to an inactivation of a module (spiJ, module 14) and 
enforces a skipping of a module. This does not stop the complete spirangien production but it 
results in four novel shortened derivatives. The mutation in the spirangien cluster 
[235]
 
represents some kind of evolutionary processes in the laboratory. Hence it shows insights into 
the evolutionary development of biosynthetic gene clusters and how effective slight mutations 
can be in the progress of novel natural compounds. 
 
 
Figure 81:  Structure of spirotoamide A (left) and reveromycin A (right) 
 
Natural compounds containing a spiroacetal group are ubiquitous in nature. Due to their 
specific structure spiroacetals exhibit various pharmaceutical activities. Recently a novel 
spiroacetal, the spirotoamide (Figure 81) was isolated and structurally characterized. 
[294]
 It 
showed cytotoxic, antibacterial and antifungal activity. Other spiroacetal examples with 
biological activity are tautomycin (anticancer), monensin (antibiotic), avermectin 
(antiparasitic) and here mentioned spirangien (antifungal). The diverse biological activities 
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and the stereospecific structures of spiroacetals made them attractive goals for organic 
synthesis. 
[295]
 Compared to chemical synthesis, the biosynthetic spiroacetal formation has not 
been completely characterized. Although the knowledge, about the biosynthetic machinery 
and single biosynthetic steps, is important for the development of novel derivatives that may 
have higher biological activity. But often responsible enzymes could not be identified or 
unstable intermediates could not be analyzed. 
[241]
  
 
For some biosynthetic spiroketal formations there are assumptions but the involved enzymes 
for the cyclization step could not be identified. Tautomycin 
[296]
 and avermectin B1a 
[297]
 are 
presumably formed through none enzymatic dehydrative cyclization mechanism 
[235]
 (refer to 
Figure 82 I). The spiroacetal formation of monensin A is well studied. It is formed by an SN2 
reaction of an epoxide and ketone intermediate 
[242;298]
 (refer to Figure 82 II). While for 
spirangien A a P450 is likely to be involved in the dehydrative cyclization process. It is 
assumed that a P450 builds a keto-diol which then cyclizes spontaneously to the spiroacetal. 
The spiroacetal formation is thermodynamically favored and not controlled by an enzyme. 
[299]
 Due to the new shortened spirangien derivatives, which were isolated and its structure 
completely characterized by NMR spectroscopy, the biosynthetic spiroketal formation of 
spirangien could be described in more detail. A proposed pathway by Frank et al. 
[175]
 could 
be affirmed. The existence of the new spirangien derivatives proves that a previous oxidation 
step for the spiroketal formation is not necessary. 
Recently Osada et al. identified the responsible enzymes which are involved in the spiroacetal 
formation of reveromycin (refer to Figure 81 and Figure 82 III). Here two enzymes are 
performing spiroacetal formation. RevG (a dihydroxy ketone synthase) conducts the 
dehydrogenation and RevJ (a spiroacetal synthase) accomplishes the cyclization. This 
spiroacetal formation was reconstructed by in vitro experiments with the precursor and RevG 
and RevJ. 
[241]
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Figure 82: Schema of different spiroacetal formations: I via a dehydrative cyclization like in the case 
of tautomycin or avermectin B1a; II via an epoxide as in monensin A; III via enzymatic 
control shown for reveromycin 
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Abbreviations 
4’-PPant 4'-phosphopantetheine 
A adenylation 
ACL acyl-CoA ligase 
ACP acyl carrier protein 
AT acyltransferase 
bp base pairs 
BPC base peak chromatogram 
C condensation 
CL coenzyme A ligase 
CP carrier protein 
DH β-hydroxyacyl dehydratase 
E epimerase 
EIC extracted ion chromatogram 
ER enoyl reductase 
HC Heterocyclization 
HPLC high performance liquid chromatography 
HR-MS high resolution mass spectrometry 
Kan kanamycin sulfate 
KR β-ketoacyl reductases 
KS ketosynthase 
LC-HR-MS liquid chromatography high resolution mass spectrometry 
LB Luria–Bertani 
MALDI matrix-assisted laser desorption ionization 
MS mass spectrometry 
MT methyltransferase 
NMR nuclear magnetic resonance 
NMR nuclear magnetic resonance 
NPs natural products 
NPs natural products 
NRPs non-ribosomal peptides 
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NRPS nonribosomal peptide synthetase 
ORF open reading frame 
Ox Oxidation 
PCA principal component analysis 
PCP peptidyl carrier protein 
PCR polymerase chain reaction 
PKs polypeptides 
PKS polyketide synthase 
PKSs polyketide synthases 
PPTase phosphopantetheinyltransferase 
RBS ribosomal binding site 
RP ribosomal peptide 
Rt retention time 
SAM S-adenosylmethionine 
SIM selective ion monitoring 
TE thioesterase 
wt wild type 
 
 
